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ABSTRACT 
Pharmacological magnetic resonance imaging (phMRI) is the use of functional 
MRI techniques to elucidate the effects that psychotropic drugs have on neural activity 
within the brain; it is an emerging field of research that holds great potential for the 
investigation of drugs that act on the central nervous system by revealing the changes in 
neural activity that mediate observable changes in behavior, cognition, and perception. 
However, the realization of this potential is hampered by several unanswered questions: 
Are the MRI measurements reliable surrogates of changing neural activity in the presence 
of pharmacological agents? Is it relevant to investigate psychiatric phenomena such as 
reward or anxiolysis in anesthetized, rather than conscious animals? What are the 
methods that yield reproducible and meaningful results from phMRI experiments, and are 
they consistent in the investigations of different drugs?  
The research presented herein addresses many of these questions with the specific 
aims of  
1) Developing pharmacological MRI methodologies that can be used in the 
conscious animal, 
2) Validating these methodologies with the investigation of a non-stimulant, 
psychoactive compound, and 
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3) Applying these methodologies to the investigation of typical and atypical 
antipsychotic drugs, classes of compounds with unknown mechanisms of therapeutic 
action 
Building on recent developments in the field of functional MRI research, we 
developed new techniques that enable the investigator to measure localized changes in 
metabolism commensurate with changing neural activity. We tested the hypothesis that 
metabolic changes are a more reliable surrogate of changes in neural activity in response 
to a cocaine challenge, than changes observed in the blood-oxygen-level-dependent 
(BOLD) signal alone. We developed a system capable of multi-modal imaging in the 
conscious rat, and we tested the hypothesis that the conscious brain exhibits a markedly 
different response to systemic morphine challenge than the anesthetized brain. We 
identified and elucidated several fundamental limitations of the imaging and analysis 
protocols used in phMRI investigations, and developed new tools that enable the 
investigator to avoid common pitfalls. Finally, we applied these phMRI techniques to the 
investigation of neuroleptic compounds by asking the question: does treatment with 
typical or atypical antipsychotic drugs modulate the systems in the brain which are direct 
or indirect (i.e. downstream) substrates for a dopaminergic agonist?  
The execution of this research has generated several new tools for the neuroscience 
and drug discovery communities that can be used in neuropsychiatric investigations into 
the action of psychotropic drugs, while the results of this research provide evidence that 
supports several answers to the questions that currently limit the utility of phMRI 
investigations. Specifically, we observed that metabolic change can be measured to 
 viii 
resolve discrepancies between anomalous BOLD signal changes and underlying changes 
in neural activity in the case of systemically administered cocaine. We found clear 
differences in the response to systemically administered morphine between conscious and 
anesthetized rats, and observed that only conscious animals exhibit a phMRI response 
that can be explained by the pharmacodynamics of morphine and corroborated by 
behavioral observations. We identified fundamental and drug-dependent limitations in the 
protocols used to perform phMRI investigations, and designed tools and alternate 
methods to facilitate protocol development.  
By applying these techniques to the investigation of neuroleptic compounds, we 
have gained a new perspective of the alterations in dopaminergic signaling induced by 
treatment with antipsychotic medications, and have found effects in many nuclei outside 
of the pathways that act as direct substrates for dopamine. A clearer picture of how 
neuroleptics alter the intercommunication of brain nuclei would be an invaluable resource 
for the classification of investigational antipsychotic drugs, and would provide the basis 
for future studies that examine the neuroplastic changes that confer therapeutic efficacy 
following chronic treatment with antipsychotic medications. 
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CHAPTER I 
INTRODUCTION 
Background and Rationale 
Many drugs that affect the central nervous system confer their effects through 
mechanisms that are still a mystery. This is especially true among drugs that are 
implicated in the treatment or in the pathology of psychiatric diseases. Drugs of abuse 
and antipsychotic agents are two pertinent examples; in the case of both classes of drugs, 
the molecular properties of the chemicals themselves are well understood. For example, it 
is largely known with which receptors and neurotransmitter transporters these chemicals 
interact, where in the brain neurons harboring these receptors and transporters exist, and 
generally, it is known what the acute effects on activity within these neurons are, 
following administration of a particular compound from either of these drug classes 
(Nestler et al., 2001; Squire et al., 2003; Katzung, 2004).  
 What is not known, in these two examples, is what connects the psychiatrically 
relevant changes in behavior and cognition to the acute effects of the drugs themselves. 
For example, cocaine, amphetamine, and methylphenidate are psychostimulants with 
varying liability for abuse, and each of these drugs prevents reuptake of dopamine, 
norepinephrine, and serotonin (Rothman and Baumann, 2003). Based on the dogma that 
increased synaptic dopamine in the nucleus accumbens (NAc) causes the reinforcement 
that leads to drug abuse (Koob and Bloom, 1988; Nestler et al., 2001; Squire et al., 2003), 
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it is surprising that methylphenidate, which has a higher affinity for the dopamine 
transporter than either cocaine or amphetamine (Han and Gu, 2006) has a lower liability 
for abuse (Nestler et al., 2001). Differences in the route of administration of these drugs 
may partially explain this difference in abuse liability; it has been shown that the rate of 
receptor occupancy by cocaine is correlated with its reinforcing characteristics 
(Woolverton and Wang, 2004; Nelson et al., 2006), a phenomenon described as the rate 
hypothesis. The evidence supporting the rate hypothesis (Gorelick, 1998) is one example 
of the complex neural response to psychotropic drugs that obscures any simple 
connections between the observed behavioral and cognitive effects, and the fundamental 
molecular actions of the drug. In the second example, the linkage between the molecular 
actions of antipsychotic drugs and their therapeutic effects is also obscure, and 
unanswered questions regarding the mechanisms by which these drugs confer therapeutic 
benefit are discussed in detail later in this, and in following chapters. 
  Neuroimaging can be used to investigate the complex cascade of changes in 
neural activity that translate the acute molecular actions of a psychotropic drug on a 
subset of neurons in the brain to the relevant changes in behavior and cognition observed 
in the animal (human and lower species) as a whole. Neuroimaging studies have been 
beneficial for the study of drugs’ effects on nociception (Becerra et al., 2001; Malisza and 
Docherty, 2001), for the development of integrative theories that describe pathological 
states such as addiction (Volkow et al., 2004), and are recognized for their growing utility 
in the design of novel drugs that act on the CNS (Wise and Tracey, 2006). Functional 
MRI (fMRI) offers a unique capability among other neuroimaging modalities such as 
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positron emission tomography (PET) and single photon emission computed tomography 
(SPECT) by providing high temporal resolution to resolve dynamic changes in neural 
activity following the administration of a psychoactive drug. Additionally, the non-
invasive nature of fMRI, and the widespread use of MRI in clinical settings suggest that 
fMRI of psychoactive drugs, termed pharmacological functional MRI or pharmacological 
MRI (phMRI), is well positioned to translate observations made in lower species to 
observations made in the clinic.  
While phMRI neuroimaging studies offer a valuable view of the changes in neural 
activity that occur throughout the whole brain following the administration of 
psychoactive drugs, several unanswered questions complicate the application of phMRI 
techniques and limit the inferences that can be made from the results obtained from 
phMRI experiments. Three of these open questions are addressed in the research that 
follows:  
1) Are the MRI measurements reliable surrogates of changing neural activity in the 
presence of pharmacological agents?  
2) Is it relevant to investigate psychiatric phenomena such as reward or anxiolysis 
in anesthetized, rather than conscious animals? And   
3) what are the methods that yield reproducible and meaningful results from 
phMRI experiments, and are they consistent in the investigations of different drugs?  
With an improved understanding of the capabilities and limitations of phMRI 
techniques, we apply phMRI to the investigation of antipsychotic drugs in an effort to 
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resolve the effect that acute treatment with these drugs has on the brain’s response to 
altered dopaminergic signaling, the neural pathway that is universally implicated in 
pharmacological treatments of psychosis.  
In the research that follows, we test the hypothesis that hemodynamic and 
metabolic markers, such as cerebral blood flow (CBF) and cerebral metabolic rate of 
oxygen consumption (CMRO2), can be reliably measured by phMRI to infer changes in 
neural activity following sensory and pharmacological stimuli. We develop new 
technology for performing simultaneous measurements of spin-echo blood-oxygenation-
level-dependent (SE BOLD) contrast and CBF in the conscious animal. We test the 
hypothesis that conscious animals will exhibit a differential fMRI response to a non-
stimulant psychoactive drug in comparison to anesthetized animals, and that the response 
observed in the conscious animal is better explained by the pharmacodynamics of the 
drug itself. And, in the final study, we test the hypothesis that dopaminergic signaling, 
observed in the conscious rat, can be modulated by pretreatment with antipsychotic 
drugs, observing that many regions of the brain beyond the immediate dopaminergic 
pathways are affected by these treatments.  
The remaining sections of this chapter provide the necessary background for the 
studies that follow, and, hopefully, provide the context and resources to adequately 
understand the current state of the art. It is hoped that the results and advances described 
in the following chapters will provide valuable direction for future phMRI studies, and 
that the modulation of dopaminergic signaling by acute pretreatment with antipsychotic 
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medications will provide a template for the comparison of novel antipsychotic drugs 
under investigation. 
The basics of MRI 
A fascinating aspect of nuclear magnetic resonance (NMR) imaging is the 
beguiling simplicity of the grayscale images that are now commonplace in clinical and 
research settings. In fact, the acquisition of even the most basic MR image is the result of 
several interdependent experiments performed on the subject or sample that reproduce 
physical phenomena which took more than 29 years to understand (Bloch et al., 1946; 
Purcell et al., 1946; Damadian, 1971; Lauterbur, 1973; Kumar et al., 1975) in research 
that warranted the award of three Nobel Prizes (Physics in 1952, Chemistry in 1991, and 
Physiology or Medicine in 2003). Although the accelerating pace of research in MRI has 
extended the capabilities of this non-invasive imaging modality beyond the imaginations 
of its original discoverers, we are continually reminded of their contributions. Every MRI 
scan reflects the fundamental process of MR image formation through the presence of 
image artifacts and in the effort required to elicit and detect the inherently weak NMR 
signal. Consequently, a basic understanding of the process of MR image formation is 
essential in order to interpret the results of contemporary MRI experiments, all of which 
build on these fundamental techniques.  
 Image formation can be considered to consist of two components. The first 
component concerns the origin and generation of the NMR signal that is detected, while 
the second component concerns the manipulation of the experimental setting to localize 
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and spatially encode the signal, enabling two or three dimensional image reconstruction. 
The NMR signal can be observed in atoms whose nuclei contain a non-integer nuclear 
magnetic moment, called spin (Rohlf, 1994; Buxton, 2002; Hornak, 2002). This nuclear 
spin, likened to electrical charge distributed on the surface of spinning subatomic 
particles, exists as quanta of ½ of the nuclear magneton in each of the protons and 
neutrons that comprise the nucleus of stable atoms.  Subatomic particles within the same 
nuclear orbit pair with one another in a manner that cancels the collective magnetic 
moment, but, in nuclear orbits that contain an odd number of protons and neutrons, there 
exists a residual magnetic moment that will interact with external magnetic fields. 
Most MRI is based on the interaction between the magnetic field of the MRI 
scanner and hydrogen atoms (spin ½ nuclei) bound in water molecules.  In addition to 1H, 
some isotopes with non-zero nuclear magnetic dipole moments that are used conjointly in 
MRI studies include: 23Na (Lee et al., 1986), 13C & 31P (H. Bomsdorf, 1988), 19F (Nelson 
et al., 1985), 17O (Pekar et al., 1991; Fiat and Kang, 1992; Fiat et al., 1993; Fiat and 
Kang, 1993) , 129Xe (Albert et al., 1996), and 3He (Middleton et al., 1995). The 
dependence of NMR signal intensity on, among other factors, the abundance of the 
nucleus being investigated, and the high biological abundance (63%) of 1H in the body 
(Hornak, 2002), explain the extensive use of 1H MRI.  
In the presence of an external magnetic field, the nuclear magnetic moment of a 
non-zero spin nucleus can assume an orientation nearly aligned with or nearly counter-
aligned with the external field, the counter aligned orientation having slightly higher 
energy (Figure 1-1, panel a; Figures and Tables are found at the end of each chapter). 
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Given a population of such spins that we will call a spin-packet, in the presence of a 
strong external magnetic field a slightly larger number of nuclear spins will align 
themselves in the lower energy configuration. The small difference between spins in the 
high and low energy states (0.0005% in a 1.5T external field at room temperature) causes 
the spin-packet to exhibit a non-zero magnetic moment, and enables the spin-packet to 
absorb and emit photons with an energy that corresponds to the transition between the 
high and low energy states of the individual spins contained within. The frequency of this 
radiation is known as the Larmor frequency (Rohlf, 1994). 
We can think of the net magnetic moment of the spin-packet (Figure 1-1, panel b) 
as being analogous to a spinning top with a bar magnet inserted through the middle along 
the axis of rotation. Under fully relaxed conditions, the magnetic moment is aligned with 
the external magnetic field. Like a spinning top in the presence of gravitational forces, if 
we displace the spin-packet’s magnetic moment from alignment with the external 
magnetic field by bombardment with radiation at the Larmor frequency (Figure 1-1, 
panel c), intrinsic angular momentum causes the spin-packet’s magnetic moment to 
precess (i.e. gyrate) about the axis of the external magnetic field, emitting radiation at the 
Larmor frequency until it reaches the fully relaxed condition or until the spins contained 
within dephase. When multiple spin-packets precess in synchrony, the emitted radiation 
can be detected as a rapidly fading signal called the free induction decay (FID) (Figure 1-
1, panel d) (Bloch et al., 1946). 
Two important factors govern the detection of the NMR signal and the 
characteristics of the FID, following displacement of the spin-packet’s magnetic moment 
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by excitation with radiation at the Larmor frequency. The first factor governs the strength 
of the emitted NMR signal, and is important during the repeated excitations used to 
collect the FIDs that are necessary to reconstruct an image. This factor is the rate at 
which the spin-packet’s magnetic moment returns to alignment with the external 
magnetic field, a rate that is referred to as longitudinal, or spin-lattice relaxation and that 
is characterized by a time constant (T1). The second factor concerns the rate at which the 
emitted signal is eroded by growing phase differences between the precessions of 
neighboring spins. Small differences in the rates of precession between neighboring spin-
packets due to microscopic and macroscopic inhomogeneities in the external magnetic 
field are unavoidable, and the effects of cancellation rapidly erode the detected signal in a 
process described by transverse, or spin-spin relaxation, which is also characterized by 
time constants measuring the rate of signal loss due to microscopic effects (T2) or 
microscopic plus macroscopic effects (T2*). T1, T2, and T2* are important factors that 
differ between tissues or samples of interest (Fullerton and Cameron, 1988) in MRI 
experiments, and images are deliberately weighted to reflect T1 and T2 or T2* contrast 
within specified ranges of these parameters. 
The second component of image formation addresses the spatial encoding of the 
FID, and describes the acquisition of many FIDs to collect the information necessary to 
reconstruct a 2-dimensional image. The concept originally put forth by Kumar, Ernst and 
others (Kumar et al., 1975; Edelstein et al., 1980) to use phase and Larmor frequency 
modulation by introducing spatially linear gradients in the X, Y, and Z directions within 
the confines of the static external magnetic field remains the basis of the MRI techniques 
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in use today. By introducing a spatially linear gradient in the magnetic field in one 
direction, and simultaneously irradiating the sample with RF energy spanning a range of 
frequencies, it is possible to excite only a thin slice of the sample being investigated. A 
second linear gradient that is applied shortly after this excitation for a fixed duration of 
time along an orthogonal direction will encode a specific phase offset that depends both 
on the strength of the gradient and the spin-packet’s location in space along the axis of 
this phase-encoding gradient. Finally, a third linear gradient applied in the remaining 
orthogonal direction during signal detection will cause the Larmor frequency of the spin-
packets to change according to their location in space along the axis of this final, read-out 
gradient. In single slice imaging, this process is repeated with incremented strengths of 
the phase encoding gradient and a composite of FIDs is collected and used to populate a 
2D matrix (k-space) that can be Fourier transformed in both the X and Y directions to 
reconstruct a 2D image corresponding to the originally excited slice of sample (Figure 1-
1, panel c). In multislice imaging, the process is repeated for each 2D slice that is 
acquired, and the strategy of interleaving these acquisitions allows multiple slices to be 
acquired in the same time that it takes to acquire one.  
The complexity of this process is most readily apparent when problems occur 
during the acquisition of the multiple FIDs. Figure 1-1, panel e illustrates the effect of 
motion on the reconstructed image, where sample displacement during the acquisition of 
phase encoded FIDs leads to a banding effect that is present in the axis of the phase 
encoding gradient across the entire reconstructed image. This simplified explanation of 
the methods and theory of MRI is intended to highlight and provide context for the 
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important aspects of the imaging experiments that are described in the studies presented 
herein, but the reader is directed to the following literature for far more detailed 
treatments of NMR Spectroscopy (Fullerton and Cameron, 1988; Hallenga, 1991) and 
basic MRI techniques (Curry et al., 1990; Brown and Semelka, 1999; Hornak, 2002; 
Paschal and Morris, 2004). 
Changing hemodynamics associated with changing neuronal metabolism  
Depsite its size, accounting for only about 2% of total human bodyweight, the brain 
consumes a stunning 20-25% (Squire et al., 2003; Shulman et al., 2004) of the total 
glucose produced and utilized by the body. Several independent studies of 
neuroenergetics suggest that the highest energetic costs in the brain are related to 
glutamate neurotransmission, and that in the awake resting state most of the energy 
consumed by the brain is used to maintain stasis amid a constant background of neural 
activity (Sibson et al., 1998; Attwell and Laughlin, 2001; Shulman et al., 2004). Models 
suggest that the majority of the energy consumed by neurons is used to maintain ion 
gradients across the neuronal membrane in pre and post synaptic neurons, and that only 
5-10% of the glucose consumed is relegated to neurotransmitter cycling, and a small 
amount is consumed for other processes within the neuron such as vesicularization (Mata 
et al., 1980; Pellerin and Magistretti, 1994; Sibson et al., 1998; Magistretti et al., 1999). 
Studies comparing glial, GABAergic, and glutamatergic glucose consumption suggest 
that only10-15% of the glucose consumed by cortical tissue is used to support glial 
processes, while the remaining energy consumption supports glutametergic and 
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GABAergic neurons (Rothman et al., 1999; Shulman et al., 2004), further supporting the 
dogma that neuronal activity and glucose metabolism are tightly coupled. 
It is not surprising that an organ with an associated energy cost as large as that of 
the brain is highly specialized so that it may operate efficiently, nor is it surprising that, 
internally, localized changes in the demand for energy are satisfied with a dynamic and 
localized response, rather than a change in supply to the entire organ. Indeed, it was 
observed more than 115 years ago that sensory stimulation increases blood flow 
selectively to the parietal cortex in animals (Roy and Sherrington, 1890), prompting the 
ongoing investigation of the mechanisms by which neuronal activity alters the cerebral 
vasculature to change the supply of oxygen and nutrients on a local scale.   
Neurogenic mechanisms hold promise as mediators of vascular dynamics; 
observations that microvessels within the brain are richly innervated and the finding that 
functional receptors for some neurotransmitters exist on the vessels themselves (Riad et 
al., 1998; Cohen et al., 1999) has been exploited for the clinical treatment of migraine 
headaches with sumatriptan succinate, a 5-HT1D receptor agonist (GlaxoSmithKline, 
2003), and supports the notion of a neural mechanism for regulating local blood flow. 
Other neurotransmitters and neuropeptides are also potential candidates, including 
noradrenaline, serotonin, acetylcholine, neuropeptide Y, and substance P (Squire et al., 
2003). Other chemicals are known to affect the cerebral vasculature, and are produced 
locally by neurons as byproducts of metabolism. Importantly, CO2 and NO are known to 
elicit a potent vasodilatory response, and are likely to play significant, if partial, roles in 
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the localized increase in cerebral blood flow (CBF) that quickly follows an increase in 
neural activity.  
 Coupling between localized changes in neural activity and local vascular 
parameters such as cerebral blood flow (CBF) and cerebral blood volume (CBV), as well 
as local metabolic parameters such as cerebral metabolic rate of glucose (CMRglu) and 
cerebral metabolic rate of oxygen (CMRO2), remains an active area of research. Although 
the proposed relationships between these parameters that account for steady state and 
dynamic observations of changing hemodynamics and metabolism associated with 
changes in neural activity are still the subject of debate (Roland et al., 1987; Fox et al., 
1988; Hyder et al., 1996; Buxton et al., 2004; Liu et al., 2004), there is good agreement 
that changes in neural activity, especially increases in rates of neuronal membrane 
depolarization, evoke a reliable response from the cerebral vasculature that can be 
exploited to localize changes in neural activity within the brain. 
The BOLD signal and functional MRI 
While fully oxygenated hemoglobin is diamagnetic, deoxygenated hemoglobin is 
paramagnetic and its presence creates microscopic distortions in the magnetic field 
surrounding erythrocytes as well as macroscopic distortions in the field surrounding 
vessels containing blood with a low level of oxygen saturation (Thulborn et al., 1982; 
Buxton, 2002). The interaction of water molecules with these field distortions causes an 
increase in the transverse relaxation rate of blood (decrease in T2) that is dependent on 
the concentration of deoxyhemoglobin (Thulborn et al., 1982), and also causes an 
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increase in the transverse relaxation rate of the tissue surrounding vessels containing 
deoxygenated blood, due to macroscopic field inhomogenities caused by the presence of 
paramagnetic deoxyhemoglobin in the vessels themselves (decreasing the T2* of this 
tissue) (Ogawa et al., 1990; Ogawa et al., 1992; Buxton, 2002). Due to the sensitivity of 
gradient echo (GE) sequences to T2* contrast (often considered to be a problem due to 
signal drop out in many regions of the brain) Seiji Ogawa and others reported in 1990 
that a GE imaging sequence revealed contrast surrounding cerebral vessels that was 
sensitive to the level of de-oxygenation of the blood they contained (Ogawa et al., 1990). 
Vessels containing high concentrations of deoxyhemoglobin, and the tissue immediately 
surrounding them appeared darker than tissue distal from these vessels, owing to the 
rapid relaxation (decreased T2*) in these areas (Ogawa et al., 1990).  
Within two years of the initial report by Ogawa et al., sequences sensitive to small 
changes in magnetic susceptibility (generating T2* weighted images) and sequences 
sensitive to changes in blood flow (generating perfusion weighted images) were used in 
functional brain mapping applications with promising results; Kwong et al. observed a 
stimulus coupled change in T2* and perfusion weighted image contrast that could be 
elicited by a pharmacological stimulus (CO2), visual stimulus (light presentation), and 
sensory-motor task (hand squeezing) (Kwong et al., 1992). Within weeks, Ogawa et al. 
reported similar results of T2* changes in the visual cortex in response to a visual 
stimulus, and coined this signal as blood-oxygenation-level-dependent (BOLD) contrast, 
laying the foundation for the future applications of MRI to functional brain mapping 
(Ogawa et al., 1992).  
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Due to the complex relationship between changes in cerebral hemodynamics in 
response to changes in neural activity, the effect on BOLD contrast due to neural 
stimulation is somewhat surprising.  Earlier work using positron emission tomography 
(PET) had revealed that as the increase in neural activity induces cerebral vasodilation, 
the quantity of arterial blood recruited to the area consistently overcompensates for the 
increase in oxidative metabolism (Fox et al., 1988).  This overcompensation may have 
evolved as a protective mechanism, guarding the neuropil against oxidative stress and 
ischemic damage (Squire et al., 2003), but it forms the basis of most fMRI imaging 
performed currently. The process of vascular changes in response to increased neural 
activity is illustrated in Figure 1 – 2. 
Noninvasive Measurement of Cerebral Blood Flow using MRI 
In addition to changes in the BOLD signal, other hemodynamic surrogates of 
neural activity can be measured non-invasively using MRI. Cerebral blood flow (CBF) 
describes the volume of blood that perfuses a given volume of cerebral tissue in a given 
period of time, and determines the supply of oxygen available to the tissue. In the clinic, 
perfusion MRI methods are increasingly used to assess CBF for the purposes of 
localizing areas affected by arterial occlusions, assessing the volume of the tissue that has 
been subjected to ischemic stress following infarction, and predicting the recovery of 
infarcted and penumbral tissue following reperfusion after a stroke (Warach et al., 1996; 
Duyn et al., 2005), assessing traumatic brain injury (Cunningham et al., 2005), and more 
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recently, for grading CNS neoplasms based on physiological parameters (Wolf et al., 
2005).  
Noninvasive measurement of CBF by MRI proceeds by manipulating the magnetic 
spins of water molecules in arterial blood within a specific location. These manipulated 
(labeled or tagged) spins are then used as an endogenous tracer and their influx or efflux 
within a given tissue volume are measured over time to determine the local perfusion. 
Figure 1-3, panel a illustrates the continuous arterial spin labeling (CASL) technique, in 
which spins are continuously inverted at the location of the carotid arteries for a period of 
several seconds. As these labeled spins travel to and diffuse into the tissue within the 
brain, a steady state of altered magnetization is developed that can be detected by MRI.  
The process of quantifying blood flow from the steady state contrast between 
labeled and unlabeled images using CASL is an important aspect of the research to 
follow. A simple model which assumes that water is a freely diffusible tracer can be used 
to quantify the relationship between changes in magnetization and blood flow according 
to a modified Bloch equation (Detre et al., 1995; Barbier et al., 2001). This is shown in 
Equation 1.01, where Mb = z-magnetization (i.e. magnetization in direction of Bo) per unit 
volume of brain tissue, Mb0 = the value of Mb under fully relaxed conditions, Ma = the z-
magnetization per unit volume of arterial blood, Mv = the z-magnetization per unit 
volume of venous blood, T1 = the spin-lattice relaxation time of brain water, and f = 
blood flow to the tissue in ml per g·s. An assumption is made that the water in the tissue 
volume of interest exists in a well mixed compartment and consequently, the efflux of 
water magnetization from this compartment (Mv) can be described in terms of the total 
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blood magnetization influx and by the respective ratio of water concentrations between 
the brain and the vascular compartments, denoted by the brain/blood partition coefficient 
(λ) (Equation 1.02).  
The labeling process is imperfect, and we must make a correction with an 
assumption of constant labeling efficiency, ranging between 0 – 100% (α); in the case of 
arterial spin inversion, this correction factor for the magnetization of arterial blood is 
incorporated by Equation 1.03. If we assume that transit times from the point of inversion 
to the location of exchange with brain water molecules is short with respect to the T1 
relaxation time of the water molecules themselves (i.e. Ma0 = Ma), we can substitute the 
value of Ma in equation 1.03 into equation 1.01, obtaining equation 1.04. During the 
initial conditions, we observe that inflowing magnetization is equal to magnetization 
outflow (i.e. Ma = Mv in equation 1.02), and introducing the factor (1-2α)f to the equality 
yields an expression (Equation 1.04) that can be substituted into Equation 1.01 to yield a 
linear ordinary differential equation (Equation 1.05), with a discrete solution (Equation 
1.06). Under steady state conditions, we can assume that t=∞ and Equation 1.06 can be 
reduced to the solution for CBF (f) indicated by Equation 1.07.  
 
0
1
b b b
a v
dM M M fM fM
dt T
−= + −      (1.01) 
 
b
v
MM λ=        (1.02) 
 17 
 
( ) 01 2a aM Mα= −       (1.03)  
 
( ) ( ) 00 1 21 2 ba afMM Mf fαα λ
−− = =     (1.04) 
 
( )
( )
00
1
0
1 2
1 21 1
bb b b b
b b
fMdM M M fM
dt T
ffM M
T T
α
λ λ
α
λ λ
−−= + −
⎛ ⎞−⎛ ⎞= − + + +⎜ ⎟⎜ ⎟⎝ ⎠ ⎝ ⎠
   (1.05) 
 
( )
1
1
0
1 1
1 21 1
ft
T
b b
f fe M M
T T
λ α
λ λ
⎛ ⎞− +⎜ ⎟⎝ ⎠ ⎛ ⎞− ⎛ ⎞= + − +⎜ ⎟ ⎜ ⎟⎝ ⎠⎝ ⎠
  (1.06) 
 
( )
0
0
1 2 1
b b
b b
M Mf
T M M
λ
α
−= ⋅ + −      (1.07) 
 
This steady state model is widely used, and typical results of the CASL experiment 
are shown in Figure 1-2, panels b-e. The steady state assumptions are acceptable under 
most conditions, but a dynamic treatment of perfusion-induced MR contrast is supplied in 
Chapter IV, where slice dependent acquisition delays must be taken into account in the 
interpretation of results.  
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Antipsychotic medications  
The history of antipsychotic drug development 
Psychosis is a defining feature of schizophrenia (American Psychiatric Association, 
1994; Breier and Berg, 1999) that can often be observed in other psychiatric diseases 
including bi-polar disorder (manic depression), unipolar depression, epilepsy, 
Alzheimer’s disease and other neurodegenerative forms of dementia, brain trauma, and in 
some cases of acute substance abuse (e.g. cocaine and phencyclidine) (American 
Psychiatric Association, 1994; National Library of Medicine (US), 2005). The primary 
components of psychosis include formal thought disorder, delusions, and hallucinations 
(American Psychiatric Association, 1994) and reflect a general failure of patients to 
understand, or to correctly interpret the stimuli from the external world (Nestler et al., 
2001). In the case of schizophrenia, these components are considered to be positive 
symptoms that are reported by patients and have been the primary focus of 
pharmacological treatments since the accidental discovery that the phenothiazine 
tranquilizer chlorpromazine ablated these symptoms. Chlorpromazine was given to 
patients as a preoperative anxiolytic (Laborit and Huguenard, 1951; Rothman et al., 
1999), and was later found to suppress symptoms of delusion and mania in psychiatric 
patients when administered repeatedly in a clinical setting (Delay et al., 1952a; Delay et 
al., 1952b; Hamon J et al., 1952).  
Following the discovery of chlorpromazine as a putative antipsychotic medication, 
the identification of other compounds with antipsychotic efficacy progressed in parallel 
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with observations that drugs having clinical efficacy for treating psychotic symptoms also 
exhibited serious dose-dependent motor side effects, termed extrapyramidal symptoms 
(EPS), including Parkinsonism, dystonia, and akathisia (Rothman et al., 1999; Kapur and 
Mamo, 2003). More than two decades elapsed before the relationship between dopamine 
receptor blockade and antipsychotic efficacy was firmly established (Seeman and Lee, 
1975; Creese et al., 1976; Seeman et al., 1976). Selective blockade of the dopamine D2 
receptor is the defining characteristic of the first generation of antipsychotic medications, 
generally known as typical antipsychotic drugs (Nestler, 2002), and all effective 
antipsychotic drugs currently in clinical use exhibit some degree of D2 receptor 
antagonism. The prevalence of EPS and other problems associated with treatment with 
first generation antipsychotic drugs (neuroleptics), as well as the lack of an effect on the 
negative symptoms of schizophrenia that include apathy, flattened affect, and social 
withdrawal (American Psychiatric Association, 1994; National Library of Medicine (US), 
2005) prompted the search for alternative compounds with improved clinical benefits, 
and with a reduced liability for serious side effects (Rothman et al., 1999; Kapur and 
Mamo, 2003). Among the drugs discovered was clozapine in 1958 by Schmutz and 
colleagues at Wander Pharmaceutical (Schmutz and Eichenberger, 1982). Clozapine 
exhibits a dramatically reduced liability for EPS (Kapur and Mamo, 2003) and has a 
radically different spectrum of receptor blockade than traditional (typical) antipsychotic 
drugs (Nestler et al., 2001; Katzung, 2004). Clozapine’s affinity for receptors other than 
D2 prompted its classification as an atypical antipsychotic drug, a class of drugs that now 
includes several other effective antipsychotic medications that were discovered 
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subsequently. A study of treatment-resistant schizophrenic patients in 1988 rejuvenated 
interest in atypical antipsychotic drugs, when these patients were found to respond to 
clozapine, but not to multiple traditional antipsychotics, such as haloperidol (Kane et al., 
1988). The successful treatment of these patients ultimately led to clozapine’s approval 
for the treatment of refractory (treatment-resistant) schizophrenia in 1990.  
Although the incidence of EPS is not a primary concern with clozapine treatment 
(Katzung, 2004), other serious and potentially fatal side effects (e.g. agranulocytosis in 
~1.3% of patients) (Novartis Pharmaceutical Corporation, 2005) are factors that limit its 
use in the clinic. In recent years several additional atypical antipsychotic medications 
have been discovered which demonstrate superiority over haloperidol for the treatment of 
psychotic symptoms with a reduced liability for EPS and other side effects, including 
olanzapine (Zyprexa), risperidone (Risperdal), quetiapine (Seroquel) (Sharma, 2001), 
Amisulpride (Solian) (Curran and Perry, 2001), and possibly ariprazole (Abilify) pending 
the outcome of ongoing investigations (Katzung, 2004). The high cost of atypical 
antipsychotics, combined with the presence of drug-specific side effects other than EPS, 
as well as impractical administration protocols for some drugs have prevented this new 
class of medication from completely supplanting the typical antipsychotic drugs as the 
first line of treatment for psychosis (Katzung, 2004). Research to identify a safe, 
effective, and practical alternative to the currently marketed atypical antipsychotics is 
ongoing. 
Receptor affinity and the enduring mystery of therapeutic action 
 21 
The atypical antipsychotic drugs that are currently available for treatment are 
antagonists at a broad spectrum of receptors with varying affinity, and appear to be 
similar only in the respect that they share a relatively lower affinity for the D2 receptor 
than typical antipsychotic medications (Nestler et al., 2001). Table 1 – 1 illustrates the 
principal receptor affinities for some marketed antipsychotic medications in comparison 
to haloperidol (Bymaster et al., 1997; Casey, 1997; Nestler et al., 2001; Trevor et al., 
2002; Katzung, 2004) and reflects a prevalance of antagonism at serotonergic, adrenergic, 
muscarinic, and histaminergic receptor subtypes. The significance of these receptors in 
the pathophysiology of psychosis (and schizophrenia in particular) is unknown, as is the 
role that antagonism (or partial agonism) of these receptors plays in the therapeutic 
efficacy observed after sustained treatment with atypical antipsychotic drugs. Of practical 
value is the fact the therapeutic window between the onset of clinical benefit and the 
onset of EPS is dramatically widened for atypical antipsychotics with respect to typical 
antipsychotics (Casey, 1997), supporting the theory that neuroplastic changes mediated 
by action at receptors other than the D2 receptor can affect positive clinical changes in 
psychotic patients. 
There is considerable debate as to which receptors, other than D2, are important 
mediators of the clinical benefits of treatment with atypical antipsychotics. Antagonism 
of the 5-HT2a receptor as well as agonism of the 5-HT1 receptor has been postulated as an 
important feature for atypical efficacy (Meltzer, 1999), but the selective 5-HT2a receptor 
antagonists M100907 and SR46349B failed to show antipsychotic efficacy that exceeded 
that of haloperidol (Shipley, 1998; Meltzer et al., 2004). Selective antagonism of the D4 
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receptor (Seeman et al., 1997) has also been investigated for therapeutic benefit, but the 
drug candidate sonepiprozole failed to demonstrate an improvement in symptoms in 
comparison to placebo (Corrigan et al., 2004). D3 receptor antagonism (Schwartz et al., 
2000) remains a viable target and the efficacy of D3 antagonists in the treatment of 
schizophrenia is currently being assessed; early results of a selective D3 antagonist did 
not suggest an improvement in psychotic symptoms (Lahti et al., 1998), but more recent 
work suggests an adjuvant role for D3 antagonism in the treatment of negative symptoms 
with supporting genetic evidence that implicates the D3 receptor as the mediator of this 
effect (Lane et al., 2005). Antagonism of muscarinic or histaminergic receptors alone 
does not appear to improve the symptoms of psychosis (Nestler, 2002). Additionally, 
recent work focused on agonism of the NMDA receptor has shown considerable promise 
in the treatment of the negative symptoms of schizophrenia (Lindsley et al., 2006), but 
the limited action of existing atypical antipsychotics at the NMDA receptor suggests that 
this receptor does not mediate their therapeutic effects.  
Alternative theories postulate that the therapeutic effects of atypical antipsychotics 
are still mediated by D2 receptor antagonism. Neuroimaging studies using positron 
emission tomography (PET) revealed >70% D2 receptor occupancy in patients treated 
with atypical antipsychotics other than clozapine (Farde et al., 1988), consistent with a 
putative therapeutic range of 60%-70% receptor occupancy for antipsychotic effects, 
below the 80% occupancy rate that is associated with the onset of EPS (Farde et al., 
1992). It has also been proposed that a distinguishing feature of atypical antipsychotic 
drugs is that these drugs preferentially occupy D2 receptors that are located extrastriatally 
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(Xiberas et al., 2001), in the thalamus and frontal and temporal cortices, possibly 
explaining the onset of therapeutic effects at doses that are lower than those required to 
induce EPS, and explaining the wider therapeutic window of atypical versus typical 
antipsychotics that are thought to occupy the D2 receptor equally within and outside of 
striatal regions (Kapur and Mamo, 2003). However, recent data indicates that some 
atypical antipsychotic drugs also occupy extrastriatal D2 receptors at consistently lower 
rates (35% less) than typical antipsychotic drugs at therapeutically relevant doses 
(Kessler et al., 2006), supporting a role for receptors other than D2 in the therapeutic 
effects of treatment with these medications.     
Activation of neural networks and their visualization by fMRI 
Functional MRI has been used extensively to visualize concomitant activation of 
regions participating in signaling networks within the brain related to sensory and 
cognitive processing. In the studies described in the following chapters, changes in fMRI 
measures are reported after sensory and nociceptive stimulation, among conscious rats 
resisting the MRI restraint apparatus, amid the constant background of auditory 
stimulation from the scanner, and following a dopaminergic challenge intended to 
stimulate dopaminergic transmission throughout the brain. A brief introduction to the 
neural networks implicated under these conditions follows, and some examples of fMRI 
research related to the detection of changes in neural activity within these networks are 
provided. 
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The spinothalamic tracts within the anterolateral system mediate sensations of pain 
and simple touch, and ascend from the dorsal roots of the spinal cord to the brain stem 
where they supply inputs to the reticular formation, superior colliculus, and several 
thalamic nuclei. Thalamic nuclei, in turn, stimulate and respond to regions of the sensory 
cortex through thalamocortical and corticothalamic fibers, in a largely parallel processing 
of sensory information (Gilman and Newman, 2003). A recent fMRI study performed at 
high resolution and high field (11.7T) demonstrated detection of this network following 
electrical forelimb sensory stimulation in anesthetized rats, noting significant activation 
of the primary and secondary somatosensory cortices, the thalamus, and the cerebellum, 
wherein it was proposed that projections from the medulla and pons to the cerebellum are 
responsible for observations of changing neural activity there (Keilholz et al., 2004). 
The basal ganglia is a collection of interconnected nuclei of critical importance in 
motor function, and is best described by the dual action of the competitive and simple 
circuits, the direct and indirect loops. In the direct loop, dopaminergic transmission from 
the substantia nigra pars compacta (SNpc) stimulates the striatum via D1 receptors, 
which inhibits the medial or internal portion of globus pallidus, disinhibiting the 
thalamus, and stimulating sections of the cerebral cortex, which, in turn, stimulate the 
striatum in a process of positive feedback. In the indirect loop, dopaminergic 
transmission from the SNpc inhibits the striatum via D2 receptors, inhibiting the lateral or 
external portion of the globus pallidus (LGP), disinhibiting the subthalamic nucleus, 
which stimulates the internal globus pallidus, inhibiting the thalamus, ultimately 
inhibiting the cortex and striatum in a process of negative feedback (Gilman and 
 25 
Newman, 2003). The competitive balance of these circuits is necessary for effective 
motor control, and activation of basal ganglia circuitry has been resolved by fMRI in 
humans executing voluntary and involuntary motor tasks (Taniwaki et al., 2006), and 
observed to be disrupted among patients suffering from Parkinson’s disease (Holden et 
al., 2006).  
Recent work, much of which was completed by a member of this examination 
committee and his colleagues, has elucidated networks activated in nociception in 
humans by fMRI  that include elements of the reward and aversion pathways in addition 
to classic spinothalamic pain circuitry (Becerra et al., 2001; Becerra et al., 2004). Animal 
fMRI studies of neural substrates activated by painful stimuli have revealed a simpler 
pattern, consisting mainly of the primary and secondary somatosensory regions, the 
cingulate, thalamus, and hypothalamus with some differences in other regions reported 
between studies (Chang and Shyu, 2001; Malisza and Docherty, 2001; Hess et al., 2006). 
These animal studies were conducted in anesthetized rats, however, and a direct 
comparison to studies in conscious humans, where pain has emotional valence, is 
difficult.  
Visual stimulus paradigms were some of the first used in the early development of 
fMRI and readily reveal neural activation in the visual cortex of both animals (Koyama et 
al., 2004; Van Camp et al., 2006) and humans (Belliveau et al., 1992; Blamire et al., 
1992; Kwong et al., 1992; Ogawa et al., 1992). The activation of the visual cortex among 
conscious rats has not been examined by fMRI, but changing visual perception due to eye 
movement and auditory perception of the noise of the scanner during experiments with 
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conscious rats may contribute to observations of changing fMRI signals in visual and 
auditory cortical regions.  
The principal dopaminergic neurons in the brain can be considered to belong to one 
of three groups of pathways. The nigrostriatal pathway extends from the substantia nigra 
to the caudate putamen, and is the pathway primarily associated with motor control and 
Parkinson’s disease (Nestler et al., 2001; Marsden, 2006). The mesolimbic pathway 
extends from the ventral tegmental area (VTA) to the limbic areas including the nucleus 
accumbens and amygdala, and the mesocortical pathway extends from the VTA to 
several cortical regions including the medial, prefrontal, cingulate, and entorhinal 
cortices. These pathways are implicated in the processing of rewarding stimuli, as well as 
in more general cognitive and emotional functions (Nestler et al., 2001; Marsden, 2006). 
An additional dopamine pathway, the tuberoinfundibular dopamine system, connects the 
arcuate and periventricular nuclei of the hypothalamus to the pituitary where it inhibits 
the production of prolactin (Nestler et al., 2001; Marsden, 2006). The extensive 
innervation of much of the brain by the mesocortical and mesolimbic dopamine neurons 
makes elucidation of these pathways by fMRI difficult, while reports of nigrostriatal 
circuitry involvement in the basal ganglia have been discussed previously.  
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Figure 1 – 1: MRI of the 1H Nucleus 
(a-d) Illustration of the origin of the nuclear magnetic resonance signal in clinical 
proton imaging. (a) Hydrogen nuclei of atoms bound in water molecules have intrinsic 
magnetic moments which nearly align or nearly counteralign with a strong external 
magnetic field, B0. (b) A large population of these spins exhibits a net magnetization that 
is aligned with the external magnetic field. (c) Irradiating the sample with RF radiation at 
the Larmor frequency causes an alteration of this net magnetization which is analogous to 
tipping the magnetization vector out of alignment with the external magnetic field, where 
it will precess about the external magnetic field (d), emitting the detected nuclear 
magnetic resonance signal, or free induction decay (FID). (e) Animal or sample motion 
during acquisition causes artifacts in the reconstructed images that manifest themselves 
as banding in the phase encoding direction (arrows), and are a significant issue in fMRI 
of conscious animals. 
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Table 1 – 1: Profiles of receptor blockade among atypical antipsychotic medications and 
haloperidol 
Drugs that are effective at treating the symptoms of psychosis exhibit a broad 
spectrum of affinity for different receptor types. The effective blockade of different 
receptor types is shown for the typical antipsychotic drug, haloperidol, and several 
atypical drugs which exhibit a broader spectrum of receptor antagonism. The degree of 
blockade is shown by “+” signs, where a larger number indicates a more potent 
antagonism of the receptor subtype. See text for citations regarding the specificity of 
these compounds. 
 
Drug D1 D2 D3 D4 α1 5-HT2 M H1
Haloperidol + +++ ++
Clozapine + ++ + ++ ++ ++ +
Quetiapine ++ + + ++ + +
Risperidone + + +++ + +
Sertindole ++ + +++
Olanzapine + + ++ ++ +
Table 1-1
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Figure 1 – 2: Hemodynamic changes following increased neural activation. 
The hemodynamic changes that result from increased neural stimulation are shown 
in schematic form. Following increased rates of neuronal membrane depolarization, 
vasoactive metabolites and putative neurogenic mechanisms cause the arterioles in the 
microvasculature to dilate with respect to baseline conditions (a). (b) Illustrates the 
increase in microvessel diameter with arrows, and the increase in cerebral blood flow 
(CBF) and cerebral blood volume (CBV) with respect to the baseline state, following 
increased neural stimulation. The resulting increase in blood flow and concomitant 
oxygen supply to the region reliably overcompensates for the increase in metabolic 
demand, and a decrease in deoxyhemoglobin concentration ([dHb]) (b) can be observed 
by MRI. 
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Figure 1 – 3: Continuous Arterial Spin Labeling (CASL) 
(a) Schematic of the arterial spin labeling and control experiments performed in 
CASL to assess blood flow. In the labeling experiment, the magnetization of arterial 
water spins is inverted with respect to the external magnetic field at the location of the 
carotid arteries, and used as an endogenous tracer. In a separate control experiment, the 
same inversion pulse is applied, but in a location outside of the animal, where it fails to 
invert any of the spins in the arterial blood. (b-c) The images acquired from these two 
experiments exhibit small differences that can be visualized when the images are 
combined (subtracted and normalized) (c), providing a measure of cerebral blood flow in 
the imaging planes. (e) This perfusion calculation is typically visualized in false color 
overlay on the original anatomical images. Figure reproduced from (Ferris et al., 2006). 
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CHAPTER II  
MEASURING ΔCMRO2 BY MULTI-MODAL IMAGING IN THE 
ANESTHETIZED RAT 
 
The work presented in this chapter is reproduced with changes in text from (Liu et 
al., 2004). Zhaohui Liu and Dr. Timothy Q. Duong were the primary contributors to this 
work, and it is with great gratitude to them and to other authors that I reproduce these 
results in this dissertation to introduce the technique which motivated much of the 
remaining research and on which much of it is based. My involvement in these studies 
was under the direction of Dr. Duong, where my contributions consisted of participation 
in a portion of the animal experiments, generating the tools enabling the group analysis of 
multisubject data, and the execution of the Monte Carlo simulation of the calculated 
results.  
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Introduction 
The complex relationship between changes in cerebral hemodynamics and changes 
in neural activity warrants careful interpretation of the BOLD signal, and it would be 
beneficial to add the capability to make a more direct measurement of local tissue 
metabolism. In this study, a technique for the non-invasive measurement of changes in 
the cerebral metabolic rate of oxygen (CMRO2) was applied to the anesthetized animal, 
and used to measure localized changes in oxygen metabolism that resulted from an 
electrical sensory stimulus. Under conditions of sensory stimulation, the relationship 
between changes in neural activity and changes in BOLD contrast has been investigated 
with concomitant electrophysiological recordings (Logothetis, 2002). Here we test the 
hypothesis that changes in CMRO2 can also be measured as a surrogate of changing 
neural activity, and that the measured changes in CMRO2 are consistent with those 
reported by others and are a valid measure that can be used in pharmacological studies.  
Theory 
Changes in the BOLD signal, as well as changes in CBF can be measured 
simultaneously using an arterial spin labeling sequence in which the control images are 
BOLD weighted (Silva et al., 1999; Duong et al., 2000). In 1998, Davis and others 
illustrated that CBF and BOLD measurements could be combined with mass 
conservation principles and a biophysical model of changes in T2* that are related to 
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changes in deoxyhemoglobin concentration in order to calculate changes in oxygen 
consumption within the tissue (CMRO2) (Ogawa et al., 1993; Yablonskiy and Haacke, 
1994; Boxerman et al., 1995a; Davis et al., 1998). Subsequently, Hoge and others re-
derived this relationship to produce an algorithmically simpler form that is now used to 
enable MRI based assessment of changes in CMRO2 (Hoge et al., 1999b). By acquiring 
BOLD and CBF changes simultaneously, the addition of a hypercapnic calibration 
experiment before the stimulus being investigated permits the measurement of changes in 
CMRO2 with the same temporal resolution as the original BOLD and CBF 
measurements.   
This methodology for determining ΔCMRO2 via MRI is based upon several 
assumptions that are important considerations in the interpretation of the results of this 
measurement. The relationship between the R2* relaxivity (1/T2*) of tissue has been 
shown to be related to the concentration of dexoxyhemoglobin, local blood volume, and a 
proportionality constant that depends partially on field strength, by Equation 2.1 
(Boxerman et al., 1995a). We assume that the signal change that we are measuring is a 
result of changing venous deoxyhemoglobin (Equation 2.2)  (Boxerman et al., 1995a; 
Hoge et al., 1999b). Assuming mass conservation (i.e. Fick’s law) (Katzung, 2004) we 
can calculate the oxidative metabolism of the tissue as a function of the concentration of 
deoxygenated hemoglobin in the venous outflow (Equation 2.3), where the factor of ¼ 
accounts for the stoichiometry of oxygen and hemoglobin binding (Alberts et al., 2002). 
It has been established that under normal conditions the relationship between CBF and 
CBV is highly predictable, and that these two values are tightly coupled (Equation 2.4) 
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(Grubb et al., 1974). Substituting this relationship into Equation 2.2, a change in BOLD 
contrast is related to a change in R2* due to changing deoxyhemoglobin concentration 
and blood flow by Equations 2.5 and 2.6, providing us with the basis for the solution that 
follows.  
 
[ ]( )*2 vdHBR A CBV dHb β= ⋅        (2.1) 
[ ]( ) [ ]( )*2 0 0v vR A CBF dHb A CBF dHbβ βα αΔ = ⋅ − ⋅      (2.2) 
[ ]( )2 4 vCMRO CBF dHb= ⋅        (2.3) 
αCBFCBV =          (2.4) 
1
*
2 −=Δ Δ⋅− RTEe
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BOLD        (2.5) 
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β βα α
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= ⋅         (2.7) 
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Under isometabolic conditions: 
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    (2.11) 
 
The parameter M is constant and represents the maximal BOLD signal change that 
can be expected from a particular tissue volume given a particular set of baseline 
parameters (Eq. 2.10); it is the scaling factor describing the sensitivity of the BOLD 
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signal to changes in blood flow and oxygen metabolism. Determination of the parameter 
M is possible if both BOLD and CBF are changed and measured while CMRO2 is held 
constant. A hypercapnic challenge has been shown to have little impact on the 
metabolism of local tissue (Horvath et al., 1994; Yang and Krasney, 1995), and we can 
assume that CMRO2 is held constant under mildly hypercapnic conditions while BOLD 
and CBF are modulated from baseline values, permitting determination of the parameter 
M. 
Materials and methods 
Animal Preparation 
Six male Sprague Dawley rats, weighing between 300-375 g, were investigated. 
Rats were anesthetized with 2% isoflurane for surgery and placement into an MR 
compatible stereotaxic headset to prevent motion during the imaging experiments. A 
femoral artery was catheterized using PE-50 tubing, and needle electrodes were inserted 
beneath the skin of the forepaws. The rats breathed spontaneously during the MR 
experiments, without mechanical ventilation. Anesthesia was reduced to 1.2% isoflurane 
during the imaging experiments, and temperature was stabilized to 37 ± 0.5° C using a 
warm water heating pad with feedback from a rectal temperature monitor. Blood pressure 
(BP) was monitored at 5 ms intervals via the arterial catheter using a BioPak digital 
acquisition system (Santa Barbara, CA), and respiration rate (RR) and heart rate (HR) 
were derived from frequency analysis of the BP signal.  
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During the hypercapnic challenge experiments, rats breathed normal air during the 
baseline period, then breathed a prepared mixture containing air and CO2 at 5% 
concentration. During forepaw stimulation experiments, graded stimulation currents of 4 
mA, 6 mA, and 8 mA with a 0.3 ms pulse duration at 3 Hz were used. In four of the six 
rats, pairs of electrodes were configured to permit selective stimulation of individual 
forepaws. In the remaining two rats, both paws were stimulated simultaneously.  
MRI experiments 
The MRI experiments were performed using a 4.7-T/40-cm bore magnet (Oxford, 
UK) equipped with a Biospec console (Bruker Biospin, Billerica, MA), and a 20-G/cm 
gradient insert with a 12cm inner diameter (ID) that is capable of a 120 μs rise time. A 
custom surface coil with a 2.3 cm ID was used for imaging, and a second coil located 
below the carotid arteries of the animal was used for arterial spin labeling (Silva et al., 
1999; Duong et al., 2000). The coils were electronically decoupled during the imaging 
experiments with a switch box that interfaced with the console (Insight Neuroimaging 
Systems, Worcester, MA). High resolution anatomical images were acquired using a fast 
spin-echo pulse sequence (RARE) with the following parameters: TR = 2 s, flip angle = 
90°, RARE factor = 16, effective TE = 104ms, matrix = 128 x 128, FOV = 2.56 x 2.56 
cm, averages = 16, thk = 1.5 mm, and eight slices were acquired.  
Functional images were acquired using the continuous arterial spin labeling 
(CASL) technique (Silva et al., 1999; Duong et al., 2000), allowing simultaneous 
measurement of BOLD and CBF changes. Images were acquired using a single shot 
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gradient echo (GE) echo planar imaging (EPI) imaging sequence, with the following 
parameters: matrix = 64 x 64, FOV = 2.56 x 2.56 cm, TE = 15ms, TR = 2s, flip angle = 
90°, thk = 1.5 mm, and eight slices were acquired, consistent with the geometry of the 
anatomical images. During arterial labeling, a 1.78 s square radiofrequency pulse was 
applied to the labeling coil in the presence of a 1.0 G/cm gradient along the direction of 
blood flow, satisfying the adiabatic inversion condition (Dixon et al., 1986; Williams et 
al., 1992). During control images, the frequency of the labeling pulse was offset and 
corresponded to a location outside of the anterior end of the animal, in a location 
symmetrically opposed to the center of the imaging planes. Labeled and control images 
were acquired sequentially, and 31 pairs of images were acquired during the baseline 
period and an additional 31 pairs were acquired during the hypercapnic challenge or 
forepaw stimulation epochs. 
Data analysis 
Data were analyzed using Stimulate (Strupp, 1996) and Matlab (MathWorks, Inc. 
Natick, MA) software packages, and repeated BOLD and CBF measurements within the 
same animal were averaged during the baseline and stimulation epochs. BOLD images 
were obtained from the control (unlabeled) images from the functional image sequence, 
and a CBF image time series was created by calculating the voxelwise CBF using 
equation 1.07, with the following values: T1 =  1.54 s, λ = 0.9, α = 0.7.  Cross-correlation 
analysis was performed on the BOLD, VBF and CMRO2 data sets to obtain percent-
change activation maps. For the calculation of CMRO2 maps, equation 2.12 was used, 
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and the value of the parameter M was determined for each voxel using the hypercapnic 
challenge data and equation 2.11. The values of the parameters in equations 2.11 and 2.12 
were: α = 0.38 (Mandeville et al., 1999) and β = 1.5 (Boxerman et al., 1995b; Davis et al., 
1998).   
1
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  (2.12) 
Regions of interest (ROI) were analyzed by defining the areas containing the 
primary and secondary somatosensory regions on the anatomical images using a rat brain 
atlas (Paxinos and Watson, 1998), and by transferring these areas to calculated maps to 
extract the mean changes in BOLD, CBF, CMRO2 for the average and timecourse 
measurements reported herein. The effects of noise on the parameter M and the change in 
CMRO2 measurements were analyzed using Monte Carlo simulation and custom software 
written in the Java programming language (Sun Microsystems, Inc., San Jose, CA). Data 
from 1 and 9 voxel ROIs in the somatosensory region were used as inputs to the 
simulation. The input parameters for the simulation were as follows: For hypercapnia 
using the 1 voxel ROI, ΔBOLD = 3.6% ± 0.9% and ΔCBF = 208% ± 55%. For 
hypercapnia using the 9 voxel ROI, ΔBOLD = 4.7% ± 0.4% and ΔCBF = 189% ± 24%.  
For 6 mA stimulation using the 1 voxel ROI, ΔBOLD = 0.9% ± 0.8% and ΔCBF = 73% 
± 45%, and for 6 mA stimlulation using the 9 voxel ROI, ΔBOLD = 3.3% ± 0.3% and 
ΔCBF = 163% ± 16% (mean ± standard deviation). Simulations were also performed 
with an artificial increase of the standard deviation of measurements from the 9 voxel 
ROI by a factor of 3.  
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Raw EPI image data sets from all subjects were manually aligned and averaged 
together using custom software (Schmidt et al., 2004), and BOLD, CBF, M, and CMRO2 
maps were calculated from coregistered datasets. Activation maps following unilateral 
stimulation revealed a bilateral response and, consequently, equal numbers of right paw 
stimulation (N = 2), left paw stimulation (N = 2), and both paw stimulation (N = 2) data 
sets were averaged together to produce the group average activation maps shown in 
Figure 2 – 2.   
Results  
Following stimulation at 4 mA, there were no statistically significant changes in 
mean arterial blood pressure (MABP), HR, or RR relative to baseline. At 6 mA, there 
were small and transient changes in HR (P = 0.06) and MABP (P = 0.01) immediately 
following the onset of stimulation, but these changes became insignificant, returning to 
near baseline levels, during the sustained stimulation period. At 8 mA, there was a large 
transient increase in HR (P < 0.01) and MABP (P < 0.01) and both measurements 
remained elevated during the stimulation period. Table 2-1 indicates the magnitude of 
changes observed during the stimulation period, in comparison to the baseline period 
before the onset of stimulation.  
Figure 2-1 illustrates anatomical images, CBF maps, M maps, and ΔBOLD, ΔCBF, 
and ΔCMRO2 activation maps for a single subject in which both forepaws were 
simultaneously stimulated. The value of the parameter M was heterogeneous throughout 
the brain, with larger values of M observed near the ventricles, cortical surface, and 
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around large draining veins. The average value of M in the primary somatosensory 
cortices was 0.05 ± 0.01 (mean ± standard deviation, N = 6). The ΔBOLD, ΔCBF, and 
ΔCMRO2 activation maps show a bilateral activation in the primary and secondary 
somatosensory cortices. This bilateral activation is clearly visible in the averaged, 
coregistered maps (Figure 2-2) , where the primary and secondary somatosensory cortices 
are clearly delineated as the most significantly active structures. While the ΔBOLD 
activation map shows enhanced activation near the cortical surface of the somatosensory 
coritices (Figure 2-2), the more uniform activation shown in these regions in the ΔCBF 
and ΔCMRO2 activation maps reflects a reduced sensitivity of the CBF measurement to 
the effects of cortical surface vessels. There were no statistically significant negative 
changes observed in BOLD, CBF, or CMRO2 activation maps of the individual or group 
averaged data.   
Figure 2-3, panel a illustrates the dynamic changes in BOLD and CMRO2 that 
accompany stimulation at various currents, measured from the somatosensory regions of 
a representative subject.  Changes in BOLD and CMRO2 increased with increasing 
stimulation amplitude in a manner that was consistent between animals. Figure 2-3, panel 
b summarizes the group average changes in BOLD (0.5% ± 0.2% at 4 mA, 1.4% ± 0.3% 
at 6 mA, and 2.0% ± 0.3% at 8 mA), CBF (23% ± 6% at 4 mA, 58% ± 9% at 6 mA, and 
87% ± 14% at 8 mA), and CMRO2 (14% ± 4% at 4 mA, 24% ± 6% at 6 mA, and 43% ± 
11% at 8 mA). The group average baseline measure of CBF was 0.91 ± 0.13 ml/g/min, 
consistent with previously reported values for the rat brain under 1.2% isoflurane 
anesthesia (Duong et al., 2001).  
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BOLD changes vs. CBF changes and CMRO2 changes vs. CBF changes were 
linearly correlated across the ranges observed for all stimulation amplitudes (Figure 2-4). 
Changes in CBF vs. changes in CMRO2 were linear with a proportionality of 2.2:1, and 
changes in CBF vs. changes in BOLD were linear with a proportionality of 40:1. While 
there was some overlap in the ranges of BOLD, CBF, and CMRO2 changes for each 
stimulation amplitude among the entire group, the mean values of changes of these 
measures were reasonably segregated (Figure 2-4).  
Monte Carlo simulation was performed to assess the propagation of noise through 
Equations 2.11 and 2.12 to assess the shape of the error distribution in measured changes 
in CMRO2, in order to investigate possible bias introduced by the nonlinear propagation 
of errors in Equation 2.12.  The results of these simulations are shown in Figure 2-5. Of 
note is the increasing skew of the M distribution with increasing width (SD) of the input 
parameters, introducing a bias toward lower M values with increasing noise in the 
original measurements of BOLD and CBF changes (Figure 2-5). This bias is nearly 
eliminated, however, with the subsequent CMRO2 calculation (Figure 2-5), a property 
that was also reported in the original work reporting this model (Davis et al., 1998).   
Discussion 
The data presented in this investigation illustrate localized increases in CMRO2 
following sensory stimulation over a range of stimulation amplitudes that were measured 
non-invasively using MRI and a biophysical model of the BOLD signal. Additionally, the 
simultaneous measurement of changes in both BOLD and CBF using the CASL 
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technique permits the measurement of changes in CMRO2 to be made with high temporal 
resolution, comparable to that of traditional functional MRI experiments that rely on 
BOLD or CBF changes alone. This technique holds promise for the investigation of 
metabolic changes induced by pharmacological stimuli, where additional insights into the 
origin of observed changes in hemodynamics may be necessary to deduce changes in 
underlying neural activity.  
The results of these estimated changes in CMRO2 are in general agreement with 
changes in CMRO2 reported using other measurement techniques. Using PET and the 
Kety-Schmidt method, a 5% change in CMRO2 was reported following visual stimulation 
in the human cortex (Fox et al., 1988), summarily ΔCMRO2 values of 16% (Davis et al., 
1998), 25% (Hoge et al., 1999a; 1999b), and 16% (Kim et al., 1999) were measured by 
calibrated MRI in the human cortex following visual stimulation, and CMRO2 changes of 
19% (Mandeville et al., 1999) reported following electrical sensory stimulation in rat 
measured by calibrated fMRI.  An advantage of calibrated fMRI measurement of CMRO2 
changes is the direct measurement of the parameter M which contains several 
physiological variables that would otherwise need to be estimated (see the definition of 
M in equation 2.10). This may explain the general consistency of the calibrated 
functional MRI results in comparison to the reported value of 5% in Fox et al.’s 1988 
PET study. Thalamic activation was not observed to be significant at the thresholds used 
for delineating sensory activation, consistent with a reduced BOLD response from these 
regions with respect to primary and secondary somatosensory regions (Keilholz et al., 
2004). 
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Monte Carlo simulation of the ΔCMRO2 measurement confirms the non-linear 
propagation of noise present in the original measurements (ΔBOLD and ΔCBF), 
highlighting the challenge to maintain adequate sensitivity in experiments measuring 
ΔCMRO2. However, skew in the probability distribution of the calculated parameter M is 
ablated by the subsequent calculation of ΔCMRO2, which appears to be normally 
distributed, suggesting that strategies for increasing the statistical power of the original 
measurements of ΔCMRO2 (e.g. multiple subjects and ROI analysis of many voxels) will 
not bias final measurement. 
This study demonstrates the use of calibrated functional MRI for the measurement 
of changes in CMRO2 following sensory stimulation in spontaneously breathing, 
isoflurane anesthetized rats. The measurements of CMRO2 changes in this study under 
the least intense electrical stimulation are consistent with reported changes in CMRO2 
resulting from a visual sensory stimulus in conscious humans. Changes in CMRO2 
increased with increasing stimulus intensity in a linear fashion, and changes in CMRO2 
were observed to be linearly correlated with changes in BOLD and CBF under the 
conditions studied. The ability to perform this measurement in a single experimental 
setting, by measuring BOLD and CBF changes simultaneously, suggests that the 
technique will be valuable in other applications, including fMRI of pharmacological 
challenges where the repeated administration of drug doses may be impractical.    
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Table 2 – 1: Respiration rate, heart rate, and mean arterial blood pressure during 
baseline and electrical forepaw stimulation 
Physiological measurements of respiration rate (RR, breaths per minute), heart rate 
(HR, beats per minute), and mean arterial blood pressure (MABP, mmHg) during 
baseline, 4 mA, 6 mA, and 8 mA electrical forepaw stimulation in the anesthetized rat are 
shown. Significant increases in HR and MABP were observed following stimulation with 
6 mA or 8 mA, but no significant changes in RR were observed or in any physiological 
parameters following stimulation at 4 mA. Table reproduced from (Liu et al., 2004). 
 
Table 2-1
Current
Baseline 61 ± 15 394 ± 35 135 ± 6
4 mA 62 ± 18 386 ± 26 (387 ± 32) 136 ± 6  (136 ± 4)
6 mA 64 ± 15 405 ± 37 (406 ± 39)* 139 ± 11 (141 ± 6)**
8 mA 64 ± 18 415 ± 38** (419 ± 44)** 143 ± 6**  (148 ± 8)**
RR HR MABP
Mean ± SD, N = 6. Values in parentheses are maximum changes in transient signal following stimulation onset. 
Statistical significance of comparisons with baseline are indicated. * P=0.06; ** P < 0.01, two tailed, paired t-test. 
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Figure 2 – 1: Anatomical images, quantitative CBF, the parameter M and changes in 
BOLD, CBF, and CMRO2 following electrical forepaw stimulation from a single 
animal 
Anatomical images at three locations from rostral (left) to caudal (right), the 
quantitative CBF images, the calculated parameter M, and changes in CBF, BOLD, and 
CMRO2 following 6 mA electrical forepaw stimulation in a single animal are shown.  
Changes are mapped on a voxelwise basis, and reflect activation in areas consistent with 
those expected from electrical forepaw stimulation (i.e. primary and secondary 
somatosensory regions). Statistical thresholds were used to eliminate background effects 
and insignificant activation. Gray scale: CBF values  0–3 ml/g/min. Color scale: M 1–
20%, CBF 80–200%, BOLD 2–10%, CMRO2 20–100%. Boxes indicate the regions 
measured and reported in Figure 2-3. Figure reproduced from (Liu et al., 2004). 
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Figure 2 – 2: Group average EPI images, quantitative CBF, and changes in CBF, 
BOLD and CMRO2 
Datasets were coregistered and combined to visualize effects that are significant at 
the group level. The result of the coregistration process is shown in the combined EPI 
images, and the resulting group average CBF map.  The group average changes in CBF, 
BOLD, and CMRO2 maps following 6 mA electrical forepaw stimulation reflect a 
reliable activation of the primary and secondary somatosensory regions and cingulate 
cortex.  Statistical thresholds were used to eliminate background effects and insignificant 
activation. Gray scale: CBF values  0–3 ml/g/min. Color scale: M 1–20%, CBF 80–
200%, BOLD 2–10%, CMRO2 20–100%. Figure reproduced from (Liu et al., 2004). 
 
 
 53 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – 3: Dynamic changes in BOLD, CBF, and CMRO2. 
(a) Changes in time in BOLD signal contrast, CBF, and CMRO2 were measured 
from the ROIs indicated in Figure 2 -1. Bilateral activation following unilateral 
simulation permitted the averaging of signal changes from bilateral ROIs in all stimulus 
conditions. The magnitude of changes is dependent on the degree of stimulation in (a) an 
individual representative animal, and (b) at group level when measured from all animals. 
Error bars = SEM, N = 6. Significance was calculated using a two tailed t-test with a 
Bonferroni multiple comparisons correction. Figure adapted from (Liu et al., 2004).
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Figure 2 – 4: Changes in BOLD, CBF and CMRO2 are correlated over the observed 
ranges of signal change. 
Changes in BOLD, CBF, and CMRO2 in the somatosensory cortex are linearly 
correlated over the ranges observed, consistent with the biophysical model. Average 
changes in these measures from all animals for each of the stimulation amplitudes (N = 6) 
are shown as crosses, bars indicate SEM. The CBF:BOLD and CMRO2:CBF ratios were 
40:1 and 2.2:1, respectively, assuming a linear relationship within the ranges observed. 
Figure reproduced from (Liu et al., 2004). 
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Figure 2-5
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Figure 2 – 5: Monte Carlo simulation of error propagation through the biophysical 
model  
Experimental data was used as input to a Monte Carlo simulation to determine error 
propagation through the biophysical model used for the measurement of changes in 
CMRO2. Probability (arbitrary units) is indicated on the vertical axis, and parameter 
values are indicated on the horizontal axes. ΔCMRO2 values are shown as percentages. 
Skew was observed in the distribution of the calculated parameter M (left panel) with 
increasing standard deviation (SD), with values trending toward lower than mean. This 
skew was summarily corrected in the calculation of changes in CMRO2 (right panel), 
which appeared to be normally distributed, but increases in the variance of ΔCMRO2 
measurements are non-linear with respect to the variances of the input measurements 
(ΔBOLD and ΔCBF), consistent an analytical analysis of error propagation. Figure 
reproduced from (Liu et al., 2004). 
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CHAPTER III 
MEASUREMENT OF CHANGES IN CMRO2 FOLLOWING COCAINE 
ADMINISTRATION IN THE ANESTHETIZED RAT 
The work presented in this chapter is reproduced with minor changes in text from 
(Schmidt et al., 2006). This work was conducted under the direction of Dr. Timothy Q. 
Duong, and it is with great gratitude to him and to other authors that I reproduce these 
results in this dissertation. My contributions to this work consisted of participation in a 
portion of the animal experiments, generating the tools and completing the analysis of the 
presented data, and synthesizing the text of the published manuscript with significant 
assistance and contributions from Dr. Duong and other authors.  
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Introduction 
If changes in CMRO2 yield a reliable surrogate of changing neural activity under 
conditions of sensory stimulation, does the same measurement following the 
administration of cocaine yield results that are consistent with cocaine’s action on the 
nervous system? Cocaine is a psychostimulant that is frequently abused and has 
reinforcing characteristics that can establish a state of addiction characterized by 
motivated drug-seeking behavior and by a loss of the ability to control use (American 
Psychiatric Association, 1994). Cocaine-mediated activation of the mesolimbic dopamine 
system has been observed using a variety of techniques (Porrino et al., 1988; Stein and 
Fuller, 1992; Marota et al., 2000), and these and other studies have illustrated the 
complexity of the brain’s response to cocaine, whereby activation occurs in many brain 
regions beyond the dopaminergic reward pathway (Bardo, 1998; Nestler, 2002; Kelley, 
2004). The successful development of therapies to treat addiction to psychostimulants 
such as cocaine and methamphetamine may require detailed information about the 
changes in neural activity that these drugs induce in other large-scale neural networks 
throughout the brain (O'Brien, 2003), and the acquisition of this information may be 
facilitated by experimental techniques that are able to observe changes in neural activity 
in vivo following administration. 
Functional MRI can be used to map brain function at higher spatial and temporal 
resolution than other modalities such as positron emission tomography (PET). Traditional 
fMRI experiments infer changes in neural activity from changes in surrogate signals such 
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as blood-oxygenation-level-dependent (BOLD) contrast, cerebral blood flow (CBF), and 
cerebral blood volume (CBV). While studies based on changes in BOLD contrast 
comprise the majority of published fMRI research, the relationship of BOLD contrast to 
neural activation is complex, and the interpretation of BOLD signal changes may be 
complicated by the presence of pharmacological agents that could affect physiology and 
the cerebral vasculature independently of changes in neural activity.  
The use of fMRI to investigate cocaine’s effects on neural circuitry in humans and 
in animal models have been reported (Breiter et al., 1997; Luo et al., 2003; Honey and 
Bullmore, 2004). Systemic administration of cocaine and other pharmacological agents 
can cause significant changes in cardiovascular physiology (Pitts et al., 1987) and 
changes in vascular tone, potentially modulating the fMRI signals independently of 
changes in neuronal activity (Gollub et al., 1998; Marota et al., 2000; Kaufman et al., 
2001; Stein, 2001). 
In addition to conventional BOLD fMRI, changes in cerebral metabolic rate of 
oxygen (CMRO2) could also be estimated to serve as a metabolic marker for changes in 
neural activity (Hyder, 2004). Stimulus-evoked changes in CMRO2 can be estimated 
from BOLD and CBF measurements using a biophysical model of the BOLD signal (See 
Chapter II) and a brief hypercapnic challenge that does not alter neural metabolism but 
does modulate CBF and BOLD contrast (Kety and Schmidt, 1948; Hafkenshiel and 
Friedland, 1952), revealing the regionally specific coupling of changes in CBF to changes 
in BOLD under isometabolic conditions. By combining the measured proportionality of 
changes in CBF to changes in BOLD contrast, the change in CMRO2 can be estimated. 
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This non-invasive technique offers several advantages over PET-based measurements by 
eliminating the need for a radioactive tracer and by enabling the measurement of dynamic 
changes in CMRO2, and has been used to estimate changes in CMRO2 following sensory 
stimulation in humans (Ogawa et al., 1993; Davis et al., 1998; Hoge et al., 1999b; Kim et 
al., 1999) and in animal models (Mandeville et al., 1999; Liu et al., 2004). 
In this study, we used the CMRO2 technique to monitor changes in neural 
metabolism following the administration of cocaine, to test the hypothesis that changes in 
CMRO2 can be measured as a surrogate of changing neural activity following a 
pharmacological challenge. Changes in CBF and BOLD contrast were measured 
simultaneously (Silva et al., 1999; Duong et al., 2000), requiring only a single 
administration of cocaine to enable estimation of changes in CMRO2. This may be an 
important feature in pharmacological investigations where drug challenges can not be 
administered repeatedly within the same animal, due to slow rates of drug clearance, 
sensitization or desensitization, or other physiological adaptations that make the response 
irreproducible over time  
Materials and methods 
Animal Preparation.  
Eleven male Sprague-Dawley rats weighing 300-375g that had not previously been 
exposed to cocaine were investigated. Rats were anesthetized with 2.5% gaseous 
isoflurane (Phoenix Pharmaceutical, St. Joseph, MO) during surgery and placed into a 
stereotaxic headset for immobilization during scanning. Isoflurane was reduced to 1.2% 
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during imaging experiments. Catheters were inserted into the left femoral vein and artery 
for the administration of cocaine and saline, and for monitoring physiology, respectively. 
Heart rate (HR), mean arterial blood pressure (MABP), and respiration rate (RR) were 
measured continuously during the MR experiment and recorded using a digital data 
acquisition system (Biopak Systems, Inc. Santa Barbara, CA). The MABP signal was 
analyzed for high and low frequency oscillations to determine HR and RR, respectively. 
Prior to the cocaine challenge experiments, a hypercapnic (5% CO2) challenge 
experiment was performed for the derivation of the calibration parameter (M) map (Davis 
et al., 1998). During the cocaine challenge experiments, a dose of 1.0 mg/kg in a 1.0 
ml/kg saline vehicle was administered intravenously over a period of approximately 10s. 
MRI Experiments. 
BOLD and CBF measurements were made on a 4.7T/40cm bore magnet (Oxford, 
UK), Bruker Biospec console (Bruker BioSpin, Billerica, MA), using a 20-G/cm gradient 
insert with a 12cm inner diameter (ID), capable of a 120-μs rise time. A 2.3cm ID surface 
coil was used for brain imaging and a separate neck coil for arterial spin labeling as 
previously described (Silva et al., 1999; Duong et al., 2000; Liu et al., 2004). Functional 
images were acquired with a single shot, gradient echo, echo-planar imaging (EPI) 
sequence in the presence (labeled images) and absence (control images) of arterial spin 
inversion. Arterial spin inversion was accomplished with a 1.7s hard radio frequency 
pulse (square pulse) applied to the neck coil in the presence of a 1.0 G/cm gradient along 
the direction of blood flow, in order to satisfy the adiabatic inversion condition (Williams 
et al., 1992). The frequency offset of the hard pulse was determined to excite arterial 
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spins within the carotid arteries. During the acquisition of control images, the sign of the 
frequency offset of the hard pulse was reversed (corresponding to a location outside of 
the animal) to control for magnetization transfer contrast unrelated to arterial spin 
labeling (Detre et al., 1992; Williams et al., 1992). Pairs of control and labeled images 
were acquired continuously throughout each experiment.  Sequence parameters were: 
data matrix=64 x 64, field of view (FOV)=2.3 cm x 2.3 cm, eight 1.5 mm thick slices, 
TE=15ms, and TR=2s. During the hypercapnic challenge experiments, 30 pairs of images 
were acquired during baseline and an additional 30 pairs of images were acquired 
following the administration of 5% CO2. During the cocaine challenge experiments, 50 
paris of images were acquired during baseline, and an additional 160 pairs acquired 
following the administration of cocaine. Anatomical images were acquired at higher 
resolution (128 x 128) using a RARE sequence, and used for co-registration of the 
functional images to a digital atlas (Paxinos and Watson, 1998). 
Data analysis. 
Custom software was developed in the Java programming language (Sun 
Microsystems, Inc., San Jose, CA) for data analysis. A BOLD image time series was 
derived from the control images, and a CBF image time series was generated by 
calculating CBF on a voxel by voxel basis as previously described (Silva et al., 1999). 
BOLD and CBF time series were analyzed for each voxel using a generalized linear 
model approach (Worsley and Friston, 1995) with a single step boxcar model as the input 
function for both the hypercapnic and cocaine challenge experiments. P values reflecting 
the likelihood of observing the timecourse correlation with the model among random data 
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were generated for each voxel, and used as thresholds. Percent change maps of BOLD 
and CBF changes following CO2 or cocaine administration were generated from voxels 
with P values less than 0.001, and all other voxels were set to zero percent change to 
reduce artifacts caused by noise in the calculated CMRO2 maps.  In Fig. 3 – 2, BOLD and 
CBF timecourses from a single subject were normalized by division with the average 
BOLD or CBF value from the 40 baseline repetitions, and ΔCMRO2 were calculated 
independently for each repetition.  
The biophysical model of the BOLD signal described in chapter II was used in 
conjunction with the hypercapnic calibration scans and M map to calculate ΔCMRO2 
maps (Davis et al., 1998; Hoge et al., 1999a) . Equations 2.10 and 2.11 recapitulate the 
formulae used in this calculation, and the variables α and β were assigned the values 0.38 
(Ueki et al., 1988) and 1.5 (Madsen et al., 1998), respectively. In the calculation of the M 
map, voxels which contained physiologically meaningless M values (imaginary values, 
negative values, and infinite values) were identified and excluded from subsequent map 
and ROI calculations. 
Each slice was manually co-registered to an atlas (Paxinos and Watson, 1998) 
using custom software (Schmidt et al., 2004) and the following degrees of freedom: x and 
y translation, independent x and y scaling, and rotation about the z axis. The original 
images were resampled in the transformation to the atlas coordinate system, and a new 
set of images that was anatomically coincident with the atlas were created. Regions of 
interest were defined and used to measure average values from the ΔCBF, ΔBOLD, 
ΔCMRO2, and M maps of each subject for the measurements presented in Table 3 – 1. 
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The ROIs analyzed using this method were: periaqueductal gray (PAG), substantia nigra 
(SN), ventral tegmental area (VTA), hippocampus (HIP), primary somatosensory cortex 
(S1), ventral posterolateral thalamic nucleus (VPL), lateral globus pallidus (LGP), 
cingulate cortex (CG), nucleus accumbens (NAc), and striatum. In Figure 3 – 1, 
calculated maps co-registered to the atlas coordinate space were averaged together on a 
voxel by voxel basis for visualization. 
Results 
Mean arterial blood pressure (MABP) increased from 113 ± 14 mmHg (mean ± 
standard deviation, N = 8) to 137 ± 33 mmHg (p < 0.05) following the injection of 
cocaine, and remained elevated at 119 ± 15 mmHg for up to 2 minutes thereafter 
(P<0.05). Respiration rate increased from the baseline level of 81 ± 7 to 89 ± 8 breaths 
per minute (bpm) during the injection, and summarily increased to 103 ± 16 bpm 1 to 2 
min after the injection. Within 5 minutes following the injection, MABP, RR, and HR 
returned to baseline levels.  
 Figure 3-1 illustrates group average changes observed in BOLD, CBF, and 
calculated CMRO2, and the group average value of the parameter M, overlaid on top of 
co-registered anatomical images; areas outside of the brain were masked. The parameter 
M, representing the maximum expected BOLD response from the tissue volume, varied 
between 8% and 17% throughout the regions investigated, consistent with previously 
conducted studies under similar experimental conditions (Liu et al., 2004). Due to the 
significant extravascular contribution to the T2* BOLD signal by large veins, the 
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parameter M was observed to be considerably higher in the vicinity of large diameter 
cortical draining veins, consistent with observations in humans (Davis et al., 1998) and 
rats at 4.7T (Liu et al., 2004) and 11.7T (Keilholz et al., 2006) field strengths. The spatial 
distribution of the parameter M did not vary significantly between subjects, hence, an 
average M map was calculated for nine subjects (Figure 3-1, panel M, Table 3-1). S1 and 
CG exhibited larger increases than midbrain nuclei, and only a moderate increase was 
observed in the hippocampus. Modest, but significant increases in CBF within the VTA 
and SN must be interpreted caustiously because of low signal to noise, susceptibility 
artifacts, and partial volume effects in these regions. Changes in CMRO2 after cocaine 
administration were positive in all regions of the brain studied, ranging from 17% to 38% 
(Table 3-1 and Figure 3-1, panel ΔCMRO2). Along the cortical surface a decrease in 
BOLD was often observed while CBF and calculated CMRO2 changes were observed to 
be positive, suggesting that the negative BOLD signal change within these cortical areas 
is not the result of image or motion artifacts (Figure 3-1, red box). The time courses of 
BOLD, CBF, and CMRO2 changes for a representative subject (Figure 3-2) illustrate the 
rapid and sustained increasees in BOLD and CBF within S1, while the increases in these 
measures were considerable smaller in the NAc.  
The parameter M relates changes in CBF and BOLD to changes in oxidative 
metabolism, and the BOLD and CBF changes observed for several ROIs with M values 
of 0.10 ± 0.02 are indicated in Figure 3-3. Iso-contour lines in Figure 3-3, panel a 
illustrate the expected changes in BOLD and CBF for given changes in CMRO2 within a 
region having an M value of 0.10 and illustrate that negative changes in BOLD may be 
 66 
observed in regions experiencing dramatically increased oxidative metabolism, 
potentially leading to erroneous inferences made from BOLD measurements alone. 
Changes in CBF and CMRO2 were linearly correlated by a ratio of approximately 2.8:1 
(Pearson’s r = 0.92) (Figure 3-3, panel b), and BOLD and CMRO2 were also linearly 
correlated (r = 0.79) (Figure 3-3, panel c). Two regions, the VTA and PAG, exhibited a 
negative and near-zero BOLD response but showed a significant increase in CBF, 
corresponding to an increase in CMRO2 (Figure 3-3, panel c). One region, the SN, 
deviated significantly from the correlative relationship observed between changes in 
BOLD, CBF, and CMRO2 exhibited by the other regions investigated, suggesting that the 
large increase in BOLD observed in this ROI may be an artifact. 
Discussion 
This study demonstrates the use of BOLD, CBF, and CMRO2 functional MRI after 
intravenous cocaine administration in the anesthetized rat with concomitant physiological 
measurements (MABP, HR, and RR). Cocaine evoked significant and heterogeneous 
changes in BOLD, CBF, and CMRO2 within the mesocortical limbic pathway and 
throughout other regions of the brain. With the exception of negative BOLD changes in 
some cortical surface areas, and within the VTA, BOLD, CBF, and CMRO2 changes 
were positive. Brain regions exhibiting increases in CMRO2 are consistent with regions 
identified as having increased metabolism of glucose in 2-deoxyglucose autoradiography 
studies reported previously (Porrino et al., 1988), and the changes in CBF that were 
observed are consistent with previously reported results (Stein and Fuller, 1992).  
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BOLD fMRI of cocaine using similar doses has been previously reported in rats 
(Chen et al., 2001; Mandeville et al., 2001; Luo et al., 2003), although the magnitude and 
sign of the BOLD responses varied between labs. Negative BOLD near the surface of the 
cortex (but not in the subcortical structures) associated with cocaine challenge was 
consistently observed in the present study. Such negative BOLD could be due to a 
marked cocaine-evoked increase in deoxyhemoglobin concentration in the large draining 
veins on the cortical surface (Krings et al., 1999). The susceptibility effects of high 
deoxyhemoglobin concentration in these veins would be enhanced at higher field 
strength, such as the 4.7T field strength used in this study. Spin-echo BOLD experiments 
which are less sensitive to macrovascular contributions (Duong et al., 2003) could be 
used to further investigate the origin of this negative BOLD signal, and may improve the 
estimation of changes in CMRO2 by suppressing macrovascular contributions, and 
preventing a possible overestimation of changing CMRO2 in these regions.  
While others have reported scattered negative BOLD responses throughout the 
brain (Luo et al., 2003), our previous work with forepaw stimulation under similar 
experimental conditions (Liu et al., 2004) did not show negative BOLD changes on the 
cortical surface. This suggests that the negative BOLD effect observed here is biological 
in origin and related to the effects of systemic cocaine challenge. Mandeville and others 
(Mandeville et al., 2001) did not observe significant negative BOLD changes at 2T. 
These differences may be due to differences in experimental conditions (e.g. anesthetics 
and ventilation protocols) and possibly may be due to magnetic field dependent effects. 
Anesthesia, in particular has been shown to impact the measured BOLD signal (Sicard et 
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al., 2003). Additionally, variations in the reported values of BOLD signal changes 
between labs may suggest that BOLD fMRI is more susceptible to non-neural 
physiological phenomena and the precise experimental conditions, than to changes in 
neural activity alone. For example, BOLD signal change is strongly dependent on 
baseline CBF and blood oxygenation (Sicard et al., 2003; Uludag et al., 2004).  
Vasoconstriction has been reported following cocaine administration (Kaufman et al., 
2001; Luo et al., 2003) and has been shown to cause negative changes in BOLD and CBF 
(Gollub et al., 1998). This explanation of the negative BOLD observed in this study is 
difficult to reconcile with the consistent observation of increased CBF in pertinent 
regions.  
In contrast to changes in BOLD, reported changes in CBF following cocaine 
administration are reasonable consistent between laboratories, despite differences in 
experimental conditions, anesthetics, and measurement techniques. Positive CBF 
increases were observed throughout the brain and were particularly pronounced in the 
neocortices. Our results are in good agreement with increases in CBF after cocaine 
administration measured by using [14C]iodoantipyrene in awake rats (Stein and Fuller, 
1992). Our estimated CBV changes, obtained from CBF changes and the Grubb et al.’s 
relation (Grubb et al., 1974) in the cingulate gyrus (CG), nucleus accumbens (NAc), 
motor cortex (S1), dorsal thalamus (VPL), and striatum are linearly correlated (r = 0.96) 
with the CBV changes measured using a monocrystalline iron oxide nanocolloid (MION) 
contrast agent (Marota et al., 2000), although our estimated CBV changes were 
consistently larger (Figure 3-4).   
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Non-invasive CMRO2 fMRI offers a valuable surrogate measure of neural 
activation. Increased neural activity has been shown to be correlated with an increased 
rate of glucose metabolism (CMRGlu) (Kennedy et al., 1976; Sokoloff et al., 1977) and 
CBF (Jones et al., 2004), however, the magnitude of stimulus-evoked changes in CMRO2 
remains controversial. Original work using PET revealed a lower than expected change in 
CMRO2 with increasing neural activity (Fox et al., 1988), while other reports have 
indicated a potent (200% - 400%) increase in CMRO2 following increased neural activity 
(Hyder et al., 1996), fueling the debate as to whether increases in metabolic demand 
within the neuropil are satisfied by aerobic or anaerobic metabolism of glucose. A recent 
investigation of this question suggests that neural metabolism during stimulation is 
primarily oxidative, and that anaerobic processes within the astrocytes primarily function 
to supply neurons with lactate for oxidative degradation to ATP (Kasischke et al., 2004), 
lending credence to the viability of CMRO2 as a marker for neural activity. Although 
CMRO2 changes associated with cocaine administration have not been reported 
previously for comparison, the magnitudes of CMRO2 changes reported herein were 
consistent with those reported using various sensory stimuli.  
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Figure 3 – 1: Group average changes in BOLD, CBF, estimated CMRO2. 
BOLD, CBF, and CMRO2 changes are shown for all subjects (N = 11) and the 
mean calibration parameter M (N = 9) in the anesthetized rat brain following intravenous 
administration of 1.0 mg/kg cocaine. Color scales to the right indicate the extent of 
positive and negative changes, or the value of the parameter M. ROIs used in the 
quantitative analysis reported in Table 3 – 1  are indicated on the anatomical images. 1—
Periaqueductal gray (PAG); 2—substantia nigra (SN); 3—ventral tegmental area (VTA); 
4—hippocampus (Hip); 5-primary somatosensory cortex (S1); 6—ventral posterolateral 
thalamic nucleus (VPL); 7—lateral globus pallidus (LGP); 8—cingulate cortex (CG); 9—
nucleus accumbens (NAc); 10—striatum. A cortical ROI which exhibited negative 
changes in BOLD but positive changes in CBF and CMRO2 is indicated by a red box. 
Figure reproduced from (Schmidt et al., 2006). 
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Table 3 – 1: Quantitative changes in BOLD, CBF, estimated CMRO2 and the parameter 
M in various regions of interest following intravenous administration of 1.0 mg/kg 
cocaine.  
Significance was determined against baseline using a two tailed t-test without a 
multiple comparisons correction. Table reproduced from (Schmidt et al., 2006). 
 
 
 
Table 3-1
PAG 0.05 ± 0.005 0.1 ± 0.2* 16 ± 1 5 ± 0 10 ± 3
SN 0.17 ± 0.01 5.4 ± 1.0 25 ± 5 5 ± 1 12 ± 3
VTA 0.16 ± 0.02 -1.2 ± 0.5 14 ± 3 4 ± 1 14 ± 2
Hip 0.11 ± 0.005 1.5 ± 0.2 52 ± 4 16 ± 1 24 ± 3
S1 0.12 ± 0.01 3.7 ± 0.2 150 ± 9 39 ± 1 46 ± 3
VPL 0.11 ± 0.01 2.5 ± 0.2 80 ± 6 21 ± 1 24 ± 4
LGP 0.08 ± 0.01 1.4 ± 0.1 49 ± 3 15 ± 1 17 ± 2
CG 0.18 ± 0.01 3.6 ± 0.4 128 ± 9 33 ± 2 55 ± 5
NAc 0.09 ± 0.01 0.6 ± 0.2* 64 ± 7 15 ± 1 34 ± 5
Striatum 0.11 ± 0.01 1.6 ± 0.2 80 ± 6 21 ± 1 33 ± 3
          ‡  Percent change in CBV maps are calculated according to: 1+ CBV % change = (1+ CBF % change) 0.38 P > 0.01  *
          †  Percent change maps calculated using a single M map combined from 9 subjects
         PAG = periaqueductal gray; SN = substantia nigra, VTA = ventral tegmental area; HIP = hippocampus; 
         S1 = primary somatosensory cortex; VPL = ventral posterolateral thalamic nucleus; LGP = lateral globus pallidus; 
        CG = cingulate cortex; NAC = nucleus accumbens
∆CMRO 2
† N=11M N=9 ∆CBF N=11ΔBOLD N=11 est. ΔCBV ‡ N=11
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Figure 3 – 2: Time dependent changes in BOLD, CBF, and CMRO2 for a single 
subject   
Time dependent changes measured for two regions of interest are shown: black 
lines represent primary somatosensory cortex (S1) and red lines represent nucleus 
accumbens (NAc). The black line represents the single step model used for analysis. 
Figure reproduced from (Schmidt et al., 2006). 
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Figure 3 – 3: Relationship among CBF, BOLD, and CMRO2 changes following 
intravenous administration of 1.0 mg/kg cocaine obtained from different brain 
regions.  
(Mean values, error bars illustrate SEM, N = 11). (a) CBF and BOLD changes for 
the regions of similar M value (Hip, S1, VPL, LGP, NAc, and striatum). Iso-countour 
lines indicate the expected coupling of changes in CBF and changes in BOLD under 
conditions of increased or decreased CMRO2 (M = 0.1). (b, c) Changes in CMRO2 as a 
function of CBF and BOLD changes. Lines indicate the least square linear regressions for 
data point that are indicated by closed circles (Pearson’s r: b: 0.92, c: 0.79). The 
substantia nigra (open circle) was excluded from the analysis in (b) and (c). Figure 
reproduced from (Schmidt et al., 2006). 
 
 76 
 
 
 
 
 
 
 
 
 
 
Figure 3 – 4: Estimates of changes in CBV from this study are correlated with 
reported changes in CBV following a similar dose of cocaine that were measured 
using MION contrast agent 
Estimates of changes in CBV derived from measurements of CBF (Grubb et al., 
1974) made in this study are correlated (Pearson’s r = 0.96) with direct measurements of 
changes in CBV using MION, but estimated changes in CBV from this study were 
consistently larger than those reported by (Marota et al., 2000). 
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CHAPTER IV 
WHOLE BRAIN ANALYSIS OF MULTIPLE SUBJECTS MANDATES 
SPIN ECHO MRI ACQUISITION: DEVELOPMENT OF A 3 COIL 
SYSTEM FOR MULTI-MODAL IMAGING IN CONSCIOUS ANIMALS 
The work presented in this chapter is reproduced with minor changes in text from a 
manuscript in revision to the Journal of Neuroscience Methods described on the 
copyright page. This work was conducted under the direction of Dr. Craig Ferris, with 
significant contributions from Dr. Rostislav Lemdiasov, Mathew Brevard, and other 
authors. It is with great gratitude to Drs. Ferris and Lemdiasov, and to other authors that I 
reproduce these results in this dissertation. My contributions to this work consisted of the 
execution of animal experiments and required modification of MRI protocols, data 
analysis, synthesis of the text presented here, and in the contribution of design 
recommendations to Dr. Lemdiasov.  
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Introduction 
Functional magnetic resonance imaging (fMRI) of conscious animals can be used 
to non-invasively map changes in neural activity within the brain with high spatial and 
temporal resolution (Lahti et al., 1998; Ludwig et al., 2004) and is a growing area of 
research with direct relevance to the fMRI research performed in humans in the clinic. 
The investigation of drugs, sensory perception, and cognition within the conscious animal 
using fMRI techniques has the potential to eliminate the confounding effects of 
anesthetics and to enable the observation of cognitive processes which are unobservable 
in the anesthetized state, such as arousal and reward (Ferris et al., 2001; Ferris et al., 
2005). The use of integrated coil and restraint systems to perform fMRI in the conscious 
animal has been previously demonstrated using a variety of imaging techniques (Lahti et 
al., 1998; Khubchandani et al., 2003; Ludwig et al., 2004), but continued progress in this 
emerging field depends upon the development and application of improved imaging 
capabilities to fully realize the potential of fMRI in the conscious animal. 
Blood-oxygen-level-dependent (BOLD) imaging is used extensively in fMRI to 
assess neural activation, where localized changes in blood deoxyhemoglobin 
concentration and changes in blood volume due to increased metabolism in the 
surrounding neuropil contribute to detectable changes in image intensity (Ogawa et al., 
1993; Boxerman et al., 1995b; Nair, 2005). BOLD contrast can be measured using 
gradient-echo (GE) acquisition which is sensitive to local changes in R2* relaxivity, or it 
can be measured using spin-echo (SE) acquisition which is sensitive to changes in R2 
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relaxivity. Images acquired with GE sequences suffer from susceptibility artifacts in 
regions containing magnetic field inhomogeneities that cause tissue to undergo rapid R2* 
relaxation, and these artifacts confound the investigation of neural activation in many 
areas of the brain. In contrast, SE acquisition provides superior coverage of these brain 
regions by reducing susceptibility artifacts, and SE BOLD contrast, while reduced in 
magnitude with respect to GE BOLD contrast, has been shown to suppress the 
contribution from large draining veins, providing a more localized signal originating from 
changes in deoxyhemoglobin concentration and blood volume within the 
microvasculature (Boxerman et al., 1995b; Bauer et al., 1999; Silvennoinen et al., 2003; 
Jochimsen et al., 2004; Hulvershorn et al., 2005). Additionally, SE acquisition requires 
that all tissue within the brain experience uniform 90° and 180° excitations, indicating the 
use of transmission coils whose field geometries are uniform across all areas of the brain.   
Consequently, optimal conditions for fMRI using SE acquisition typically entail a two-
coil configuration where uniform excitation is achieved through the use of a volume 
resonator, and an electronically decoupled surface coil is used for detection of the emitted 
nuclear magnetic resonance signal. 
Detection of localized changes in cerebral blood flow (CBF) is an additional fMRI 
measurement that can be used to infer changes in neural activity (Colebatch et al., 1991; 
Madsen et al., 1991; Hoge et al., 1999b; Kim et al., 1999; Mandeville et al., 1999) and 
various techniques for measuring CBF by MRI are reviewed in (Barbier et al., 2001). 
Arterial spin labeling fMRI protocols are able to detect changes in CBF and use water 
molecules within the blood as an endogenous tracer, eliminating the need for exogenous 
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contrast agents. The reduced contrast to noise ratio of CBF measurements made using 
arterial spin labeling techniques with respect to changes in the BOLD signal (Lu et al., 
2003) often precludes the use of CBF measurements alone in fMRI experiments. 
However, when changes in BOLD and CBF are monitored simultaneously it is possible 
to use redundancy between the two measures to identify image artifacts due to non-neural 
phenomenon, and it is also possible to make quantitative inferences of metabolic changes 
in the underlying tissue (Davis et al., 1998; Hoge et al., 1999b; Kim et al., 1999). 
Continuous arterial spin labeling (CASL) is a technique which is commonly used to 
acquire simultaneous measurements of BOLD contrast and CBF, and requires, in the case 
of multi-slice imaging experiments, that an additional coil be placed near the neck of the 
animal for arterial spin inversion (Silva et al., 1995; Zhang et al., 1995).  
It was the goal of this study to explore the feasibility of simultaneously measuring 
changes in SE BOLD and CBF in the conscious rat. A novel three coil system and 
integrated restraint was developed which uses a volume coil for uniform excitation of all 
tissue within the brain, a surface coil located above the brain for improved detection of 
the emitted signal, and a small surface coil located below the neck of the animal for 
arterial spin inversion. Longer acquisition times associated with SE BOLD weighted 
images revealed arterial spin labeling contrast dynamics predicted by kinetic models 
(Buxton et al., 1998) and illustrate an intrinsic limitation of the multislice CASL imaging 
technique. Functional activation was observed using electrical hindpaw stimulation, and 
illustrates the potential of this coil configuration to measure changes in SE BOLD and 
CBF within the conscious animal in a single experimental setting. 
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Materials and Methods 
MRI experiments were carried out on a 4.7T/40cm magnet (Oxford, UK), Bruker 
Biospec console (Bruker BioSpin Corp., Billerica, MA), and a 20 G/cmn gradient with 12 
cm inner diameter and 120 μs rise time. Three actively decoupled coils were used for 
imaging: a 10 cm microstrip resonator volume coil was used for excitation, a 2.5 cm 
surface coil was used for detection, and a butterfly coil located beneath the neck of the rat 
was used for arterial spin labeling (Insight Neuroimaging LLC., Worcester, MA). Images 
were acquired using the pseudo-continuous arterial spin labeling (pseudo-CASL) 
technique with a single shot spin echo echo-planar-imaging (SE EPI) sequence. Arterial 
spin labeling was accomplished with a square radiofrequency pulse of varying duration (1 
s – 4 s)  in the presence of a 1.0 G/cm gradient along the direction of blood flow in the 
carotid arteries, satisfying the adiabatic fast passage inversion condition. The frequency 
offset of the labeling pulse was reversed with respect to the center of the imaging 
geometry during control image acquisition. Acquisition parameters were: data matrix = 
64 x 64, FOV = 3.0 cm x 3.0 cm, nine 1.5 mm thick slices, TE = 54 ms, and TR = 2.7 s 
for the experiments illustrated in Figures 4 – 2a, 4 – 3 and 4 – 4. Data were analyzed 
using AFNI and custom software developed in the Java programming language (Sun 
Microsystems, Inc.) (Schmidt et al., 2004). 
Male Sprague-Dawly rats weighing 400-450 g were studied. Rats were anesthetized 
with 1.2% isoflurane and placed into an integrated coil and head restraint system. 
Anesthesia was subsequently discontinued, and rats were allowed to fully recover 
consciousness before being placed in the magnet for imaging experiments. Air or air with 
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10% CO2 concentration was continually supplied to the internal cavity of the coil and 
restraint system at a flow rate of 2.0 L/min. During electrical hindpaw stimulation 
experiments, electrodes were placed subcutaneously in both hind paws, and an electrical 
pulse of 0.33 ms duration and 1.5 mA was delivered at 3 Hz for a period of 130 s.   
Results 
The three coil imaging and restraint system that was developed is illustrated in 
Figure 4 – 1. Based upon an existing coil and restraint system (Insight Neuroimaging, 
LLC.) a third coil for arterial spin labeling was positioned below the carotid arteries of 
the rat. The third coil contains a figure 8 loop with crossover which is 1 cm in width and 
5 mm in length, and field simulations of this coil geometry (Figure 4 – 2, panel a) 
predicted uniform coverage of the carotid arteries.  Tuning, matching and decoupling 
circuitry was located 20cm from the neck coil to remove the animal from contact with 
electrical components. A coaxial cable with minimal impedance connected the neck coil 
loop to electronic tuning and matching circuitry that was designed using the Advanced 
Design System software (Agilent Technologies, Inc. Palo Alto, CA).  
The field distribution of the neck coil (ASL coil) was optimized with a custom 
software application (Lemdiasov, 2004) capable of predicting the magnetic flux density 
beneath the neck of the rat. A multi-channel decoupling circuit (Figure 4 – 2, panel b) 
was implemented at the interface between the MR system and the three RF coils, and the 
volume transmit and surface receive coils were detuned during the application of the 
arterial labeling pulse. This circuit uses a control signal implemented in the pulse 
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sequence to switch the active coil during arterial labeling, excitation, and signal detection 
via p-type, intrinsic, n-type (PIN) diodes implemented in the three coils. The quality 
factor of the dedicated arterial spin labeling coil loaded with a conscious 400g rat ranged 
between 3 and 4. Due to the location of the surface coil used for signal detection, and the 
limited detection sensitivity of the volume coil used for excitation, direct measurements 
of arterial spin inversion efficiency by examination of the carotid arteries were not made. 
However, estimates of labeling efficiency made by comparison of ASL contrast to 
contrast obtained with other coils with known efficiency and an estimate by non-linear 
regression to a dynamic model of ASL contrast (Figure 4 – 3, panel b) suggest inversion 
efficiency values between 75 and 80 percent. 
Spin echo BOLD contrast is measured simultaneously with appropriate T2 
weighting of the control image that is acquired during the CASL experiment. Figure 4 – 3 
(panel a) illustrates the change in ASL contrast and BOLD contrast as measured in a 
whole brain region of interest during an experiment in which a 10% CO2 challenge was 
applied after baseline signal collection. Contrast between the labeled and control 
experiments (ASL contrast) is visible as the difference in signal intensity between 
sequential images, and the change in BOLD contrast following the CO2 challenge is 
apparent as the change in signal intensity of the control images only. In this manner, 
consistent sampling of changes in CBF and BOLD contrast are acquired throughout the 
duration of the experiment, and concomitant increases in both CBF (as revealed by 
increased ASL contrast) and BOLD contrast following CO2 administration are apparent. 
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The CASL technique applies an arterial label for a duration sufficient to establish 
the maximum contrast between control and labeled images, typically requiring a label 
duration of more than three seconds.  However, in practice, it is common to abbreviate 
the label duration (i.e. pseudo-CASL) in order to increase the number of acquired images 
and, hence, the signal-to-noise ratio of data collected in a fixed length experiment. 
Dynamics that describe the approach to maximal contrast between the control and labeled 
images during the label application period, and the decline in contrast following the 
termination of the label have been previously described (Equation 4.1), and observed in 
arterial spin labeling experiments in humans (Buxton et al., 1998). In this equation, f is 
rate of cerebral blood flow, ΔM(t) is the change in magnetization within a voxel at time t, 
Δt is the transit time for blood from the label location to the voxel, τ is the label duration, 
α is the inversion efficiency, MOB is the initial magnetization of blood in the voxel, T1B is 
the T1 of the blood in the voxel, and T1' is the apparent T1 of the tissue and blood in the 
voxel. These theorized dynamics accurately predict the rise and fall of ASL contrast in 
pseudo-CASL experiments observed in the conscious animal under 10% CO2 
administration using SE echo-planar-imaging (EPI) acquisition (Figure 4 – 3, panel b). 
Model parameters for the regression displayed in Figure 4 – 3 (panel b – solid lines) were 
determined by non-linear regression of Equation 4.1 to observed data using supplied 
parameters for CBF (200 mL/100mg-min under 10% CO2), T1 of blood at 4.7T and 37°C 
(1.9s), label duration (1.75s), and transit time (150ms). The apparent T1 of tissue and 
labeling efficiency were determined to be 1.16s and 0.79, respectively. 
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 f = ΔM (t)e
t−Δt−τ( )/ ′/T1
2MOB ′T1αe−Δt /T1B 1− e−τ / ′T1( )     (4.1) 
Of particular interest in simultaneous SE BOLD and CBF acquisition is the time 
dependent drop in ASL contrast following termination of the labeling pulse (Figure 4 – 3, 
panel b, grey line).  Longer echo times associated with SE BOLD weighting prolong slice 
acquisition time and prolong the total acquisition time in multi-slice imaging experiments 
with respect to GE BOLD weighted acquisitions.  Changes in contrast due to post-
labeling acquisition delays introduce systematic errors that must be accounted for in 
quantitative calculations of CBF, and, although these contrast changes are self correcting 
in measurements of relative CBF change for images acquired with the same post labeling 
delay, the corresponding change in the contrast to noise ratio of the relative CBF 
measurements impacts the effect size of relative changes in CBF (tΔf) in a manner 
dependent on the post-label delay duration (Equation 4.2).  
 tΔf = ΔfσM e t−Δt−τ( )/ ′T1        (4.2) 
This change in effect size affects analyses that apply a uniform statistical threshold 
to all slices, as is the practice in many software analysis packages, and Figure 4 – 4 
illustrates statistical parametric map artifacts that result from different post-label delays 
associated with each slice in a multi-slice SE BOLD CASL experiment. Following a 10% 
CO2 challenge, both BOLD and CBF are increased throughout the brain, BOLD signal 
increases of up to 10% and CBF increases of more than 100% were observed. Applying a 
uniform statistical threshold to maps of relative changes in BOLD and CBF reveals a 
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deficit of voxels containing significantly increased CBF in slices acquired with increasing 
post labeling delays (Figure 4 – 4). 
Despite these limitations, it is possible to use the pseudo-CASL technique to 
simultaneously measure SE BOLD and CBF changes resulting from electrical hindpaw 
stimulation in the conscious rat. Dramatically increased signal variance due to motion 
artifacts requires that ROI analyses of data from multiple animals be used as a reliable 
measure of activation. Figure 4 – 5 illustrates the change in BOLD and CBF measured in 
the hindpaw somatosensory region. Median values of changes in SE BOLD and CBF for 
7 animals reflect a rapid increase in both measures following the start of electrical 
stimulation, and these changes are sustained for a period following the termination of 
stimulation. Mean values of ΔBOLD and ΔCBF for all animals during the initial baseline 
and stimulation epochs reflect increases in BOLD and CBF (1.2% and 49%, respectively) 
which are significant (p<0.05) at the group level only, a result of the large variance in 
these signals as measured in the conscious animal. 
In this study, the use of a novel 3 coil imaging and restraint system has been 
demonstrated to simultaneously measure changes in SE BOLD and ASL contrast in the 
conscious rat. Changes in SE BOLD and ASL contrast following a 10% CO2 challenge 
reflect increases which are consistent with observations using alternate image acquisition 
protocols in anesthetized animals (Sicard et al., 2003).  Dynamic changes in ASL contrast 
are accentuated by the longer acquisition times associated with SE BOLD contrast, and 
must be taken into account in the statistical analysis of combined SE BOLD and ASL 
imaging protocols based on the pseudo-CASL technique. Despite this confound in the 
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specific case of SE BOLD weighted pseudo CASL protocols, the novel hardware 
configuration presented herein permits the combined use of ASL and SE imaging 
protocols in the conscious animal within the same setting, and is expected to have broad 
application in the fMRI research. 
Discussion 
The three coil imaging and restraint system developed in this study presents a novel 
capability enabling two coil SE imaging and ASL measurement of perfusion within the 
same experimental setting, and this work is the first demonstration of simultaneous SE 
BOLD and ASL acquisition in the conscious animal using three radiofrequency coils. 
With sufficient improvements in sensitivity, the signal to noise ratio of this technique will 
be adequate to make metabolic inferences with a calibration experiment, in conscious or 
anesthetized animals. Currently, this system enables ASL experiments to be conducted in 
conjunction with traditional two-coil imaging experiments in conscious or anesthetized 
animals, without requiring a reconfiguration of the imaging coils or removal of the 
animal from the magnet.    
 The large variance of the BOLD and CBF measurements is an impediment to 
imaging experiments using conscious animals. While immobilization of the skull can be 
achieved using stereotacticly positioned ear bars and a bite bar, contractions of the jaw 
and facial muscles can contribute to phase encoding artifacts that contaminate voxels 
within the brain, deleteriously affecting measurements of both BOLD and CBF. 
Additionally, sub-voxel motion (less than 400 μm in rat studies) can cause partial volume 
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effects that confound statistical parametric mapping algorithms that examine each voxel 
independently (Turner et al., 1998). These artifacts are less severe following acclimation 
(King et al., 2005) and in functional imaging experiments that use non-aversive stimuli, 
such as neutral scents or anxiolytic and sedative drugs. Additionally, the ASL signal is 
sensitive not only to changes in signal intensity caused by these artifacts, but it is also 
sensitive to potential changes in arterial spin labeling efficiency caused by animal motion 
in the region of the neck coil.  
Dynamics of ASL contrast are a limiting factor in multi-slice imaging experiments 
designed to measure CBF where the acquisition time is long. Quantitative CBF 
measurements from CASL and pseudo-CASL protocols are particularly susceptible to 
these dynamics and require a correction to compensate for post-labeling delays. Although 
the loss of ASL signal does not affect measurements of relative CBF change as calculated 
from slices acquired with the same post-labeling delay, the loss of ASL contrast with 
increasing post-labeling delay directly impacts statistical parametric mapping algorithms 
commonly used to delineate areas of activation. Multi-slice experiments require that a 
slice-specific statistical threshold be used to create a uniform representation of activated 
regions. 
Future studies are planned to improve the stability of the ASL signal and increase 
the sensitivity of CBF measurements made within the conscious animal. These 
improvements may be accomplished by improving arterial inversion efficiency and 
reducing the susceptibility of inversion efficiency to animal motion on the neck coil, a 
suspected source of the variability observed in our measurements. Modified neck coil 
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geometries that increase the volume of the homogeneous B1 field surrounding the carotid 
arteries may be an effective strategy to address this challenge. Alternatively, ASL 
sequences using trains of hyperbolic secant adiabatic inversion pulses of shorter duration 
than the block pulse used in adiabatic fast passage may reduce the probability that 
spurious animal motion adversely affects inversion efficiency. The use of less aversive 
stimuli than the noxious electrical hindpaw stimulation used in this study also reduces 
animal motion and improves ASL stability, an effect that is visible in the clear patterns of 
increased CBF following a benign CO2 challenge. Improvements in the stability of 
concurrently measured ASL and BOLD signals would be a valuable advance, as a 
growing volume of research uses these measurements to map metabolic changes in neural 
tissue with the use of calibrated biophysical models.  
Overall, the ability to perform arterial spin labeling in the conscious animal using a 
three coil imaging system represents a significant advance in fMRI research capabilities. 
In continuous ASL experiments measuring only CBF, it is possible to increase the label 
duration sufficiently to achieve the maximal contrast of the steady state condition, with 
gains in sensitivity with respect to the multi-modal pseudo-CASL approach used here. 
Such measurements can be made prior to, and following, a two coil BOLD fMRI 
experiment to control for perturbations in baseline CBF. These control measurements of 
CBF may be particularly valuable in pharmacological studies, where the drug under 
investigation may directly or indirectly interact with the cerebral vasculature, causing 
changes in the BOLD signal that are not the result of modulated neural activity. 
Anticipating future improvements in stability and sensitivity, three coil configurations 
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may enable novel multi-parameter functional imaging studies to investigate 
pharmacological mechanisms, cognition, and perception in the conscious animal.  
Additionally, the similarity of this configuration to perfusion imaging techniques used in 
the clinic suggest that this tool will be especially applicable to investigations using 
animal models of stroke, where there is direct translation between the MRI endpoints 
obtained in conscious animals to conscious humans in the clinic. 
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Figure 4 – 1: Three coil imaging and integrated restraint system.  
A schematic of the system developed is illustrated. A micro-strip resonator volume 
coil is used for sample excitation, a concave surface coil located directly above the head 
of the rat is used for signal detection, and a butterfly (figure 8 geometry) coil located 
below the neck of the rat is used for arterial spin labeling. The three coils are integrated 
into a cylindrical animal restraint with a rigid bite bar, nose clamp, and ear bars to 
minimize animal motion (nose clamp and ear bars are not shown). Figure reproduced 
from manuscript in revision for Journal of Neuroscience Methods.  
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Figure 4 – 2: Simulated B1 field strength near the arterial labeling coil and active 
decoupling electronics.  
(a) A simulation of the B1 field generated by the neck coil illustrates a 
homogeneous field in the region of the carotid arteries, and low field strength outside of 
this region, minimizing saturation effects in tissue of interest. (b) Schematic of the active 
decoupling circuitry implemented to switch the active coil during arterial labeling, 
excitation, and signal detection. Figure reproduced from manuscript in revision for 
Journal of Neuroscience Methods. Figure and legend produced by Rosti Lemdiasov. 
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Figure 4 – 3: Arterial spin labeling contrast in pseudo-CASL with SE BOLD weighted 
acquisition 
(a) Signal intensity measured from a single subject within a whole brain ROI 
during a 100 repetition pseudo-CASL experiment in which a CO2 challenge was 
introduced after 220 s (grey bar), and sustained for the remainder of the experiment. 
Changes in CBF are assessed by the change in contrast between sequential control (high 
values, filled circle) and labeled (low values, open circle) signal intensities, and changes 
in BOLD are assessed by changes in the signal intensity obtained from control images 
only. (b) Arterial spin labeling contrast is accurately predicted by a kinetic model of 
arterial spin labeling contrast (Equation 4.1). Within whole brain regions of interest under 
continuous 10% CO2 administration, contrast increases with increasing label duration 
(closed circles, N=6), and contrast declines to nominal levels following termination of the 
labeling pulse at 1.75s (open circles, N=12) in a manner consistent with the model (solid 
lines) using the following parameters: CBF = 200 mL/100mg-min, T1 blood = 1.9s, T1 
apparent = 1.15s, labeling efficiency = 0.79, transit time = 150 ms. Error bars = SEM. 
Figure reproduced from manuscript in revision for Journal of Neuroscience Methods.  
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Figure 4 – 4: Effect size artifacts are visible in activation maps using statistical 
thresholds.  
Four rostral slices from a representative subject acquired in an interleaved, 9 slice 
acquisition illustrate the effect size artifact resulting from varying post-label delays 
corresponding to the acquisition time for each slice (top). BOLD increases are seen 
globally throughout the brain (top row) and are equally significant in all slices. CBF 
changes are seen globally throughout the brain but fewer voxels contain significant 
increases with increasing post-labeling delay (white arrows). Color scale reflects 0-10% 
for BOLD maps, and 0-150% for CBF maps. Colored voxels illustrating BOLD changes 
were thresholded to significance greater than P = 0.001, and CBF voxels were 
thresholded to significance greater than P = 0.01. Figure reproduced from manuscript in 
revision for Journal of Neuroscience Methods.  
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Figure 4 – 5: BOLD and CBF changes within the hindpaw primary somatosensory 
cortex following electrical stimulation.  
(a) median changes in the BOLD and CBF signals as a function of time during a 
functional experiment using electrical hindpaw (HP) stimulation in the conscious rat (N = 
7). Both BOLD and CBF signals increase rapidly following the onset of stimulation, and 
remain elevated after the termination of stimulation before returning to baseline. The 
BOLD signal continues to drop to a level below the initial baseline period following 
termination of the electrical stimulation. (b) mean changes during baseline and 
stimulation epochs reflect significant increases in BOLD (1.2 %, P < 0.05) and CBF 
(49%, P < 0.05). The large variances in these measurements reflect signal changes 
resulting from small amplitude motion of the animal within the restraint. (N = 7, error 
bars = SEM). Figure reproduced from manuscript in revision for Journal of Neuroscience 
Methods.  
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CHAPTER V 
CONSCIOUS ANIMALS EXHIBIT A BOLD RESPONSE TO 
MORPHINE THAT DIFFERS FROM ANESTHETIZED ANIMALS 
The work presented in this chapter has not yet been submitted for review. This 
work was conducted under the direction of Dr. Craig Ferris, where my contributions 
consisted of the design and execution of animal experiments, data analysis, and the 
synthesis of the text presented here.  
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Introduction  
Changes in multiple functional MRI signals (e.g. CBF, CBV, and BOLD) can be 
readily observed following the administration of stimulants such as cocaine and 
amphetamine (Li and Suojanen, 1995; Marota et al., 2000; Mandeville et al., 2001; Luo 
et al., 2003; Schwarz et al., 2003; Schmidt et al., 2006), however, this class of drugs 
comprises only a fraction of the psychoactive compounds of potential interest in 
pharmacological fMRI investigations. The challenges of measuring changes in the fMRI 
signals that result from the administration of non-stimulant psychoactive compounds 
have not been fully resolved. Additionally, conflicting reports of both increases and 
decreases in BOLD signal intensity following the administration of cocaine to conscious 
animals (Febo et al., 2004; Mandeville et al., 2005) suggests that the cognitive status of 
the animal may have a profound effect on the observed changes in the fMRI signals. 
Although performing fMRI experiments with conscious animals requires additional 
technical considerations (Ludwig et al., 2004), if it is shown that pertinent differences are 
observed in the fMRI response from conscious vs. anesthetized animals, it is likely that 
this additional effort is necessary to probe the psychologically relevant actions of drugs 
that act on the central nervous system.  
Opiates are a significant class of drugs that are used extensively for the clinical 
management of pain (Nestler, 2002; Katzung, 2004; Corbett et al., 2006), and that are 
frequently abused for their ability to induce a profound state of euphoria (American 
Psychiatric Association, 1994; National Institutes of Health, 1997; Katzung, 2004). The 
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beneficial use of opiates in clinical applications is complicated by serious side effects that 
emerge with sustained use including acquired tolerance and reduced analgesic effect, 
physical dependence, and psychological dependence as well as by acute side effects 
including constipation, respiratory depression, nausea, and reduced renal function 
(Katzung, 2004). The burden to the health care system due to opiate abuse is also 
significant; in 1997, the financial impact to society of the then approximately 600,000 
opiate dependent addicts in the United States was estimated at greater than $20B per year 
(National Institutes of Health, 1997). Presently, the number of opioid-dependent people 
in the US is estimated at about 750,000 (Katzung, 2004). As a result of the therapeutic 
interest in opiates with a reduced spectrum of adverse side effects and the need for more 
effective strategies to treat opiate addiction and stem elicit opiate use, the interaction of 
opiates with the central nervous system has been extensively studied at molecular and 
macroscopic scales.  
Morphine is the prototype of clinical opioid analgesics, and both heroin and 
morphine are commonly abused by opioid addicts. Heroin is a prodrug that is 
metabolized to 6-monoacetylmorphine and morphine (Inturrisi et al., 1983; Corbett et al., 
2006), which have high affinity for the μ opioid receptor that is distributed throughout 
several areas of the brain including the periaqueductal gray (PAG), nucleus accumbens 
and ventral tegmental area, the areas believed to mediate the effects of supraspinal 
analgesia and reward, respectively (Nestler et al., 2001; Squire et al., 2003). The opioid 
receptors μ (MOR), δ (DOR), κ (KOR) are G-protein coupled receptors that act to inhibit 
neurotransmitter release (Nestler et al., 2001; Williams et al., 2001; Corbett et al., 2006) 
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and differences in the localization of these receptors confer the differences observed in 
neural response to selective opioid receptor agonists. For example, agonism of the MOR 
causes an increase in neural activity within the PAG that is understood to result from 
inhibition of the GABAergic interneurons acting there (Williams et al., 2001), and it has 
been shown that agonists acting at MOR and other receptor subtypes can cause a 
reduction in glutamate, GABA, and glycine release throughout the CNS (Williams et al., 
2001). Intravenously administered morphine has a half-life in the blood of approximately 
1.9 h (Katzung, 2004), and users report that the euphoric, sedative, and anxiolytic effects 
of self-administration, a state referred to as being “on the nod”, are onset 5 – 15 minutes 
following administration, and maintained for a period of several hours, with diminishing 
effects observed on a subjective scale beginning after approximately 2 hr  (Zacny et al., 
1994).  
Recently, fMRI was employed by several investigators to study the effects of 
opiates on neural activity within the rodent brain in anesthetized animals (Xu et al., 2000; 
Xi et al., 2002; Luo et al., 2004; Xi et al., 2004). This literature reports changes in the 
BOLD signal following heroin administration, and presents a valuable basis for 
comparison with data collected following morphine administration, an active metabolite 
of heroin. Of interest is the relatively short duration of BOLD signal changes reported in 
these studies of anesthetized rats, wherein the non-linear regressions that were used in 
these studies were tuned to a time scale that is relatively short, on the order of 10 min, 
compared to the pharmacodynamic profile of morphine.  
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In this study, we examined the effects of administering (0.3 mg / kg) morphine 
sulphate on the fMRI signals measured from conscious and anesthetized animals to 
investigate the potential differences between these experimental conditions. We also 
assessed the ability of multi-modal imaging to detect changes in BOLD and CBF 
following the administration of a non-stimulant, psychoactive compound. In conscious 
rats, this rewarding and analgesic dose of morphine reduced the frequency of struggle 
events, induced small and transient changes in heart and respiration rates, and induced a 
slow onset and regionally specific drop in the spin-echo (SE) BOLD signal that is 
consistent with morphine’s pharmacokinetics. This response was not observed among 
anesthetized animals. 
Materials and Methods 
Animal preparation 
Fourteen male Sprague Dawley rats (300 – 375 g) were studied. Vehicle (saline) or 
vehicle plus morphine sulphate (Sigma-Aldrich, St. Louis, MO) preparations were 
administered during the MRI experiments in an injection volume of 1 mL/kg and a dose 
of 0.3 mg/kg morphine sulphate for morphine scans. Tail veins were catheterized for 
vehicle or vehicle plus morphine administration under anesthesia. Rats were anesthetized 
with 1.2% isoflurane and placed into an MR compatible integrated coil and head restraint 
system (Insight Neuroimaging Systems, LLC., Worcester, MA). Anesthesia was either 
maintained or discontinued. For conscious scans, rats were allowed to fully recover 
consciousness in the restraint before imaging. Physiology was monitored by pulse 
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oximetry measured at the base of the tail, and recorded using a BioPak Systems data 
acquisition system (Santa Barbara, CA) at a sample rate of 5 ms. 
MRI experiments 
MRI experiments were carried out on a 4.7T/40cm magnet (Oxford, UK), Bruker 
console (Bruker BioSpin Corp., Billerica, MA). Concurrent measurements of changes in 
SE BOLD and CBF were acquired over a period of 15 minutes. Three actively decoupled 
coils were used for imaging: a 10 cm microstrip resonator volume coil was used for 
excitation, a 2.5 cm surface coil was used for detection, and a butterfly coil located 
beneath the neck of the rat was used for arterial spin labeling (Insight Neuroimaging 
LLC., Worcester, MA). Images were acquired using the continuous arterial spin labeling 
technique (CASL) (Silva et al., 1999) with a single shot spin echo echo-planar-imaging 
(SE EPI) sequence.  Acquisition parameters were: data matrix = 64 x 64, FOV = 3.0 cm x 
3.0 cm, nine 1.5 mm thick slices, TE = 55 ms, and TR = 2.7 s. During arterial spin 
labeled image acquisitions, a square radiofrequency labeling pulse of 1.75 sec duration 
was used for arterial spin inversion in the presence of a 10 G/cm gradient in the direction 
of blood flow, satisfying the adiabatic inversion condition (Williams et al., 1992). During 
the control image acquisitions, the frequency of the radiofrequency pulse was offset to 
correspond to a location outside of the anterior aspect of the animal that was equidistant 
from the center of the imaging planes as the labeling pulse (Silva et al., 1999). Control 
(unlabeled) and arterial spin labeled images were acquired sequentially, and 170 pairs of 
images were acquired during the experiments. 
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Data analysis 
Data were analyzed using the software package AFNI (Cox, 1996) and custom 
software developed in Java (Sun Microsystems, Inc., San Jose, CA) (Schmidt et al., 
2004). Small amplitude and subvoxel motion was corrected using the program 3dvolreg 
(Cox, 1996). BOLD measurements were derived from the control images in the acquired 
dataset, and quantitative CBF maps were calculated from each pair of images using 
equation 1.07 and the parameter values:  T1 =  1.54 s, λ = 0.9, α = 0.7 (Duong et al., 
2000; Liu et al., 2004). BOLD and CBF image time courses were normalized to percent 
change on a voxel by voxel basis by division with the average value of the voxel during 
the baseline period preceding vehicle or morphine injection. Two scans of morphine 
administered to anesthetized rats, and three scans of saline administered to anesthetized 
rats exhibited a hardware related artifact that was removed with a low pass filter. A 
spectrogram was created from the pulse oximetry data for measurement of HR using a 
fast Fourier transform (Cooley and Tukey, 1965) implemented in Java, with a rolling 
aperature of 1024 samples (5.2 s). Animal motion events were derived from the pulse 
oximetry data by detection of rapid, large amplitude changes in excess of the 
physiological range of changes due to heart beats and respiration (amplitude change > 5 
standard deviations of prior 200 samples). Due to artifacts in the spectrograms in some 
subjects as a result of animal motion, the pulse oximetry data were manually sampled 
with an interval of 10 s at 45 s and 200 s after the injection of morphine for the 
measurements displayed in Table 5-1. 
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To prevent co-registration errors between subjects as a result of the non-linear 
deformation of the SE EPI images, regions of interest (ROIs) were defined for each 
subject independently and average BOLD and CBF changes were measured from each 
ROI. Figure 5-1 illustrates the template used for the definition of ROIs (Paxinos and 
Watson, 1998); ROIs were defined bilaterally for the primary somatosensory cortex (S1), 
hippocampus, nucleus accumbens (NAc), cingulate cortex, association cortex, orbital 
cortex, olfactory nucleus, primary motor cortex (M1), caudate putamen (CPu), insular 
cortex, secondary somatosensory cortex (S2), lateral globus pallidus (LGP), piriform 
cortex, thalamus, hypothalamus, auditory cortex, visual cortex, periaqueductal gray 
(PAG), ventral tegmental area (VTA), substantia nigra (SN), pontine nuclei , and raphe 
nucleus. The average changes over time in BOLD and CBF with respect to baseline were 
determined using these ROIs and the normalized BOLD and CBF image timecourses.  
Results  
In anesthetized rats, a significant drop in the BOLD signal was observed in all 
regions investigated within 30 s following the administration of morphine (0.3 mg/kg) 
(Figure 5-2, panel a). Within 4 minutes, the BOLD signal returned to baseline levels. 
Following the administration of vehicle alone to anesthetized rats, no significant changes 
in the BOLD signal were observed within any of the regions investigated. The depression 
of the BOLD signal was correlated in time with reduced cardiac output and reduced 
respiratory output (Figure 5-2, panel b) that was significant at the group level in 
anesthetized animals (Table 5-1). Heart rate (HR) and respiratory rate (RR) were reduced 
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on average by 16.1% ± 1.3% and 18.6% ± 4.8%  (% change  ± SEM, N = 6), 
respectively, 45 s after the administration of morphine. At 200 s following the 
administration of morphine HR and RR were still significantly depressed in anesthetized 
animals by 5.4% ± 2.1% and 6.3% ± 2.4%, but the BOLD signal had returned to baseline 
levels (Figure 5-2, panel a).   
In contrast to anesthetized rats, no significant changes in HR or RR were observed 
in conscious rats at 45 s or 200 s following the administration of morphine (Table 5-1), 
and SE BOLD remained at or above baseline levels for 175 s after the injection of 
morphine or vehicle alone (Figure 5-3, panel b). At 200-225 s after the injection of 
morphine, a regionally specific drop in the BOLD signal was observed in some of the 
ROIs investigated, and the depression in the BOLD signal was sustained for the duration 
of the experiment (675 s following the injection) (Figure 5-3 panel b). This late onset 
drop in the BOLD signal following morphine administration was regionally specific, was 
not observed in any regions investigated in anesthetized animals, and, when averaged 
over the period of 225 – 675 s following injection, was significantly different at the group 
level in conscious animals in comparison to vehicle controls within the association 
cortex, orbital cortex, olfactory nucleus, primary motor area (M1), cingulate cortex, 
primary somatosensory area (S1), caudate putamen (CPu), insular cortex, secondary 
somatosensory region (S2), lateral globus pallidus, hippocampus, auditory cortex, and 
visual cortex (Figure 5-4). Unexpectedly, sites mediating supraspinal analgesia (e.g. 
periaqueductal gray) did not exhibit significant changes in BOLD after the administration 
of morphine, in comparison to vehicle controls (Figure 5-4). Significant changes in 
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cerebral blood flow (CBF) were not observed at the group level in any of the regions 
investigated, suggesting that the limited sensitivity of the pseudo-CASL technique may 
prevent detection of small CBF reductions that should be observed in neural deactivation 
paradigms.  
Among conscious animals, the frequency of struggle events was significantly 
reduced following the administration of morphine, while there was no significant change 
in the frequency of struggle events following the administration of saline alone (Figure 5-
5). 
Discussion 
Transient BOLD changes observed in anesthetized vs. conscious rats 
Heroin has been previously shown to elicit a transient drop in the gradient echo 
(GE) BOLD signal shortly after administration, in spontaneously breathing, urethane 
anesthetized rats (Xu et al., 2000). A similar drop in BOLD signal intensity was 
consistently observed in isoflurane anesthetized rats in this study, following the 
administration of 0.3 mg/kg morphine sulphate. Mechanical ventilation of the rats in Xu 
et al.’s study was shown to reduce or eliminate this drop in the BOLD signal, and 
implicated a systemic change in blood oxygen saturation as a source of the signal change 
in spontaneously breathing anesthetized animals. Our data support this observation with 
the correlation in time among reductions in respiration rate, heart rate, and BOLD signal 
intensity (Figure 5-2, Table 5-1).  While tracheotomy and mechanical ventilation may 
also be effective for eliminating global BOLD signal changes due to the physiological 
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effects of morphine in the anesthetized animal, the surgical procedure cannot easily be 
extended to the conscious animal, and the procedure itself precludes or severely 
complicates the use of the same animal at a later date in longitudinal studies.  
Previous studies of heroin’s effects on the BOLD signal in anesthetized rats that 
were mechanically ventilated revealed regionally specific activations (increases in BOLD 
signal intensity) that included the mesolimbic system, cingulate cortex, frontal cortex, 
olfactory cortex, entorhinal cortex, hippocampus, and hypothalamus (Xu et al., 2000). 
The onset of these activations was rapid (within 2 min) and the duration of these 
activations was short (not longer than 10 min) relative to the half life of morphine, an 
ultimate metabolite of heroin. Due to the overwhelming influence of the presumed 
increase in dexoyhemoglobin concentration resulting from reduced cardiac and 
respiratory output following morphine administration in anesthetized rats, BOLD signal 
increases in these animals were not observed, consistent with our expectations and with 
previously published results (Xu et al., 2000). Surprisingly, increases in the BOLD signal 
were not observed in conscious animals within any of the regions investigated, despite 
the absence of significant effects on RR and HR (Table 5-1), and the absence of the 
transient drop in the BOLD signal present in anesthetized animals (Figure 5-2).  
In conscious rats, and in contrast to the BOLD dynamics observed in anesthetized 
rats in both this and in Xu et al.’s study (Xu et al., 2000), the BOLD signal returned to or 
slightly (but not significantly) exceeded baseline levels within 50 seconds following 
administration of both vehicle and vehicle with morphine, but returned to baseline levels 
within 100 s (Figure 5-3, panel b) . This pattern was consistent throughout many of the 
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regions investigated, but in no region was the increase in BOLD due to morphine 
administration greater than or significantly different from the increase in BOLD due to 
vehicle alone. Hemodynamic factors could account for the transient increase in BOLD, 
including vasoconstriction due to hypertension induced by the injection, which would 
cause a reduction in CBV without a dramatic change in CBF or CMRO2, thereby 
increasing the BOLD signal intensity (see Equation 2.1). This hemodynamic explanation 
is difficult to reconcile with the observations of decreasing BOLD or reduced BOLD 
responsivity under hypocapnic conditions, such as hyperventilation (Weckesser et al., 
1999; Makiranta et al., 2004), but is supported by the observation of increased BOLD 
signal in some structures following a pressor challenge (Henderson et al., 2004); also, 
acute hypertension induced by injection would be expected to activate the baroreceptor 
reflex, but a significant change in HR was not observed at 45 s post injection in the pulse 
oximetry data (Table 5-1). Another possible explanation is that sensory stimulation from 
the injection alone causes changes in neural activity throughout several regions in the 
brain. This explanation is consistent with the nearly significant increase in BOLD 
observed at the group level within S1 among conscious rats (Figure 5-3). 
Conscious, but not anesthetized, animals exhibit BOLD signal changes consistent 
with the pharmacodynamics of morphine 
In conscious rats receiving morphine, a late onset drop in the BOLD signal was 
observed in several regions of the brain that was significant at the group level, and 
significantly different from group wide BOLD changes in these regions following the 
administration of saline (Figure 5-4). The time of onset of this drop in BOLD, 
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approximately 200 s after injection (Figure 5-3), is consistent with the onset of anxiolytic, 
analgesic, and euporhic effects reported by medicinal and recreational opioid users 
(Zacny et al., 1994; Katzung, 2004), and the reduction in BOLD signal intensity was 
maintained for the duration of the experiment, consistent with the 1.9 hr half life of 
morphine in the blood. Consequently, these late onset changes in the BOLD signal are 
better explained by the expected pharamcodynamics of morphine, than the transient 
changes in the BOLD signal observed during the 2 – 3 minutes immediately following 
the injection. 
If we assume that BOLD signal changes following vehicle and morphine injection 
do, in fact, reflect local changes in neural activity, then the regionally specific, late onset 
drop in BOLD signal intensity following morphine administration is consistent with the 
muted sensory perception and analgesia expected from the drug. The significantly 
reduced rate of struggling (i.e. reduced motor activity) observed after the injection of 
morphine (Figure 5-5) is consistent with the fMRI observations that BOLD signal 
intensity is significantly reduced in M1, CPu, and LGP with respect to saline injected 
animals during this latter portion of the experiment (Figure 5-4). The significant 
reduction in BOLD with respect to saline injected animals that was observed in primary 
(S1) and secondary (S2) somatosensory, auditory, and visual cortices is consistent with 
reduced sensory stimulation due to analgesia and anxiolysis, and the drop in BOLD 
among frontal cortical regions is consistent with a muted state of consciousness.  
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Limitations of the technique 
This study collected both BOLD and CBF measurements simultaneously (Silva et 
al., 1999; Duong et al., 2000; Schmidt et al., 2006), in an effort to validate a multi-modal 
imaging approach to pharmacological MRI of non-stimulant drugs. Not only were 
significant changes in CBF undetectable, but significant changes in the BOLD signal 
were detectable only in ROI based analyses at the group level. Statistical parametric maps 
calculated from individual subjects from the BOLD signal alone and tuned to assess the 
significance of the late onset drop in the BOLD signal at the individual voxel level were 
contaminated by artifacts due to animal motion, and unsuitable for publication.  
Additionally, non-linear distortion of the EPI images prevented a coregistration 
approach to data analysis, and required the definition of each ROI in individual subjects. 
EPI distortion and inter-subject errors in ROI definition may contribute to the high 
variance observed in measurements made in small nuclei such as the PAG, entorhinal 
cortex, and VTA. Consequently, EPI based multi-modal imaging approaches may be 
suitable in only a subset of pharmacological studies, where changes of interest in BOLD 
and CBF are expected to be large in amplitude, as in the hemodynamic changes following 
the administration of a psychostimulant (Schmidt et al., 2006).  Blood pool contrast 
agents used to measure changes in CBV have been shown to be effective in localizing 
changes in hemodynamics associated with neural activity induced by a drug (Marota et 
al., 2000), and the reduced sensitivity of changes in CBV to systemic changes in blood 
oxygenation may make CBV measurements a desirable alternate to BOLD imaging in 
some circumstances.  
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In a separate set of experiments, 10 mg / kg naloxone was administered 8 min after 
the administration of morphine sulfate to assess the reversibility of the late onset drop in 
BOLD signal among conscious rats. This dose was sufficiently aversive that animal 
motion immediately following naloxone administration contaminated measurements of 
the BOLD signal, preventing reliable detection of BOLD signal changes (data not 
shown).  Future studies using a reduced dose of naloxone with reduced potential for 
aversion may reveal a partial reversal of the late onset drop in BOLD signal, further 
supporting the hypothesis that this change in signal is due to morphine’s agonism of the 
MOR. 
Physiological changes following morphine administration, such as decreased HR 
and RR, and the absence of these changes among conscious rats, suggest that 
autoregulatory reflexes may be intact in conscious but not anesthetized animals. These 
autoregulatory reflexes may induce detectable changes in neural activity within the 
medulla in regions that regulate respiration, but these changes were not observable in this 
study, due to the selection of imaging geometry that was focused on anterior cortical 
areas. Future fMRI and phMRI studies may reveal specific changes in BOLD or CBF 
measures within the vagal system in response to chemical challenge or activation of the 
carotid body reflex, but the technical challenges of making these observations in rats are 
difficult to anticipate. 
Implications for pharmacological functional MRI 
 115 
Despite the technical difficulty associated with imaging conscious animals, 
pertinent differences in the fMRI response to morphine between anesthetized and 
conscious rats suggests that investigations of other psychotropic drugs may also yield 
different results if performed in conscious vs. anesthetized animals. In anesthetized rats, 
transient and global reductions in SE BOLD following morphine injection are observed 
to dissipate within minutes, far more rapidly than morphine is cleared from tissue or 
plasma.  In contrast, late onset changes in SE BOLD in conscious rats are consistent with 
the pharmacokinetics of morphine and suggest that morphine induces a complex neural 
response that is dominated by secondary actions in regions that are not direct substrates 
for opiates (Nestler, 2002). Functional MRI of the conscious rat may help to elucidate the 
secondary neural effects that are associated with the reward, anxiolysis, and euphoria that 
accompanies intravenous injection of opiates of abuse, and fMRI of conscious animals 
may be a difficult but important technique for determining the changes in neural activity 
induced by a drug under investigation. 
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Figure 5 – 1: Regions of interest investigated. 
(a) A template was used for definition of the regions of interest investigated in this 
study. Due to the limited resolution of the functional MRI scans, regions were aggregated 
in the manner shown in, and defined bi-laterally on the functional images. The figure 
shows only unilateral definition to illustrate the aggregation of sub regions defined in the 
atlas. Regions defined are: 1 – Association Ctx, 2 – Orbital Ctx, 3 – Olfactory Nucleus, 4 
– Cingulate Ctx, 5 – Primary motor area (M1), 6 – Primary somatosensory cortex (S1), 7 
– Insular Ctx, 8 – Caudate putamen (CPu), 9 – Nucleus accumbens (NAc), 10 – Lateral 
globus pallidus (LGP), 11 – Secondary somatosensory cortex (S2), 12 – Piriform Ctx, 13 
– Hypothalamus, 14 – Thalamus, 15 – Hippocampus, 16 – Ventral tegmental area (VTA), 
17 – Substantia nigra (SN), 18 – Periaqueductal gray (PAG), 19 – Auditory Ctx, 20 – 
Visual Ctx, 21 – Raphe Nucleus (b) Non-linear distortion of the functional (SE EPI) 
images, especially visible in ventral and lateral brain regions such as the amygdala, 
prevents a coregistration based approach to multi-subject analysis. 
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Figure 5 – 2: Changes in BOLD signal intensity in the thalamus correlate with 
physiological changes observed following morphine administration in anesthetized 
rats. 
 (a) Consistent with previous reports, transient decreases in SE BOLD are observed 
in group average time courses of anesthetized rats following morphine administration. No 
change in BOLD signal intensity is observed following administration of vehicle (saline). 
(black bar indicates injection period, N=6, error bars = SEM) (b) Spectral analysis of 
pulse oximetry data from a single anesthetized rat reveals a drop in heart rate (arrow) and 
decreased respiration (arrow head) following morphine injection that is correlated in time 
with the decreased BOLD signal intensity.  
 120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conscious
Saline 0.7% ± 2.2% 1.9% ± 2.3%
Morphine 4.7% ± 7.1% -0.4% ± 5.2%
Anesthetized
Saline 0.7% ± 2.9% 1.1% ± 3.4%
Morphine -16.1% ± 1.3%** -5.4% ± 2.1%*
Conscious
Saline 3.0% ± 3.1% 6.2% ± 4.1%
Morphine 3.8% ± 10.3% -6.3% ± 9.2%
Anesthetized
Saline 4.3% ± 8.3% -2.8% ± 5.8%
Morphine -18.6% ± 4.8%** -6.3% ± 2.4%*
45 s post injection 200 s post injection
H
ea
rt 
R
at
e 
%
 c
hg
R
es
pi
ra
tio
n 
R
at
e 
%
 c
hg
**  p < 0.01             * p < 0.05
Table 5-1
 121 
Table 5 – 1: Changes in heart rate (HR) and respiration rate (RR) following saline or 
morphine administration in conscious and anesthetized rats (N = 6).  
Changes in HR and RR post injection were compared with the baseline period 
preceding injection of saline or morphine in conscious and anesthetized animals. 
Anesthetized rats exhibited a significant reduction in RR and HR at 45s and 200s 
following the injection of morphine. No significant changes were observed following the 
injection of saline in anesthetized rats, and no significant changes were observed 
following saline or morphine injections in conscious rats. Significance was determined 
using a two tailed t-test, without a correction for multiple comparisons. 
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Figure 5 – 3: Group average SE BOLD signal changes within S1 in conscious and 
anesthetized rats following morphine or vehicle injection.  
Injections of morphine or vehicle induce transient and insignificant increases in 
BOLD contrast within S1 in conscious rats. In anesthetized rats a transient decrease in 
BOLD is observed following morphine injection and no change is observed following 
vehicle injection. Morphine administered to conscious rats produces a regionally specific 
decrease in BOLD (late onset drop in BOLD) that is observed after 4 minutes following 
injection. The temporal pattern of BOLD responses in conscious rats is thus more 
consistent with the pharmacokinetics of i.v. morphine than the BOLD response observed 
in anesthetized rats. (black bars indicate injection period, N = 6, error bars = SEM). 
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Figure 5 – 4: Late onset changes in the BOLD signal among all regions investigated 
in conscious and anesthetized rats.  
Significant changes in BOLD contrast following morphine administration in 
comparison to vehicle controls were observed during the late onset period (600 – 900 s) 
within the Association Ctx, Orbital Ctx, Olfactory Nucleus, Primary motor area (M1), 
Cingulate Ctx, Primary somatosensory cortex (S1), Caudate putamen (CPu),  Nucleus 
Accumbens (NAc), Insular Ctx, Secondary somatosensory cortex (S2), Lateral globus 
pallidus (Lateral GP), Piriform Ctx, Hippocampus, Auditory Ctx, and Visual Ctx.  No 
significant changes with respect to vehicle controls were observed in anesthetized rats 
during this period.  ** p < 0.01, * p < 0.05. Significance was determined from a two 
tailed t-test, without a correction for multiple comparisons. (N = 6, error bars = SEM).  
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Figure 5 – 5: The frequency of struggle events decreases following morphine 
administration in conscious rats.  
The frequency of animal struggle events among conscious rats was significantly  
reduced following the administration of morphine when compared to the administration 
of saline (** p<0.01, error bars indicate SEM, N = 6, significance determined using a two 
tailed t-test). 
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CHAPTER VI  
BOLD SIGNAL CHANGES IN RESPONSE TO INTRACEREBRAL 
VENTRICULAR APOMORPHINE CHALLENGE IN THE CONSCIOUS 
RAT ARE MODULATED BY PRETREATMENT WITH 
NEUROLEPTICS 
The work presented in this chapter has not been submitted for review. This work 
was conducted under the direction of Dr. Craig Ferris, where my contributions consisted 
of the design and execution of animal experiments, data analysis, and the synthesis of the 
text presented here. Drs. Craig Ferris and Pamela Skoubis completed the animal 
experiments in the olanzapine pretreated group, and Tara Messenger contributed 
significantly to the animal experiments in the saline control group.  
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Introduction 
Schizophrenia is a chronic and debilitating disease that ranks among the 10 most 
significant causes of disability, affecting approximately 1% of the population worldwide 
(Murray et al., 1996). Medications to treat the psychotic symptoms of schizophrenia have 
been available since the early 1950’s (see Chapter I) and greatly improve the prognosis of 
most patients suffering from this disease. The benefits of treatment with older drugs (e.g. 
haloperidol) are tempered by the virtual guarantee of adverse side effects affecting the 
patient’s motor control. Classified as extrapyramidal side effects (EPS), treatment with 
neuroleptics can induce rigidity, tremors, and infrequently the devastating neurological 
syndrome Tardive Dyskinesia, a potentially permanent disorder characterized by 
repetitive, involuntary, purposeless movements (Nestler et al., 2001). Beginning with the 
1990 approval by the FDA of the atypical antipsychotic drug clozapine for the treatment 
of schizophrenia, a new generation of drugs have been developed to offer patients greater 
efficacy with reduced motor side effects, including olanzapine, quetiapine, risperidone, 
aripiprazole. However, patients taking these atypical antipsychotic drugs still suffer from 
a myriad of serious side effects, including: diabetes mellitus, seizures, weight gain, EPS, 
sexual dysfunction, somnolence, asthenia, nausea, hyperglycemia, and the potentially life 
threatening condition of agranulocytosis (Alvir et al., 1993; Nestler et al., 2001; Kinon et 
al., 2004). 
A significant barrier hindering the development of new, atypical antipsychotic 
medications with reduced severity and incidence of side effects is our incomplete 
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understanding of the mechanisms by which typical and atypical antipsychotic drugs 
confer their therapeutic efficacy. In addition to not knowing which receptor or receptors, 
other than D2, are responsible for the therapeutic effects of atypical antipsychotic 
medications (see Chapter I), another fundamental question hinders the rational design of 
novel antipsychotic drugs. In the case of both typical and atypical antipsychotic drugs, 
therapeutic effects are observed only after several weeks of sustained treatment with the 
medication (Nestler et al., 2001; Squire et al., 2003; Katzung, 2004). It is generally 
believed that treatment with any of these medications causes a gradual change in neural 
signaling through neural plastic changes and synaptic remodeling, and that this change in 
signaling confers the therapeutic effects possibly by correcting abnormal communication 
between brain regions such as the striatum, frontal cortex and hippocampus (Horacek et 
al., 2006). The complex response of the intact, conscious brain to stimulation of a 
particular type of receptor (see Chapter V) further confounds our understanding of the 
neural signaling altered by treatment with antipsychotic drugs, and makes it difficult to 
anticipate the substrates ultimately affected by chronic treatment with antipsychotic 
medications.  
The use of neuroimaging to investigate changes in neural signaling, with the hopes 
of identifying the neural substrates that are responsible for the pathogenic state and that 
are altered in the treated state of schizophrenic patients, has increased dramatically in 
recent years. A positron emission tomography (PET) study of glucose metabolism in 
treated schizophrenic patients that abstained from their haloperidol treatment for a period 
of 30 days illustrated that glucose metabolism is decreased in striatal and thalamic areas, 
 130 
and increased in frontal cortical areas with respect to untreated controls (Holcomb et al., 
1996), suggesting that these sites may be important mediators of therapeutic effects. In a 
later study, acute treatment with haloperidol was found to induce changes in neural 
metabolism that differed significantly between responding and non-responding patients 
(Bartlett et al., 1998), where  non-responding patients exhibited a response to acute 
haloperidol challenge that was similar to haloperidol administered to healthy (non-
schizophrenic) adults (Bartlett et al., 1996). Functional paradigms have been used to 
assess differences in brain function under task conditions among schizophrenic patients 
compared with healthy individuals (Holcomb et al., 2000; Lahti et al., 2001; Medoff et 
al., 2001), and the effects of treatment with antipsychotic medications on correcting 
functional abnormalities (Juckel et al., 2006) may be informative for understanding the 
signaling networks in the brain that are modulated by chronic antipsychotic treatment. 
We investigated the effects of acute treatment with typical, atypical, and 
investigational antipsychotic drugs on correlated brain activation following a 
dopaminergic challenge (apomorphine). If acute treatment with antipsychotic drugs 
modulates networks of brain activation that contain nuclei beyond the dopaminergic 
pathways, it may be possible to develop a putative fingerprint of the effects of treatment 
with known antipsychotics for use in the classification and development of novel drugs, 
and for use in identifying patterns of signaling that are altered under chronic vs. acute 
treatment conditions. 
Materials and methods 
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Animal preparation 
Thirty six male Sprague Dawley (SD) rats (300-375 g) were studied. Animals were 
pretreated 45 min prior to scanning with i.p. injection (0.5 mL/kg) of either DMSO 
(Sigma Aldrich), saline, saline and haloperidol (Sigma Aldrich), saline and olanzapine (a 
generous gift from Dr. Gerard Fox at Abbott Laboratories, North Chicago, IL), DMSO 
and clozapine (Sigma Aldrich), or DMSO and SB277011 (a generous gift from Dr. 
Gerard Fox at Abbott Laboratories, North Chicago, IL). Animals were anesthetized with 
2% gaseous isoflurane during surgery, and the anesthesia was reduced to 1.2% during 
placement into an MRI compatible coil and restraint system (Insight Neuroimaging 
Systems, LLC., Worcester, MA). During surgery, a cannula (PE-50 polyethylene tubing, 
Fisher Scientific) was placed into the left lateral ventricle through a small bore hole in the 
skull located 4mm laterally and caudally to the bregma, and inserted a distance of 5mm 
(Figure 6-1, panel d) for the intracerebral ventricular (ICV) administration of 
apomorphine (Sigma Aldrich). Apomorphine was prepared in a 0.5 mg / mL 
concentration and administered to the ventricle with a volume of 10 μL (5 μg of 
apomorphine). The cannula was fixed in place with adhesive and the incision in the scalp 
was summarily sealed. Anesthesia was discontinued after the animal was placed into the 
coil and restraint system, and the animal was allowed to recover consciousness before 
scanning. 
 
MRI methods 
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MRI experiments were carried out on a 4.7T/40cm magnet (Oxford, UK), Bruker 
console (Bruker BioSpin Corp., Billerica, MA). Two actively decoupled coils were used 
for imaging: a 10 cm microstrip resonator volume coil was used for excitation, and a 2.5 
cm ID surface coil was used for signal detection (Insight Neuroimaging, LLC., 
Worcester, MA). High resolution anatomical RARE images were acquired with the 
following parameters: matrix = 128 x 128, FOV = 3 cm x 3 cm, thk = 1.2, rare factor = 8, 
effective TE = 55 ms, TR = 3s, averages = 6, and 12 slices were acquired. Due to spatial 
distortion associated with SE and GE EPI methods (Figure 6-1, panels a – c), functional 
BOLD weighted images were acquired using a RARE sequence with the same geometry 
as the anatomical images and the following sequence parameters: matrix = 64 x 64, 
effective TE = 56 ms, TR = 1.5s, and rare factor = 16. Eighty images were recorded 
sequentially in the functional experiments, and apomorphine was administered via ICV at 
the 30th repetition (180 s).  
Data analysis 
Small amplitude and subvoxel motion in the timecourse data was corrected using 
the program 3dvolreg (Cox, 1996). Functional datasets were coregistered to a common 
anatomical template (Figure 6-1, panel e) using custom software developed in the Java 
programming language and based on the image analysis software ImageJ (Abramoff et 
al., 2004; Schmidt et al., 2004). Regions of interest were defined for several areas using 
the common anatomical template (Figure 6-1, panel e), and changes in BOLD signal 
intensity were measured from within these regions for each functional dataset 
independently. ROIs were defined bilaterally for the amygdala, auditory cortex, cingulate 
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cortex, caudate putamen (CPu), entorhinal cortex, frontal cortex, hippocampus, 
hypothalamus, insular cortex, lateral globus pallidus (LGP), primary motor cortex (M1), 
periaqueductal gray (PAG), prelimbic area, primary somatosensory cortex (S1), 
secondary somatosensory cortex (S2), substantia nigra (SN), thalamus, visual cortex, and 
ventral tegmental area (VTA). 
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Correlation matrices were created for each animal, and averaged together to form 
single correlation matrix representative of the group. Matrices were shaded to illustrate 
correlations greater than 0.28  (significant at the individual test level at p < 0.005) and, 
correlation coefficients exceeding 0.75 (individual p < 10-16) are shaded in the darkest 
color. These thresholds were selected to discriminate correlations among known 
networks of information processing within the brain (see Appendix A, Figures A – 4 
through A – 7 for additional illustrations of resolved networks). Due to the large number 
of comparisons the family-wise error rate (FWER) among drug treatment groups is 0.85 
(Bonferroni correction), but the expected rate of false positive detection (FDR) among 
shaded correlations in Figures 6 – 3 through 6 – 8 is below 0.05 in all cases (Benjamini 
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and Hochberg, 1995). The standard error of the mean of the average correlation matrices 
are shown in Figures A - 1 through A - 3 in the appendix. Equation 6.1 illustrates the 
calculation used to generate the Pearson’s R correlation coefficient, where subscripts i 
and j indicate the ROI being compared, and subscripts Si and Sj indicate the standard 
deviation of the signal measured from within the respective ROI; S (bar) indicates the 
average BOLD signal measured from within the ROI, and N indicates the number of 
repetitions from which signal was measured. Statistical significance was determined from 
inference for correlation (Equation 6.2), and p values were determined from a two-tailed 
evaluation of Student’s t-distribution. Correlation analysis was performed using the 
software package Excel (Microsoft, Inc., Redmond, WA).  
Results 
Intracerebral ventricular administration of apomorphine (5 μg, 10 μL injection 
volume) to conscious animals induces temporally complex changes in BOLD signal 
contrast that vary regionally and between animals (Figure 6-2). In order to detect 
coincident activation of brain areas, a marker of functional connectivity, correlation 
analysis was performed by comparing the BOLD signal changes between regions of 
interest at each time point. Regions of interest were defined on high resolution anatomical 
images, and used to measure average BOLD signal changes over time from functional 
datasets of each animal that had been co-registered to the anatomical dataset (Figure 6-1, 
panel e).   
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For comparison, BOLD signal changes from anesthetized rats experiencing 
electrical forepaw stimulation (see Chapter 2 for methods) were subjected to the 
correlation analysis. BOLD signal changes in the primary somatosensory cortex (S1) 
were highly correlated with BOLD signal changes in the secondary somatosensory cortex 
(S2) in a single subject (Figure 6-3, panel a) while BOLD signal changes measured from 
a background ROI were not correlated with BOLD signal changes measured from S1 
from this subject. Among all animals undergoing electrical forepaw stimulation (N = 6), 
the average correlation coefficient observed between various regions of interest is 
illustrated in Figure 6-3, panel c, and revealed a general correlation among all areas 
investigated except for the visual cortex and thalamus. BOLD signal changes in the 
thalamus did, however, correlate significantly with BOLD signal changes in the primary 
motor area across all animals. Highly significant correlations were observed between 
primary and secondary somatosensory regions, primary motor areas, and areas within the 
basal ganglia such as the lateral globus pallidus, suggesting the detection of functional 
connectivity between these areas. BOLD signal changes from a background ROI did not 
correlate with BOLD signal changes from any of the regions investigated, at the group 
level.  
Correlation analysis of BOLD signal changes among animals receiving 
pretreatment with either saline or DMSO vehicles revealed similar patterns of correlative 
BOLD response following the administration of apomorphine (Figure 6-4). Elements of 
the basal ganglia such as the CPu, thalamus, and lateral globus pallidus (LGP) exhibited a 
correlated response. BOLD signal changes in the thalamus were also correlated with 
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those in S2, while a lack of correlation in S1 may reflect the significant aggregation of 
sensory areas in this ROI. The hippocampus exhibited little correlation with other 
regions, and the frontal cortex and cingulate cortex exhibited heterogeneous correlations 
with other areas that differed between saline and DMSO pretreatments.  
Pretreatment with 1.0 mg / kg haloperidol altered the pattern of correlation when 
compared with the correlation observed during apomorphine challenge among rats pre-
treated with vehicle (saline) alone. Figure 6-5 panel a illustrates the correlations observed 
among animals pretreated with haloperidol, and Figure 6-5, panel b illustrates the 
correlations that are disrupted by pretreatment with haloperidol (red) and the correlations 
that were observed in haloperidol pretreated animals, but not in vehicle controls (blue). 
Correlation was disrupted between several (more than 2) ROIs and the amygdala, 
auditory cortex, frontal cortex, hypothalamus, insular cortex, LGP, S2 and SN, and 
selectively disrupted in the cingulate, CPu, PAG, S1, Thalamus, and visual cortex. New 
patterns of correlation were observed between several ROIs and the hippocampus, LGP, 
PAG, and visual cortex. Correlations were selectively (two or one) disrupted between 
regions and the cingulate cortex, CPu, entorhinal cortex, PAG, S1, thalamus, and visual 
cortex, while new correlations were selectively observed between regions and the 
auditory cortex, cingulate corted, CPu, frontal cortex, hypothalamus, insular cortex, and 
prelimbic area.  
Figure 6 – 6 illustrates the results of pretreatment with 20 mg / kg clozapine in 
comparison to pretreatment with vehicle (DMSO) alone. Correlation was disrupted 
between several ROIs and the amygdala, auditory cortex, cingulate, CPu, entorhinal 
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cortex, hypothalamus, insular cortex, PAG, prelimbic area, S2, SN, and the thalamus, 
while new correlations were observed between several regions and the frontal cortex, 
hippocampus, LGP, and PAG. Correlations were selectively disrupted in the LGP, and 
new correlations were selectively observed in the amygdala, auditory cortex, M1, and 
VTA.    
The results of pretreatment with 3 mg / kg olanzapine are illustrated in Figure 6 – 7 
with comparison of pretreatment with vehicle alone. Correlation was disrupted between 
multiple ROIs and the auditory cortex, cingulate cortex, CPu, frontal cortex, LGP, 
prelimbic area, and S2, while new correlations were observed between multiple areas and 
the entorhinal cortex, LGP, PAG, S1, and SN. Correlations were selectively disrupted 
between various areas and the amygdala, hypothalamus thalamus, and visual cortex, 
while new correlations were selectively observed between various areas and the 
amygdala, cingulate cortex, frontal cortex, hypothalamus insular cortex, visual cortex, 
and VTA. 
Figure 6 – 8 illustrates the results of pretreatment with 10 mg / kg of the selective 
D3 receptor antagonist SB277011 in comparison to animals pretreated with vehicle 
(DMSO) alone. Markedly less disruption of correlations was observed in animals 
pretreated with SB277011 than animals treated with the typical antipsychotic haloperidol, 
or the atypical antipsychotics clozapine and olanzapine. Correlations were disrupted 
between several regions and the auditory cortex, CPu, hypothalamus, insular cortex, PAG 
and thalamus, while new correlations were observed between several regions and the 
CPu, frontal cortex, LGP, M1, and SN. Correlations were selectively disrupted between 
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regions and the amygdala, cingulate, hippocampus, LGP, prelimbic area, S2, and SN, 
while new correlations were selectively observed between regions and the amygdala, 
cingulate, entorhinal cortex, hypothalamus, insular cortex, S1, and S2.  
 
Discussion 
ICV administration of apmorphine in the conscious animal 
Apomorphine has been shown to induce systemic changes in blood pressure and 
hemodynamics that have been linked to a global reduction in BOLD signal intensity that 
obscures BOLD signal changes due to neural activation in the anesthetized animal 
(Kalisch et al., 2005). Concurrent with Kalish et al.’s publication of their study, we 
observed similar BOLD signal changes in the conscious animal that precluded the 
systemic administration of apomorphine in this study. ICV has been demonstrated as an 
effective route for the administration of cocaine in conscious rat studies (Febo et al., 
2004) and it was thus used in this study to ablate the physiological effects of 
apomorphine that would otherwise contaminate the BOLD signal.  
Regional correlation among animals pretreated with vehicles alone 
Pretreatment with either saline or DMSO resulted in similar patterns of correlated 
BOLD signal changes following an apomorphine challenge administered ICV (Figure 6 – 
4). Many nuclei outside of the dopaminergic pathways exhibited correlated responses in a 
manner that is consistent with the functional circuitry of the brain. Correlations between 
 139 
the cingulate cortex and S2, and M1 are consistent with our observations that these areas 
are concomitantly activated following electrical forepaw stimulation (Figure 2 – 1, Figure 
6 – 2, panel c), and supported by correlation between the cingulate and CPu in both 
vehicle controls. In saline pretreated animals, correlations throughout the basal ganglia 
are prominent (CPu, LGP, and Thalamus), although correlation between the CPu and S2 
is stronger than correlation between the CPu and M1 in these animals. In DMSO 
pretreated animals, the CPu exhibited reduced correlation with the LGP, but retained 
correlation with other elements of the basal ganglia observed in saline pretreated animals. 
The anesthetic effects of DMSO (Jacob and Herschler, 1986) may be a factor causing 
reduced motor and sensory stimulation. Frontal cortical and CPu correlation was also 
disrupted in animals pretreated with DMSO as was correlation between the frontal cortex 
and M1, PAG, and prelimbic areas, while correlation between the frontal cortex and 
cingulate and S2 was apparent in both groups.  
Interestingly, S1 and the hippocampus exhibited little correlation with other regions 
investigated. The large ROIs used for these measurements may be a confounding factor 
in correlation analysis. Also, the number of correlations disrupted in animals pretreated 
with DMSO (14) was equal to the number of correlations observed in these animals that 
were not observed in saline pretreated animals, suggesting that this may reflect a general 
limit of the specificity of this analysis.  In Appendix A, Figures A – 4 through A – 7 
illustrate the comparison of observed correlations to known dopaminergic, motor, and 
sensory networks within the brain. 
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Effects of pretreatment with haloperidol, clozapine, olanzapine and the selective D3 
antagonist SB277011 
Pretreatment with haloperidol, clozapine, and olanzapine disrupted a number of 
correlations observed in the vehicle controls consistent with the action of these drugs as 
antagonists; several (haloperidol - 23, clozapine - 37, and olanzapine - 25) distinct 
correlations that were observed in control animals pretreated with vehicle alone were not 
observed in animals that were pretreated with antipsychotic medications. In contrast, the 
number of new correlations observed in pretreated animals was consistent with the 
variance observed between vehicle controls (haloperidol - 16, clozapine - 13, and 
olanzapine - 17). Figure 6 – 9 panel a,  illustrates the features common between 
haloperidol, clozapine, and olanzapine, and indicates disruption of observed correlations 
between the CPu, amygdala and auditory cortex, disruption of correlations between the 
insular and cingulate cortices, and disruption of correlations observed between the LGP 
and hypothalamus. 
In clozapine and olanzapine pretreated animals, a marked disruption in correlation 
between the CPu and other regions was observed; common among both groups were 
disruptions in correlation between the CPu and amygdala, auditory cortex, cingulate 
cortex, prelimbic area, S2, and thalamus (Figure 6 – 9, panel b). Also common among 
these two groups was the disruption of correlations between S2 and the cingulate cortex.  
These disruptions were not apparent in animals pretreated with haloperidol or the D3 
antagonist SB277011, and are consistent with the broader spectrum of antagonism of 
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these drugs (Table 1 – 1), and also include several regions that are innervated by 5-HT 
afferents.  
In contrast to clozapine and olanzapine pretreated animals, haloperidol pretreated 
animals exhibited disruption in correlations observed in vehicle controls between the 
LGP and S2, the frontal cortex and S2, and between the amygdala and auditory cortex 
with several other regions. Surprisingly, the correlation of BOLD signal changes within 
the CPu and other regions was relatively unaffected by pretreatment with haloperidol. 
 Consistent with the atypical antipsychotics clozapine and olanzapine, and in 
contrast to the typical antipsychotic haloperidol, pretreatment with the selective D3 
receptor antagonist SB277011 (Figure 6 – 9, panels c – d) disrupted correlation between 
the CPu, Thalamus, and insular cortex, while correlations were observed between the 
CPu and other regions  including M1, LGP, PAG, and SN that were not observed in 
vehicle controls. It is possible that extrastriatal actions of the atypical antipsychotics and 
SB277011 are the primary contributors to the correlations observed between the CPu and 
other structures. SB277011 has 100 fold higher selectivity for the D3 receptor (Reavill et 
al., 2000) than for the D2 receptor, and D3 receptors are distributed focally throughout 
limbic areas of the brain, (Shafer and Levant, 1998; Gurevich and Joyce, 1999) and in 
thalamic nuclei and the cerebral cortex (Stanwood et al., 2000). Similarly, olanzapine and 
clozapine have reduced affinity for the D2 in comparison to haloperidol, but high affinity 
for several other receptors that are located extrastriatally.  
Implications for the characterization of known and novel antipsychotic drugs 
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This study examines the correlative BOLD response in the conscious rat to an 
apomorphine challenge delivered directly to the brain, and compares this response to that 
observed when animals are pretreated with drugs known to have antipsychotic effects. 
The approach presented herein is unprecedented and technical challenges confound the 
interpretation of our results; however, the data presented in this study may provide a 
valuable basis for the development of a fingerprint of antipsychotic drug actions on the 
intact and conscious brain.  
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Figure 6 – 1: Criteria for selection of functional imaging protocol, location of the 
intracerebral ventricular cannula, and regions of interest defined. 
(a-c) Representative images from functional datasets illustrate the differences in 
distortion and signal dropout due to susceptibility artifacts in BOLD weighted sequences 
acquiring (a) single shot gradient echo EPI, (b) single shot spin echo EPI, and (c) the fast 
spin echo (FSE) used in this study. (d) A representative anatomical image illustrating the 
placement of the canulla for apomorphine infusion in the left cerebral ventricle. (e) 
Illustration of the regions of interest measured. 1 – frontal cortex, 2 – primary motor area 
(M1), 3 – cingulate cortex, 4 – caudate putamen (CPu), 5 – prelimbic area, 6 – primary 
somatosensory region (S1), 7 – lateral globus pallidus (LGP), 8 – secondary 
somatosensory region (S2), 9 – insular cortex, 10 – amygdala, 11 – hypothalamus, 12 – 
hippocampus, 13 – thalamus, 14 –  auditory cortex, 15 – visual cortex, 16 – substantia 
nigra (SN), 17 – periaqueductal gray (PAG), 18 – entorhinal cortex, 19 – ventral 
tegmental area (VTA).   
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Figure 6 – 2: BOLD signal changes induced by apomorphine exhibit complex 
temporal dynamics and intersubject variability. 
Changes in BOLD contrast following the ICV administration of apomorphine to 
conscious rats pretreated with saline exhibit complex temporal dynamics and intersubject 
variability. Time courses of measurements from three ROIs and two animals (A & B) are 
shown. 
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Figure 6 – 3: Correlation analysis of BOLD signal changes under electrical forepaw 
stimulation in anesthetized rats. 
(a) Correlation of BOLD contrast changes in primary and secondary somatosensory 
regions following electrical stimulation of the forepaw in a representative anesthetized 
rat. (b) Correlation of BOLD contrast changes in the primary somatosensory region from 
the same rat compared with BOLD contrast changes measured from a background region 
of interest. (c) Correlation matrix showing group average correlation coefficients for 
multiple regions of interest (N = 6).  
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Cingulate 41% 37% 100% 41% 35% 33% 10% 36% 47% 16% 40% 28% 63% 17% 56% 21% 21% 17% 17%
CPu 40% 34% 41% 100% 22% 25% 11% 41% 47% 20% 21% 20% 31% 4% 43% 18% 29% 21% 27%
Entorhinal Ctx 45% 22% 35% 22% 100% 17% 12% 27% 32% 2% 21% 8% 17% 6% 26% 47% 18% 16% 19%
Frontal Ctx 21% 21% 33% 25% 17% 100% 16% 26% 22% 19% 22% 25% 26% 3% 31% 17% 16% 18% 12%
Hippocampus 20% 8% 10% 11% 12% 16% 100% 30% 11% 18% 12% 17% -2% -6% 26% 15% 7% 10% 17%
hypothalamus 66% 39% 36% 41% 27% 26% 30% 100% 43% 32% 18% 39% 31% 0% 54% 30% 30% 23% 26%
Insular Ctx 52% 32% 47% 47% 32% 22% 11% 43% 100% 16% 25% 20% 32% 8% 54% 12% 37% 13% 7%
LGP 17% 31% 16% 20% 2% 19% 18% 32% 16% 100% 22% 45% 22% 8% 24% 25% 7% 3% 20%
M1 17% 12% 40% 21% 21% 22% 12% 18% 25% 22% 100% 26% 20% 10% 34% 20% 2% -3% 7%
PAG 20% 42% 28% 20% 8% 25% 17% 39% 20% 45% 26% 100% 29% 9% 37% 27% 9% 21% 24%
Prelimbic 27% 28% 63% 31% 17% 26% -2% 31% 32% 22% 20% 29% 100% 16% 41% 15% 7% 11% 10%
S1 -3% 11% 17% 4% 6% 3% -6% 0% 8% 8% 10% 9% 16% 100% 15% 7% 8% 6% -6%
S2 57% 45% 56% 43% 26% 31% 26% 54% 54% 24% 34% 37% 41% 15% 100% 30% 29% 18% 22%
SN 34% 30% 21% 18% 47% 17% 15% 30% 12% 25% 20% 27% 15% 7% 30% 100% 11% 9% 20%
Thalamus 29% 29% 21% 29% 18% 16% 7% 30% 37% 7% 2% 9% 7% 8% 29% 11% 100% 16% -4%
Visual Ctx 17% 26% 17% 21% 16% 18% 10% 23% 13% 3% -3% 21% 11% 6% 18% 9% 16% 100% 12%
VTA 20% 17% 17% 27% 19% 12% 17% 26% 7% 20% 7% 24% 10% -6% 22% 20% -4% 12% 100%
r > 0.28 r > 0.75
 149 
Figure 6 – 4: Correlation analysis of BOLD signal changes following apomorphine 
challenge in conscious rats pre-treated with saline or DMSO.  
Average correlation coefficients are shown. N = 6 in each group. 
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Figure 6 – 5: Correlation analysis of BOLD signal changes following apomorphine 
challenge in conscious rats pretreated with haloperidol.  
Average correlation coefficients are shown. N = 6 in each group. Shading defined as in 
Figure 6 – 4. 
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Amygdala 2.0 1.0 -1.0 1.0 1.0 -1.0 -1.0 2.0 2.0 1.0 -1.0 -1.0 -1.0 -1.0 1.0 1.0 1.0 -1.0 -1.0
Aud Ctx 1.0 2.0 1.0 1.0 -1.0 1.0 -1.0 1.0 1.0 1.0 -1.0 2.0 -1.0 -1.0 2.0 1.0 0.0 1.0 -1.0
Cingulate -1.0 1.0 2.0 2.0 -1.0 2.0 -1.0 0.0 1.0 0.0 2.0 2.0 2.0 -1.0 2.0 -1.0 -1.0 -1.0 -1.0
CPu 1.0 1.0 2.0 2.0 -1.0 2.0 -1.0 -1.0 -1.0 2.0 -1.0 0.0 2.0 -1.0 2.0 -1.0 2.0 -1.0 -1.0
Entorhinal Ctx 1.0 -1.0 -1.0 -1.0 2.0 -1.0 -1.0 -1.0 2.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 2.0 -1.0 -1.0 -1.0
Frontal Ctx -1.0 1.0 2.0 2.0 -1.0 2.0 -1.0 -1.0 -1.0 0.0 2.0 1.0 2.0 -1.0 1.0 -1.0 -1.0 -1.0 -1.0
Hippocampus -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 2.0 -1.0 0.0 -1.0 -1.0 0.0 -1.0 -1.0 0.0 -1.0 -1.0 0.0 -1.0
hypothalamus 2.0 1.0 0.0 -1.0 -1.0 -1.0 -1.0 2.0 1.0 1.0 -1.0 0.0 -1.0 -1.0 2.0 1.0 2.0 -1.0 -1.0
Insular Ctx 2.0 1.0 1.0 -1.0 2.0 -1.0 0.0 1.0 2.0 -1.0 -1.0 -1.0 -1.0 -1.0 2.0 2.0 -1.0 0.0 -1.0
LGP 1.0 1.0 0.0 2.0 -1.0 0.0 -1.0 1.0 -1.0 2.0 -1.0 -1.0 0.0 -1.0 1.0 -1.0 -1.0 -1.0 -1.0
M1 -1.0 -1.0 2.0 -1.0 -1.0 2.0 -1.0 -1.0 -1.0 -1.0 2.0 0.0 2.0 -1.0 2.0 -1.0 -1.0 -1.0 -1.0
PAG -1.0 2.0 2.0 0.0 -1.0 1.0 0.0 0.0 -1.0 -1.0 0.0 2.0 0.0 -1.0 2.0 2.0 -1.0 0.0 -1.0
Prelimbic -1.0 -1.0 2.0 2.0 -1.0 2.0 -1.0 -1.0 -1.0 0.0 2.0 0.0 2.0 -1.0 2.0 -1.0 -1.0 -1.0 -1.0
S1 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 2.0 1.0 -1.0 -1.0 -1.0 -1.0
S2 1.0 2.0 2.0 2.0 -1.0 1.0 0.0 2.0 2.0 1.0 2.0 2.0 2.0 1.0 2.0 -1.0 2.0 2.0 -1.0
SN 1.0 1.0 -1.0 -1.0 2.0 -1.0 -1.0 1.0 2.0 -1.0 -1.0 2.0 -1.0 -1.0 -1.0 2.0 -1.0 -1.0 -1.0
Thalamus 1.0 0.0 -1.0 2.0 -1.0 -1.0 -1.0 2.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 2.0 -1.0 2.0 0.0 -1.0
Visual Ctx -1.0 1.0 -1.0 -1.0 -1.0 -1.0 0.0 -1.0 0.0 -1.0 -1.0 0.0 -1.0 -1.0 2.0 -1.0 0.0 2.0 -1.0
VTA -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 2.0
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A
Amygdala 100% -1% 16% 8% 15% 2% 24% 38% 32% 10% 11% 17% 13% 10% 20% 20% 7% 17% -16%
Aud Ctx -1% 100% 22% 28% 12% 12% 20% 20% 23% 13% 18% 33% 14% 17% 35% 28% 35% 27% 13%
Cingulate 16% 22% 100% 58% 8% 48% 25% 29% 20% 35% 48% 44% 70% 23% 43% 25% 24% 26% 3%
CPu 8% 28% 58% 100% 2% 33% 24% 23% 14% 36% 20% 37% 48% 14% 43% 18% 33% 22% 8%
Entorhinal Ctx 15% 12% 8% 2% 100% 3% 19% 4% 35% -3% -1% 5% 2% 4% -1% 30% 4% 16% 0%
Frontal Ctx 2% 12% 48% 33% 3% 100% 15% 11% 12% 29% 28% 23% 41% 8% 21% 6% 12% 20% 2%
Hippocampus 24% 20% 25% 24% 19% 15% 100% 19% 38% 12% 18% 32% 13% -12% 34% 24% 14% 55% -2%
hypothalamus 38% 20% 29% 23% 4% 11% 19% 100% 22% 21% 15% 29% 24% 19% 35% 14% 35% 17% 1%
Insular Ctx 32% 23% 20% 14% 35% 12% 38% 22% 100% 9% 18% 20% 5% 7% 31% 31% 25% 33% -13%
LGP 10% 13% 35% 36% -3% 29% 12% 21% 9% 100% 20% 24% 32% 27% 27% 17% 18% 16% 8%
M1 11% 18% 48% 20% -1% 28% 18% 15% 18% 20% 100% 29% 34% 22% 28% 13% 10% 21% -6%
PAG 17% 33% 44% 37% 5% 23% 32% 29% 20% 24% 29% 100% 42% 24% 45% 37% 26% 32% 22%
Prelimbic 13% 14% 70% 48% 2% 41% 13% 24% 5% 32% 34% 42% 100% 25% 31% 16% 13% 18% 6%
S1 10% 17% 23% 14% 4% 8% -12% 19% 7% 27% 22% 24% 25% 100% 19% 5% 16% 0% -6%
S2 20% 35% 43% 43% -1% 21% 34% 35% 31% 27% 28% 45% 31% 19% 100% 16% 42% 35% 3%
SN 20% 28% 25% 18% 30% 6% 24% 14% 31% 17% 13% 37% 16% 5% 16% 100% 21% 25% 21%
Thalamus 7% 35% 24% 33% 4% 12% 14% 35% 25% 18% 10% 26% 13% 16% 42% 21% 100% 30% 9%
Visual Ctx 17% 27% 26% 22% 16% 20% 55% 17% 33% 16% 21% 32% 18% 0% 35% 25% 30% 100% 7%
VTA -16% 13% 3% 8% 0% 2% -2% 1% -13% 8% -6% 22% 6% -6% 3% 21% 9% 7% 100%
Haloperidol
Comparison 
with Vehicle
Figure 6-5
r > .28 in both 
groups
r > .28 only in 
vehicle group
r > .28 only in 
haloperidol group  
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Figure 6 – 6: Correlation analysis of BOLD signal changes following apomorphine 
challenge in conscious rats pretreated with clozapine. 
Average correlation coefficients are shown. N = 6 in each group. Shading defined as in 
Figure 6 – 4. 
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A
Amygdala 100% 32% 20% 21% 22% 32% 26% 44% 30% 33% 25% 28% 10% 14% 33% 22% 10% 23% 4%
Aud Ctx 32% 100% 14% 15% 23% 20% 38% 21% 33% 33% 24% 26% 16% 7% 47% 18% 12% 27% 12%
Cingulate 20% 14% 100% 14% 17% 37% 3% 14% 10% 12% 43% 12% 44% 17% 23% 15% 6% 22% 4%
CPu 21% 15% 14% 100% 11% 11% 6% 13% 15% 14% 12% 18% 16% 9% 19% 13% 1% 4% 2%
Entorhinal Ctx 22% 23% 17% 11% 100% 20% 28% 21% 23% 22% 22% 22% 9% 11% 18% 19% 7% 10% 7%
Frontal Ctx 32% 20% 37% 11% 20% 100% 27% 29% 21% 22% 33% 26% 26% 14% 34% 24% 9% 23% -2%
Hippocampus 26% 38% 3% 6% 28% 27% 100% 35% 19% 30% 19% 30% 10% 14% 31% 27% 20% 17% 4%
hypothalamus 44% 21% 14% 13% 21% 29% 35% 100% 27% 26% 20% 23% 9% 9% 28% 20% 13% 11% -4%
Insular Ctx 30% 33% 10% 15% 23% 21% 19% 27% 100% 28% 20% 16% 4% 3% 34% 9% 1% 14% 6%
LGP 33% 33% 12% 14% 22% 22% 30% 26% 28% 100% 19% 23% 17% 4% 29% 15% 22% 21% 2%
M1 25% 24% 43% 12% 22% 33% 19% 20% 20% 19% 100% 28% 14% 18% 31% 17% 8% 25% 2%
PAG 28% 26% 12% 18% 22% 26% 30% 23% 16% 23% 28% 100% 15% 6% 28% 29% 16% 20% 1%
Prelimbic 10% 16% 44% 16% 9% 26% 10% 9% 4% 17% 14% 15% 100% 4% 13% 6% 7% 9% 3%
S1 14% 7% 17% 9% 11% 14% 14% 9% 3% 4% 18% 6% 4% 100% 12% 8% -2% 5% 4%
S2 33% 47% 23% 19% 18% 34% 31% 28% 34% 29% 31% 28% 13% 12% 100% 18% 13% 22% 5%
SN 22% 18% 15% 13% 19% 24% 27% 20% 9% 15% 17% 29% 6% 8% 18% 100% -3% 21% 32%
Thalamus 10% 12% 6% 1% 7% 9% 20% 13% 1% 22% 8% 16% 7% -2% 13% -3% 100% 5% -7%
Visual Ctx 23% 27% 22% 4% 10% 23% 17% 11% 14% 21% 25% 20% 9% 5% 22% 21% 5% 100% 6%
VTA 4% 12% 4% 2% 7% -2% 4% -4% 6% 2% 2% 1% 3% 4% 5% 32% -7% 6% 100%
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Amygdala 2.0 2.0 1.0 1.0 1.0 0.0 -1.0 2.0 2.0 0.0 -1.0 -1.0 -1.0 -1.0 2.0 1.0 1.0 -1.0 -1.0
Aud Ctx 2.0 2.0 1.0 1.0 -1.0 -1.0 0.0 1.0 2.0 2.0 -1.0 1.0 -1.0 -1.0 2.0 1.0 1.0 -1.0 -1.0
Cingulate 1.0 1.0 2.0 1.0 1.0 2.0 -1.0 1.0 1.0 -1.0 2.0 1.0 2.0 -1.0 1.0 -1.0 -1.0 -1.0 -1.0
CPu 1.0 1.0 1.0 2.0 -1.0 -1.0 -1.0 1.0 1.0 -1.0 -1.0 -1.0 1.0 -1.0 1.0 -1.0 1.0 -1.0 -1.0
Entorhinal Ctx 1.0 -1.0 1.0 -1.0 2.0 -1.0 -1.0 -1.0 1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 1.0 -1.0 -1.0 -1.0
Frontal Ctx 0.0 -1.0 2.0 -1.0 -1.0 2.0 -1.0 0.0 -1.0 -1.0 0.0 -1.0 -1.0 -1.0 2.0 -1.0 -1.0 -1.0 -1.0
Hippocampus -1.0 0.0 -1.0 -1.0 -1.0 -1.0 2.0 2.0 -1.0 0.0 -1.0 0.0 -1.0 -1.0 0.0 -1.0 -1.0 -1.0 -1.0
hypothalamus 2.0 1.0 1.0 1.0 -1.0 0.0 2.0 2.0 1.0 1.0 -1.0 1.0 1.0 -1.0 2.0 1.0 1.0 -1.0 -1.0
Insular Ctx 2.0 2.0 1.0 1.0 1.0 -1.0 -1.0 1.0 2.0 0.0 -1.0 -1.0 1.0 -1.0 2.0 -1.0 1.0 -1.0 -1.0
LGP 0.0 2.0 -1.0 -1.0 -1.0 -1.0 0.0 1.0 0.0 2.0 -1.0 1.0 -1.0 -1.0 0.0 -1.0 -1.0 -1.0 -1.0
M1 -1.0 -1.0 2.0 -1.0 -1.0 0.0 -1.0 -1.0 -1.0 -1.0 2.0 0.0 -1.0 -1.0 2.0 -1.0 -1.0 -1.0 -1.0
PAG -1.0 1.0 1.0 -1.0 -1.0 -1.0 0.0 1.0 -1.0 1.0 0.0 2.0 1.0 -1.0 2.0 0.0 -1.0 -1.0 -1.0
Prelimbic -1.0 -1.0 2.0 1.0 -1.0 -1.0 -1.0 1.0 1.0 -1.0 -1.0 1.0 2.0 -1.0 1.0 -1.0 -1.0 -1.0 -1.0
S1 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 2.0 -1.0 -1.0 -1.0 -1.0 -1.0
S2 2.0 2.0 1.0 1.0 -1.0 2.0 0.0 2.0 2.0 0.0 2.0 2.0 1.0 -1.0 2.0 1.0 1.0 -1.0 -1.0
SN 1.0 1.0 -1.0 -1.0 1.0 -1.0 -1.0 1.0 -1.0 -1.0 -1.0 0.0 -1.0 -1.0 1.0 2.0 -1.0 -1.0 0.0
Thalamus 1.0 1.0 -1.0 1.0 -1.0 -1.0 -1.0 1.0 1.0 -1.0 -1.0 -1.0 -1.0 -1.0 1.0 -1.0 2.0 -1.0 -1.0
Visual Ctx -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 2.0 -1.0
VTA -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 0.0 -1.0 -1.0 2.0
Figure 6-6
r > .28  in both 
groups
r > .28 only in 
vehicle group
r > .28 only in 
clozapine group
Clozapine
Comparison 
with Vehicle
 152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – 7: Correlation analysis of BOLD signal changes following apomorphine 
challenge in conscious rats pretreated with olanzapine.  
Average correlation coefficients are shown. N = 6 in each group. Shading defined 
as in Figure 6 – 4. 
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Amygdala 100% 42% 25% 21% 29% 16% 12% 51% 50% 24% 9% 38% 23% 30% 54% 38% 39% 27% 9%
Aud Ctx 42% 100% 31% 20% 18% 11% 14% 41% 30% 17% 16% 34% 25% 15% 39% 34% 20% 38% 3%
Cingulate 25% 31% 100% 16% 14% 24% 7% 27% 23% 15% 31% 21% 62% 32% 27% 28% 16% 39% 0%
CPu 21% 20% 16% 100% 3% 11% 11% 20% 20% 12% 9% 20% 22% 14% 19% 15% 11% 8% -7%
Entorhinal Ctx 29% 18% 14% 3% 100% 26% 8% 27% 18% 39% 14% 31% 22% 21% 38% 47% 26% 16% 30%
Frontal Ctx 16% 11% 24% 11% 26% 100% 28% 19% 7% 29% 16% 24% 27% 22% 23% 25% 11% -3% 13%
Hippocampus 12% 14% 7% 11% 8% 28% 100% 15% 7% 5% 7% 14% 7% 9% 13% 18% 9% -5% 2%
hypothalamus 51% 41% 27% 20% 27% 19% 15% 100% 45% 25% 14% 38% 27% 24% 49% 36% 35% 24% 14%
Insular Ctx 50% 30% 23% 20% 18% 7% 7% 45% 100% 20% 5% 31% 18% 24% 49% 29% 41% 22% 4%
LGP 24% 17% 15% 12% 39% 29% 5% 25% 20% 100% 20% 29% 22% 41% 31% 29% 16% 16% 16%
M1 9% 16% 31% 9% 14% 16% 7% 14% 5% 20% 100% 11% 23% 23% 15% 23% 2% 14% 8%
PAG 38% 34% 21% 20% 31% 24% 14% 38% 31% 29% 11% 100% 24% 24% 47% 53% 19% 15% 23%
Prelimbic 23% 25% 62% 22% 22% 27% 7% 27% 18% 22% 23% 24% 100% 20% 30% 31% 16% 23% 7%
S1 30% 15% 32% 14% 21% 22% 9% 24% 24% 41% 23% 24% 20% 100% 27% 28% 13% 28% 8%
S2 54% 39% 27% 19% 38% 23% 13% 49% 49% 31% 15% 47% 30% 27% 100% 42% 44% 24% 18%
SN 38% 34% 28% 15% 47% 25% 18% 36% 29% 29% 23% 53% 31% 28% 42% 100% 21% 27% 27%
Thalamus 39% 20% 16% 11% 26% 11% 9% 35% 41% 16% 2% 19% 16% 13% 44% 21% 100% 10% 5%
Visual Ctx 27% 38% 39% 8% 16% -3% -5% 24% 22% 16% 14% 15% 23% 28% 24% 27% 10% 100% -4%
VTA 9% 3% 0% -7% 30% 13% 2% 14% 4% 16% 8% 23% 7% 8% 18% 27% 5% -4% 100%
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Amygdala 2.0 2.0 -1.0 1.0 2.0 -1.0 -1.0 2.0 2.0 1.0 -1.0 0.0 -1.0 0.0 2.0 2.0 2.0 -1.0 -1.0
Aud Ctx 2.0 2.0 2.0 1.0 -1.0 1.0 -1.0 2.0 2.0 1.0 -1.0 2.0 -1.0 -1.0 2.0 2.0 -1.0 2.0 -1.0
Cingulate -1.0 2.0 2.0 1.0 -1.0 1.0 -1.0 -1.0 1.0 -1.0 2.0 1.0 2.0 0.0 1.0 -1.0 -1.0 0.0 -1.0
CPu 1.0 1.0 1.0 2.0 -1.0 1.0 -1.0 -1.0 -1.0 1.0 -1.0 -1.0 1.0 -1.0 1.0 -1.0 1.0 -1.0 -1.0
Entorhinal Ctx 2.0 -1.0 -1.0 -1.0 2.0 -1.0 -1.0 -1.0 1.0 0.0 -1.0 0.0 -1.0 -1.0 0.0 2.0 -1.0 -1.0 0.0
Frontal Ctx -1.0 1.0 1.0 1.0 -1.0 2.0 -1.0 -1.0 -1.0 0.0 1.0 1.0 1.0 -1.0 1.0 -1.0 -1.0 -1.0 -1.0
Hippocampus -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 2.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0
hypothalamus 2.0 2.0 -1.0 -1.0 -1.0 -1.0 -1.0 2.0 2.0 1.0 -1.0 0.0 -1.0 -1.0 2.0 2.0 2.0 -1.0 -1.0
Insular Ctx 2.0 2.0 1.0 -1.0 1.0 -1.0 -1.0 2.0 2.0 -1.0 -1.0 0.0 -1.0 -1.0 2.0 2.0 0.0 -1.0 -1.0
LGP 1.0 1.0 -1.0 1.0 0.0 0.0 -1.0 1.0 -1.0 2.0 -1.0 0.0 -1.0 0.0 2.0 0.0 -1.0 -1.0 -1.0
M1 -1.0 -1.0 2.0 -1.0 -1.0 1.0 -1.0 -1.0 -1.0 -1.0 2.0 -1.0 1.0 -1.0 1.0 -1.0 -1.0 -1.0 -1.0
PAG 0.0 2.0 1.0 -1.0 0.0 1.0 -1.0 0.0 0.0 0.0 -1.0 2.0 -1.0 -1.0 2.0 2.0 -1.0 -1.0 -1.0
Prelimbic -1.0 -1.0 2.0 1.0 -1.0 1.0 -1.0 -1.0 -1.0 -1.0 1.0 -1.0 2.0 -1.0 2.0 0.0 -1.0 -1.0 -1.0
S1 0.0 -1.0 0.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 0.0 -1.0 -1.0 -1.0 2.0 1.0 -1.0 -1.0 -1.0 -1.0
S2 2.0 2.0 1.0 1.0 0.0 1.0 -1.0 2.0 2.0 2.0 1.0 2.0 2.0 1.0 2.0 0.0 2.0 1.0 -1.0
SN 2.0 2.0 -1.0 -1.0 2.0 -1.0 -1.0 2.0 2.0 0.0 -1.0 2.0 0.0 -1.0 0.0 2.0 -1.0 -1.0 -1.0
Thalamus 2.0 -1.0 -1.0 1.0 -1.0 -1.0 -1.0 2.0 0.0 -1.0 -1.0 -1.0 -1.0 -1.0 2.0 -1.0 2.0 -1.0 -1.0
Visual Ctx -1.0 2.0 0.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 1.0 -1.0 -1.0 2.0 -1.0
VTA -1.0 -1.0 -1.0 -1.0 0.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 2.0
Figure 6-7
r > .28  in both 
groups
r > .28 only in 
vehicle group
r > .28 only in 
olanzapine group
Olanzapine
Comparison 
with Vehicle
 153 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – 8: Correlation analysis of BOLD signal changes following apomorphine 
challenge in conscious rats pretreated with SB277011. 
Average correlation coefficients are shown. N = 6 in each group. Shading defined 
as in Figure 6 – 4. 
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Figure 6 – 9: Common features between different pretreatment groups. 
Similar patterns of disruption of correlations that were observed in control (vehicle 
pretreated) groups were seen among animals pretreated with typical, atypical, and 
investigational antipsychotic drugs. (a) Common features between haloperidol, clozapine, 
and olanzapine. (b) Common features between clozapine and olanzapine. (c) Common 
features between clozapine and SB277011. (d) Common features between olanzapine and 
SB277011.  
Figure 6-9
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CHAPTER VII 
COMPREHENSIVE DISCUSSION 
 Marston Bates was an American zoologist in the 20th century who is quoted as 
having described research as “the process of going up alleys to see if they are blind.” This 
metaphor is not as cynical as it may first seem, and it astutely describes the presented 
work and ongoing efforts to validate and improve upon phMRI techniques for the 
investigation of psychotropic drugs. Although the avenues explored in the presented 
research failed to yield a universally superior technique for the investigation of the 
actions of drugs on neural activity within the brain, the limitations of these approaches 
are of value in the design and execution of future research, and the knowledge that these 
techniques provide relevant information under carefully controlled circumstances should 
motivate future phMRI investigations. 
Pharmacological MRI is an emerging field with tremendous potential for the 
investigation of psychotropic compounds that is gaining widespread recognition in 
applications such as drug discovery (Wise and Tracey, 2006) and the study of addiction 
(Volkow et al., 2004). The growing literature of pharmacological MRI studies reflects the 
accelerating use of this technology in psychopharmacological research applications, in 
spite of unanswered questions that may significantly impact the interpretation of findings. 
Three questions, in particular, are of central importance for the interpretation of published 
work and for the design and execution of future psychopharmacological research using 
pmMRI; these questions are: Are the functional MRI measurements reliable surrogates of 
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changing neural activity in the presence of pharmacological agents? Is it relevant to 
investigate psychiatric phenomena such as reward or anxiolysis in anesthetized, rather 
than conscious animals? What are the methods that yield reproducible and meaningful 
results from phMRI experiments, and are they consistent in the investigations of different 
drugs, or between conscious and anesthetized animals? The methodological aspects of the 
research presented herein address these questions, and provide incremental advances in 
our understanding of their answers.  
Impact of findings 
In Chapters II and IV, novel techniques and technology were developed for the 
investigation of psychotropic compounds using MRI. These techniques permit dynamic 
observation of hemodynamic and putative metabolic changes using a non-invasive 
imaging modality that enables the identification of complex temporal changes that are 
obscured using traditional autoradiographic techniques (e.g. 2-deoxyglucose) or alternate 
imaging modalities (e.g. PET). The non-invasive nature of these protocols, and the 
similarity between MRI experiments performed in research settings and the MRI scans 
that are routinely performed in the clinic, holds promise that phMRI research in lower 
species will be easily translated to clinically observable phenomena. If this translation is 
realized, it would present an opportunity to validate animal models of psychiatric disease 
and exploit surrogate markers of drug action that are observed in the clinic for the 
development of novel drugs with improved efficacy. 
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 In Chapter III, we illustrated that a multi-modal imaging approach can be used to 
obtain redundant measurements for use in the identification of artifacts unrelated to 
changing neural activity in response to a pharmacological challenge. While these 
redundant measures arguably contain little new information for traditional fMRI 
experiments using a sensory or cognitive stimulus (where BOLD signal changes are 
within published and normal physiological ranges), they were shown to be valuable in the 
investigation of a psychostimulant that induced unexpected changes in BOLD signal 
contrast. In the presented study, the collection of BOLD measurements alone may have 
led to erroneous inferences of changing neural activity, while the collection of multiple 
measurements, simultaneously, provided a sound basis for inference, and presented a 
novel approach for use in other pharmacological investigations. Many drugs of abuse are 
stimulants (e.g., methamphetamine), and it is logical to assume that investigations of 
these drugs will face many of the same challenges as were encountered in our 
investigation of cocaine. 
In Chapter IV, a novel system was developed for multi-modal imaging in the 
conscious rat, representing a significant new capability for the MR research community. 
As we discovered in our investigation of morphine administered in the conscious animal 
(Chapter V), this technology faces many challenges related to animal motion that will 
need to be resolved before multi-modal imaging in the conscious animal supplants 
research performed with anesthetized preparations. Nonetheless, this technological 
advance is a necessary first step towards that end, and logical directions for the 
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improvement of the technology should guide the development of prototypes with greater 
resistance to problems associated with multi-modal imaging in the conscious animal. 
In Chapter V, we addressed the debated issue of differences observed in the fMRI 
response to pharmacological challenge in conscious versus anesthetized animals. With 
the possible exception of general anesthetics, the primary interest in the investigation of 
psychoactive drugs is the effect that these drugs have on the conscious experience after 
acute or chronic administration. Given the number of published studies using 
anesthetized preparations, it is surprising that little effort has been made to demonstrate 
that the fMRI effects observed in anesthetized animals are, indeed, similar to those 
observed in conscious animals following the administration of a given psychoactive drug. 
Pertinacious resistance to imaging conscious animals may be related to the technical 
difficulty associated with these experiments, which is considerable, but our results from 
the administration of morphine to conscious and anesthetized animals provides evidence 
that this may be a necessary hardship in order to collect relevant data. Only in awake rats 
was an effect consistent with the pharmacodynamics of morphine observed, and we 
expect this result to motivate future research in the conscious animal. 
In Chapter VI, we used a SE BOLD weighted imaging sequence with minimal 
anatomical distortion to investigate the effects that antipsychotic medications have on 
dopaminergic signaling induced by an apomorphine challenge delivered directly to the 
brain in the conscious rat. Our goals were to elucidate the changes induced in networks of 
signaling within the brain that are both within and beyond the primary dopaminergic 
pathways, and to develop a potential fingerprint of the actions of antipsychotic drugs for 
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use in the classification of novel antipsychotic compounds. The circumstances of this 
study were challenging, and several changes in the experimental approach are 
recommended for the reproduction of these and similar results in the future. Nonetheless, 
differences in the brains’ response to a dopaminergic challenge were observed when 
animals were pretreated with various typical, atypical, and experimental antipsychotic 
drugs, and it is expected that this work will motivate future studies to examine the 
changes in the brains’ response to dopaminergic challenge that occur following chronic 
treatment with these drugs, under therapeutically relevant conditions (Nestler et al., 2001; 
Katzung, 2004). 
Considerations for phMRI data analysis 
In addition to the methods and results reported herein, a number of unsuccessful 
data analysis strategies were explored that warrant consideration in the general context of 
phMRI experimentation. Unlike traditional fMRI experiments, which elicit a roughly 
binary response to cognitive or sensory stimuli, phMRI experiments elicit complex 
changes in the BOLD signal in response to a pharmacological challenge (see Chapters 
IV, V & VI). Consequently, traditional analysis techniques that rely on the statistical 
power of repetitive stimulus presentation or a priori hemodynamic response functions 
(Worsley and Friston, 1995; Buxton, 2002) are generally inapplicable to phMRI data. 
Additionally, techniques that rely on non-linear regression strategies (Xu et al., 2000; Xi 
et al., 2002; Luo et al., 2004) may detect changes that differ significantly from the 
pharmacodynamics of the drug under investigation, obscuring the meaning of statistical 
significance. Also unlike traditional fMRI experiments, each stimulus (drug) may have a 
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completely different set of effects on MRI measurements. From complex, direct actions 
on neural substrates to indirect actions on the peripheral physiology, no one protocol will 
be suitable for phMRI investigations of all drugs. 
Emerging analysis strategies that are based on the correlated response of multiple 
brain areas to pharmacological challenge, such as principal components analysis (Thirion 
and Faugeras, 2003; Viviani et al., 2005; Liu et al., 2006; Wang et al., 2006), or the direct 
correlation analysis illustrated herein, represent a sensitive new tool for examining the 
coordinated responses of various brain regions, and may yield results which are more 
relevant to our understanding of the neural basis of action of psychotropic drugs than 
traditional fMRI data analysis methods. The raw correlation analysis approach presented 
in Chapter VI suffers from limited specificity, and further work on the receiver operating 
characteristics of this analysis is warranted. 
Future directions 
Investigation of the function of antipsychotic drugs 
Clinical efficacy is observed in many, but not all schizophrenic patients, only after 
weeks of treatment with antipsychotic medications, implicating gradual neuroplastic 
changes as the potential therapeutic mechanism, rather than the acute effects of 
antipsychotic drugs on neurotransmission (Hyman and Nestler, 1996; Nestler et al., 2001; 
Squire et al., 2003).  Several studies have revealed anatomical changes following chronic 
treatment with antipsychotic drugs, generally reflecting an increase in striatal structures 
in both animals (Benes et al., 1985; Chakos et al., 1998) and human patients (Chakos et 
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al., 1994; Keshavan et al., 1994; Gur et al., 1998) following treatment with typical 
antipsychotic drugs (e.g. haloperidol), but treatment with atypical antipsychotic drugs 
does not seem to cause a change in striatal volume, and can reverse presumed increases in 
striatal volume when patients are switched from typical to atypical antipsychotic drugs 
during the course of treatment (Scherk and Falkai, 2006). Further, evidence for 
neurogenesis as a result of treatment with antipsychotic drugs is lacking, suggesting that 
relevant neuroplastic changes following extended treatment with antipsychotic drugs are 
likely due primarily to synaptic remodeling (Konradi and Heckers, 2001). 
Schizophrenia has been considered to be a disorder of functional connectivity 
between the prefrontal cortex and temporal cortices (Bogerts, 1997; Friston, 1998), and 
research has illustrated several changes in the architecture, function, and gene expression 
of striatal and extrastriatal (i.e. prefrontal cortex, hippocampus, and thalamus) neurons 
following treatment with haloperidol, for review, see (Konradi and Heckers, 2001). 
Functional MRI studies of task-related activation have revealed differences between 
schizophrenic patients and normal adults (Braus et al., 2002; Paulus et al., 2002; Kubicki 
et al., 2003; Honey et al., 2005; Tan et al., 2005), as well as between different treatments 
among schizophrenic patients (Zipursky et al., 1998; Honey et al., 1999; Juckel et al., 
2006). These changes in function may be the result of changes in neurotransmission that 
result from synaptic remodeling as a result of exposure to antipsychotic drugs. 
Understanding these changes in neurotransmission in greater detail will have two 
immediate benefits: (1) the relevant changes in neurotransmission may be used as a 
screening tool for the characterization and development of novel antipsychotic drugs, and 
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(2) the changes in neurotransmission may be directly related to the pathology of 
schizophrenia, providing additional insights into the causes of positive symptoms, and the 
changes sufficient for their remission. 
A canonical model of psychosis using animals does not exist, and while we have 
proposed an apomorphine challenge (Chapter VI) as a means to stimulate a relevant and 
measurable response that can be modulated by antipsychotic medications, other 
pharmacological models of psychosis may also be valuable for investigation. Antagonists 
of the NMDA receptor such as phencyclidine (Nestler et al., 2001) and MK801 (Wong et 
al., 1986), and antagonists of the 5-HT2A receptor such as lysergic acid diethylamide 
(LSD) elicit psychotic symptoms such as dissociation and hallucinations (Katzung, 
2004). The effects of these drugs can be modulated with antipsychotic medications 
(Miller et al., 1992; Schroeder et al., 2000; Linn et al., 2003; Hashimoto et al., 2005), and 
these modulations may be detectable by phMRI using techniques similar to those 
presented in Chapter VI. The insights gained from such experiments may reveal aspects 
of modulated neural signaling that relate directly to positive symptoms of psychosis (e.g., 
hallucinations) in a more specific manner than observations following a dopaminergic 
challenge such as apomorphine. 
Further improvements in phMRI methodology are required 
The research presented in Chapter V demonstrates significant differences in the 
phMRI response to morphine challenge in conscious vs. anesthetized rats. It is the 
opinion of the author that future phMRI studies will need to demonstrate consistency 
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between results obtained from anesthetized and conscious animals before inferences can 
be made regarding a drug’s action in the conscious animal. The technical difficulty 
associated with performing phMRI experiments in conscious animals is considerable, 
primarily due to animal motion during image acquisition, and may explain the low 
frequency of published results using conscious preparations. However, novel restraint 
systems with integrated coil designs (Insight Neuroimaging Systems, LLC., Worcester, 
MA) greatly facilitate the process of imaging conscious animals, and the improvement of 
these systems and the methods for their use to further reduce animal motion is ongoing.  
Multimodal imaging, specifically the measurement of CBF in the same 
experimental setting for measuring changes in BOLD or CBV, was shown to be an 
important capability in the interpretation of changes in neural activity following the 
administration of cocaine in Chapter III. The challenges of multimodal imaging in the 
conscious animal, specifically the use of arterial spin labeling techniques with multislice 
acquisition, are discussed in Chapter IV. These challenges will require significant 
experimental effort to address, and will likely require innovative changes in neck coil 
design, and may require the use of alternate labeling strategies such as spatially selective 
adiabatic inversion pulses (Zhan et al., 2002; Moffat et al., 2005). Currently, the 
technology is insufficient for the reliable detection of significant changes at the voxel 
level under several stimulus paradigms. While ROI based analysis is an effective means 
of increasing statistical power, it suffers from subjective influence and errors in the 
definition of ROIs, and can result in reduced statistical power when all voxels within the 
region are not activated equivalently. Future advances in this particular aspect of the 
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hardware and pulse sequences used in conscious animal phMRI experiments will enable 
redundant measurement of changing hemodynamics resulting from pharmacological 
challenge, permitting the identification of signal artifacts and the estimation of changes in 
metabolism related to neural activation.  
 Final comments 
Like any contemporary research, the work presented in this dissertation is work still 
in progress. Pharmacological MRI methods will undergo many future improvements 
before the ability to monitor changes in neural activity elicited by psychoactive drugs is 
reliably measured and reproducible between laboratories. Similarly, the reported 
modulation of neural activity resulting from a dopaminergic challenge by pretreatment 
with antipsychotic drugs is a preliminary glimpse of a phenomenon that requires 
additional investigation; both to answer new questions raised earlier in this chapter, as 
well as to address limitations of the technique discussed in Chapter VI. Hopefully, the 
incremental progress reported in the present studies will motivate this research, and 
provide a basis for future investigations that will help to elucidate the pathological 
mechanisms of psychiatric diseases, and guide the development of novel therapies to treat 
them. 
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Figure A – 1: Standard errors of group mean correlation matrices in saline and 
DMSO pretreatment groups (N = 6) 
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Aud Ctx 11% 0% 13% 17% 14% 13% 14% 5% 10% 12% 14% 12% 11% 17% 6% 9% 13% 12% 8%
Cingulate 12% 13% 0% 14% 13% 6% 12% 5% 5% 11% 13% 9% 3% 16% 13% 9% 9% 8% 5%
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PAG 13% 12% 9% 15% 9% 10% 9% 7% 9% 13% 10% 0% 10% 9% 5% 7% 6% 12% 4%
Prelimbic 6% 11% 3% 12% 11% 9% 9% 5% 3% 3% 6% 10% 0% 11% 7% 8% 11% 4% 6%
S1 13% 17% 16% 11% 17% 14% 11% 11% 13% 12% 17% 9% 11% 0% 18% 9% 11% 9% 2%
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SN 7% 9% 9% 10% 5% 13% 9% 4% 7% 10% 10% 7% 8% 9% 6% 0% 6% 9% 6%
Thalamus 13% 13% 9% 14% 5% 6% 14% 10% 10% 10% 6% 6% 11% 11% 14% 6% 0% 10% 3%
Visual Ctx 4% 12% 8% 8% 10% 5% 12% 5% 7% 13% 9% 12% 4% 9% 9% 9% 10% 0% 8%
VTA 3% 8% 5% 5% 5% 5% 5% 7% 8% 4% 6% 4% 6% 2% 4% 6% 3% 8% 0%
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Amygdala 0% 10% 11% 11% 9% 7% 11% 5% 7% 15% 10% 14% 9% 4% 7% 7% 14% 7% 5%
Aud Ctx 10% 0% 9% 13% 13% 11% 13% 13% 7% 9% 13% 11% 9% 9% 11% 11% 11% 7% 7%
Cingulate 11% 9% 0% 14% 9% 10% 10% 8% 11% 9% 16% 13% 7% 9% 12% 8% 14% 7% 7%
CPu 11% 13% 14% 0% 9% 9% 8% 13% 16% 14% 13% 13% 11% 5% 15% 13% 16% 7% 7%
Entorhinal Ctx 9% 13% 9% 9% 0% 13% 9% 10% 11% 14% 10% 17% 7% 11% 10% 10% 5% 12% 13%
Frontal Ctx 7% 11% 10% 9% 13% 0% 10% 8% 7% 7% 10% 7% 10% 4% 10% 5% 12% 9% 4%
Hippocampus 11% 13% 10% 8% 9% 10% 0% 13% 8% 9% 10% 16% 8% 4% 15% 11% 12% 8% 6%
hypothalamus 5% 13% 8% 13% 10% 8% 13% 0% 10% 7% 9% 10% 9% 8% 6% 9% 14% 7% 5%
Insular Ctx 7% 7% 11% 16% 11% 7% 8% 10% 0% 10% 11% 9% 9% 7% 8% 10% 14% 7% 13%
LGP 15% 9% 9% 14% 14% 7% 9% 7% 10% 0% 10% 11% 4% 11% 12% 10% 15% 6% 6%
M1 10% 13% 16% 13% 10% 10% 10% 9% 11% 10% 0% 15% 15% 4% 16% 11% 7% 3% 8%
PAG 14% 11% 13% 13% 17% 7% 16% 10% 9% 11% 15% 0% 10% 8% 15% 11% 10% 8% 3%
Prelimbic 9% 9% 7% 11% 7% 10% 8% 9% 9% 4% 15% 10% 0% 6% 12% 8% 15% 5% 5%
S1 4% 9% 9% 5% 11% 4% 4% 8% 7% 11% 4% 8% 6% 0% 12% 4% 10% 9% 6%
S2 7% 11% 12% 15% 10% 10% 15% 6% 8% 12% 16% 15% 12% 12% 0% 8% 17% 8% 5%
SN 7% 11% 8% 13% 10% 5% 11% 9% 10% 10% 11% 11% 8% 4% 8% 0% 10% 5% 10%
Thalamus 14% 11% 14% 16% 5% 12% 12% 14% 14% 15% 7% 10% 15% 10% 17% 10% 0% 7% 16%
Visual Ctx 7% 7% 7% 7% 12% 9% 8% 7% 7% 6% 3% 8% 5% 9% 8% 5% 7% 0% 5%
VTA 5% 7% 7% 7% 13% 4% 6% 5% 13% 6% 8% 3% 5% 6% 5% 10% 16% 5% 0%
DMSO STDERR
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Figure A – 2: Standard errors of group mean correlation matrices in haloperidol and 
clozapine pretreatment groups (N = 6) 
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Amygdala 0% 13% 8% 9% 10% 14% 8% 13% 10% 5% 8% 8% 10% 11% 11% 8% 10% 5% 4%
Aud Ctx 13% 0% 12% 13% 14% 10% 22% 20% 18% 15% 7% 14% 16% 8% 16% 13% 11% 15% 9%
Cingulate 8% 12% 0% 15% 13% 11% 16% 6% 18% 7% 14% 8% 7% 14% 13% 11% 9% 14% 6%
CPu 9% 13% 15% 0% 16% 13% 17% 7% 21% 11% 8% 13% 16% 4% 17% 14% 9% 14% 3%
Entorhinal Ctx 10% 14% 13% 16% 0% 6% 8% 13% 12% 5% 10% 19% 15% 9% 18% 8% 13% 11% 12%
Frontal Ctx 14% 10% 11% 13% 6% 0% 10% 5% 13% 6% 11% 9% 9% 20% 12% 7% 7% 7% 7%
Hippocampus 8% 22% 16% 17% 8% 10% 0% 17% 14% 11% 12% 12% 12% 21% 19% 10% 22% 16% 3%
hypothalamus 13% 20% 6% 7% 13% 5% 17% 0% 23% 4% 10% 6% 6% 8% 14% 7% 15% 12% 14%
Insular Ctx 10% 18% 18% 21% 12% 13% 14% 23% 0% 8% 13% 17% 14% 13% 26% 6% 21% 10% 9%
LGP 5% 15% 7% 11% 5% 6% 11% 4% 8% 0% 6% 7% 9% 9% 9% 8% 9% 8% 6%
M1 8% 7% 14% 8% 10% 11% 12% 10% 13% 6% 0% 11% 7% 16% 7% 6% 10% 13% 4%
PAG 8% 14% 8% 13% 19% 9% 12% 6% 17% 7% 11% 0% 9% 11% 6% 10% 7% 12% 9%
Prelimbic 10% 16% 7% 16% 15% 9% 12% 6% 14% 9% 7% 9% 0% 8% 13% 12% 9% 10% 7%
S1 11% 8% 14% 4% 9% 20% 21% 8% 13% 9% 16% 11% 8% 0% 6% 5% 11% 7% 5%
S2 11% 16% 13% 17% 18% 12% 19% 14% 26% 9% 7% 6% 13% 6% 0% 14% 12% 14% 9%
SN 8% 13% 11% 14% 8% 7% 10% 7% 6% 8% 6% 10% 12% 5% 14% 0% 9% 7% 4%
Thalamus 10% 11% 9% 9% 13% 7% 22% 15% 21% 9% 10% 7% 9% 11% 12% 9% 0% 12% 9%
Visual Ctx 5% 15% 14% 14% 11% 7% 16% 12% 10% 8% 13% 12% 10% 7% 14% 7% 12% 0% 3%
VTA 4% 9% 6% 3% 12% 7% 3% 14% 9% 6% 4% 9% 7% 5% 9% 4% 9% 3% 0%
Haloperidol STDERR
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Amygdala 0% 11% 12% 14% 10% 9% 13% 11% 13% 9% 11% 9% 10% 7% 10% 11% 7% 11% 4%
Aud Ctx 11% 0% 10% 14% 7% 7% 9% 12% 11% 7% 7% 9% 4% 8% 8% 8% 8% 13% 8%
Cingulate 12% 10% 0% 4% 8% 8% 13% 9% 9% 11% 15% 11% 5% 5% 8% 7% 3% 13% 7%
CPu 14% 14% 4% 0% 10% 6% 13% 12% 13% 15% 7% 9% 11% 9% 16% 3% 4% 6% 3%
Entorhinal Ctx 10% 7% 8% 10% 0% 7% 14% 11% 14% 10% 9% 9% 8% 7% 9% 7% 7% 9% 2%
Frontal Ctx 9% 7% 8% 6% 7% 0% 12% 7% 11% 11% 15% 11% 7% 7% 7% 10% 8% 15% 5%
Hippocampus 13% 9% 13% 13% 14% 12% 0% 11% 15% 13% 16% 13% 7% 11% 11% 12% 14% 16% 6%
hypothalamus 11% 12% 9% 12% 11% 7% 11% 0% 13% 9% 10% 7% 10% 6% 9% 12% 12% 11% 10%
Insular Ctx 13% 11% 9% 13% 14% 11% 15% 13% 0% 12% 10% 10% 10% 9% 11% 14% 2% 14% 5%
LGP 9% 7% 11% 15% 10% 11% 13% 9% 12% 0% 14% 9% 6% 10% 9% 11% 8% 10% 4%
M1 11% 7% 15% 7% 9% 15% 16% 10% 10% 14% 0% 9% 13% 11% 10% 11% 4% 15% 6%
PAG 9% 9% 11% 9% 9% 11% 13% 7% 10% 9% 9% 0% 8% 6% 7% 10% 8% 11% 3%
Prelimbic 10% 4% 5% 11% 8% 7% 7% 10% 10% 6% 13% 8% 0% 7% 6% 7% 2% 8% 6%
S1 7% 8% 5% 9% 7% 7% 11% 6% 9% 10% 11% 6% 7% 0% 13% 2% 1% 5% 5%
S2 10% 8% 8% 16% 9% 7% 11% 9% 11% 9% 10% 7% 6% 13% 0% 11% 8% 13% 5%
SN 11% 8% 7% 3% 7% 10% 12% 12% 14% 11% 11% 10% 7% 2% 11% 0% 7% 10% 5%
Thalamus 7% 8% 3% 4% 7% 8% 14% 12% 2% 8% 4% 8% 2% 1% 8% 7% 0% 6% 8%
Visual Ctx 11% 13% 13% 6% 9% 15% 16% 11% 14% 10% 15% 11% 8% 5% 13% 10% 6% 0% 6%
VTA 4% 8% 7% 3% 2% 5% 6% 10% 5% 4% 6% 3% 6% 5% 5% 5% 8% 6% 0%
Clozapine STDERR
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Figure A – 3: Standard errors of group mean correlation matrices in olanzapine and 
SB277011 pretreatment groups (N = 6) 
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Amygdala 0% 13% 14% 9% 13% 7% 9% 8% 12% 10% 12% 4% 7% 14% 10% 9% 15% 17% 8%
Aud Ctx 13% 0% 16% 13% 15% 11% 8% 14% 14% 12% 13% 10% 11% 15% 15% 13% 12% 17% 11%
Cingulate 14% 16% 0% 13% 16% 11% 9% 15% 9% 12% 19% 13% 10% 13% 14% 14% 7% 11% 9%
CPu 9% 13% 13% 0% 8% 9% 7% 11% 9% 15% 12% 10% 8% 12% 10% 9% 9% 10% 3%
Entorhinal Ctx 13% 15% 16% 8% 0% 11% 9% 11% 15% 9% 14% 12% 11% 13% 11% 10% 8% 22% 8%
Frontal Ctx 7% 11% 11% 9% 11% 0% 14% 6% 11% 11% 10% 7% 9% 13% 8% 7% 5% 12% 5%
Hippocampus 9% 8% 9% 7% 9% 14% 0% 6% 6% 5% 6% 6% 6% 8% 5% 10% 6% 7% 3%
hypothalamus 8% 14% 15% 11% 11% 6% 6% 0% 8% 12% 13% 8% 9% 16% 10% 10% 12% 17% 6%
Insular Ctx 12% 14% 9% 9% 15% 11% 6% 8% 0% 11% 8% 7% 6% 12% 12% 10% 13% 14% 10%
LGP 10% 12% 12% 15% 9% 11% 5% 12% 11% 0% 11% 10% 8% 15% 13% 11% 7% 16% 11%
M1 12% 13% 19% 12% 14% 10% 6% 13% 8% 11% 0% 11% 18% 15% 12% 14% 4% 13% 6%
PAG 4% 10% 13% 10% 12% 7% 6% 8% 7% 10% 11% 0% 6% 12% 7% 7% 9% 14% 8%
Prelimbic 7% 11% 10% 8% 11% 9% 6% 9% 6% 8% 18% 6% 0% 10% 9% 10% 7% 10% 5%
S1 14% 15% 13% 12% 13% 13% 8% 16% 12% 15% 15% 12% 10% 0% 17% 15% 11% 14% 11%
S2 10% 15% 14% 10% 11% 8% 5% 10% 12% 13% 12% 7% 9% 17% 0% 11% 15% 16% 9%
SN 9% 13% 14% 9% 10% 7% 10% 10% 10% 11% 14% 7% 10% 15% 11% 0% 10% 17% 9%
Thalamus 15% 12% 7% 9% 8% 5% 6% 12% 13% 7% 4% 9% 7% 11% 15% 10% 0% 8% 6%
Visual Ctx 17% 17% 11% 10% 22% 12% 7% 17% 14% 16% 13% 14% 10% 14% 16% 17% 8% 0% 15%
VTA 8% 11% 9% 3% 8% 5% 3% 6% 10% 11% 6% 8% 5% 11% 9% 9% 6% 15% 0%
Olanzapine STDERR
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Amygdala 0% 6% 14% 16% 16% 23% 6% 11% 17% 12% 17% 20% 16% 8% 11% 14% 18% 19% 15%
Aud Ctx 6% 0% 8% 6% 10% 10% 10% 6% 9% 5% 5% 9% 4% 10% 10% 9% 8% 6% 5%
Cingulate 14% 8% 0% 14% 19% 19% 10% 13% 19% 12% 19% 18% 9% 13% 17% 12% 11% 11% 19%
CPu 16% 6% 14% 0% 23% 19% 6% 13% 21% 17% 19% 17% 16% 17% 20% 20% 10% 11% 17%
Entorhinal Ctx 16% 10% 19% 23% 0% 27% 13% 14% 18% 15% 22% 25% 16% 14% 23% 14% 5% 12% 13%
Frontal Ctx 23% 10% 19% 19% 27% 0% 4% 22% 23% 20% 19% 8% 13% 8% 18% 27% 13% 12% 10%
Hippocampus 6% 10% 10% 6% 13% 4% 0% 7% 6% 9% 7% 9% 5% 14% 7% 8% 2% 7% 4%
hypothalamus 11% 6% 13% 13% 14% 22% 7% 0% 18% 13% 15% 16% 12% 9% 11% 14% 20% 17% 16%
Insular Ctx 17% 9% 19% 21% 18% 23% 6% 18% 0% 12% 21% 19% 15% 5% 17% 17% 16% 16% 17%
LGP 12% 5% 12% 17% 15% 20% 9% 13% 12% 0% 15% 14% 14% 8% 14% 10% 11% 12% 13%
M1 17% 5% 19% 19% 22% 19% 7% 15% 21% 15% 0% 18% 18% 14% 16% 16% 11% 8% 16%
PAG 20% 9% 18% 17% 25% 8% 9% 16% 19% 14% 18% 0% 13% 15% 13% 18% 6% 7% 8%
Prelimbic 16% 4% 9% 16% 16% 13% 5% 12% 15% 14% 18% 13% 0% 4% 11% 14% 4% 7% 12%
S1 8% 10% 13% 17% 14% 8% 14% 9% 5% 8% 14% 15% 4% 0% 18% 5% 16% 8% 7%
S2 11% 10% 17% 20% 23% 18% 7% 11% 17% 14% 16% 13% 11% 18% 0% 17% 17% 11% 18%
SN 14% 9% 12% 20% 14% 27% 8% 14% 17% 10% 16% 18% 14% 5% 17% 0% 11% 17% 21%
Thalamus 18% 8% 11% 10% 5% 13% 2% 20% 16% 11% 11% 6% 4% 16% 17% 11% 0% 10% 9%
Visual Ctx 19% 6% 11% 11% 12% 12% 7% 17% 16% 12% 8% 7% 7% 8% 11% 17% 10% 0% 9%
VTA 15% 5% 19% 17% 13% 10% 4% 16% 17% 13% 16% 8% 12% 7% 18% 21% 9% 9% 0%
SB277011 STDERR
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Figure A – 4: Correlations observed among sensory and motor pathways in 
electrical forepaw stimulation analysis. 
All of the highly significant correlations (r > 0.75) and several other significant 
correlations (r > 0.28) are shown circled in red boxes (bottom panel). These regions 
recapitulate the sensory and motor circuitry expected to be stimulated following electrical 
forepaw stimulation (top panel).  
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Cingulate 68% 100% 57% 51% 34% 72% 76% 82% 79% 69% 88% 86% 29% 0% 1%
CPu 46% 57% 100% 42% 20% 47% 51% 57% 47% 46% 57% 57% 18% -4% 5%
Frontal Ctx 31% 51% 42% 100% 24% 32% 39% 45% 38% 44% 47% 45% 7% 7% 1%
Hippocampus 35% 34% 20% 24% 100% 34% 38% 36% 32% 23% 37% 39% 14% 7% -3%
hypothalamus 67% 72% 47% 32% 34% 100% 73% 70% 72% 48% 76% 74% 26% 1% -3%
Insular Ctx 59% 76% 51% 39% 38% 73% 100% 74% 71% 52% 77% 75% 24% -2% -1%
LGP 69% 82% 57% 45% 36% 70% 74% 100% 74% 57% 81% 79% 27% -2% 4%
M1 69% 79% 47% 38% 32% 72% 71% 74% 100% 51% 81% 78% 29% 0% 3%
Prelimbic 50% 69% 46% 44% 23% 48% 52% 57% 51% 100% 60% 58% 18% -3% -2%
S1forepaw 73% 88% 57% 47% 37% 76% 77% 81% 81% 60% 100% 91% 28% 3% -1%
S2 76% 86% 57% 45% 39% 74% 75% 79% 78% 58% 91% 100% 26% 3% 1%
Thalamus 33% 29% 18% 7% 14% 26% 24% 27% 29% 18% 28% 26% 100% -8% 4%
Visual Ctx 2% 0% -4% 7% 7% 1% -2% -2% 0% -3% 3% 3% -8% 100% -12%
Background 2% 1% 5% 1% -3% -3% -1% 4% 3% -2% -1% 1% 4% -12% 100%
Figure A-4
r > 0.28 r > 0.75
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Figure A – 5: Correlation between regions of the mesolimbic dopamine network 
following ICV apomorphine administration.   
Red boxes indicate correlations exceeding 0.28 (bottom panel) that were observed 
between components of the mesolimbic dopamine network (top panel) in animals that 
were pretreated with vehicle only. Shading defined as in Figure A – 4. 
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Amygdala 100% 41% 25% 31% 40% 27% 15% 68% 56% 41% 18% 27% 17% 15% 47% 37% 38% 9% 2%
Aud Ctx 41% 100% 39% 30% 23% 36% 20% 39% 37% 32% 25% 44% 26% 21% 59% 37% 26% 40% 17%
Cingulate 25% 39% 100% 38% 11% 52% 26% 28% 35% 19% 46% 34% 63% 26% 44% 22% 27% 19% 8%
CPu 31% 30% 38% 100% 15% 32% 18% 27% 28% 32% 12% 26% 36% 7% 31% 21% 35% 2% 4%
Entorhinal Ctx 40% 23% 11% 15% 100% 14% 5% 24% 34% 28% 6% 20% 11% 10% 8% 48% 17% -8% 4%
Frontal Ctx 27% 36% 52% 32% 14% 100% 12% 22% 23% 21% 34% 32% 38% 22% 41% 19% 27% 20% 6%
Hippocampus 15% 20% 26% 18% 5% 12% 100% 17% 23% -3% 11% 20% 24% 14% 27% 17% 20% 19% 8%
hypothalamus 68% 39% 28% 27% 24% 22% 17% 100% 52% 28% 16% 28% 18% 11% 47% 32% 40% 11% 7%
Insular Ctx 56% 37% 35% 28% 34% 23% 23% 52% 100% 26% 24% 25% 27% 20% 53% 29% 27% 20% 1%
LGP 41% 32% 19% 32% 28% 21% -3% 28% 26% 100% 22% 18% 18% 16% 32% 17% 26% -2% -4%
M1 18% 25% 46% 12% 6% 34% 11% 16% 24% 22% 100% 20% 36% 25% 30% 12% 7% 17% -7%
PAG 27% 44% 34% 26% 20% 32% 20% 28% 25% 18% 20% 100% 25% 14% 36% 42% 19% 20% 19%
Prelimbic 17% 26% 63% 36% 11% 38% 24% 18% 27% 18% 36% 25% 100% 19% 32% 18% 17% 15% 8%
S1 15% 21% 26% 7% 10% 22% 14% 11% 20% 16% 25% 14% 19% 100% 35% 9% 10% 21% 1%
S2 47% 59% 44% 31% 8% 41% 27% 47% 53% 32% 30% 36% 32% 35% 100% 22% 37% 33% 12%
SN 37% 37% 22% 21% 48% 19% 17% 32% 29% 17% 12% 42% 18% 9% 22% 100% 25% 15% 22%
Thalamus 38% 26% 27% 35% 17% 27% 20% 40% 27% 26% 7% 19% 17% 10% 37% 25% 100% 5% 9%
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Figure A – 6: Correlation between regions associated with nociception and sensory 
information processing following ICV apomorphine administration.   
Red boxes indicate correlations exceeding 0.28 (bottom panel) that were observed 
between components of known sensory and nociceptive information processing networks 
(top panel) in animals that were pretreated with vehicles only. Shading defined as in 
Figure A – 4. 
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Figure A – 7: Correlation between regions associated with motor control and 
sensory information processing following ICV apomorphine administration.   
Red boxes indicate correlations exceeding 0.28 (bottom panel) that were observed 
between components of known motor control and sensory information processing 
networks (top panel) in animals that were pretreated with vehicles only. Shading defined 
as in Figure A – 4.  
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APPENDIX B 
CONSIDERATIONS IN CHOOSING AN IMAGING METHOD FOR 
phMRI EXPERIMENTS 
The neuroscience investigator planning to use phMRI to probe the effects of drugs 
on neural activity within the brain is faced with several questions that dramatically affect 
the study design. The answers to these questions are not easily obtained, and guidance for 
making assumptions in phMRI study design is scant. Beyond the question of whether to 
perform experiments using conscious or anesthetized animals, the variety of technical 
approaches and data presented in this dissertation raises some specific questions 
regarding technical strategy: Should I try to acquire multiple measures simultaneously? 
Which is better, BOLD, CBF, or CBV? Can I administer my drugs peripherally, or will 
ICV administration be necessary? What spatial and temporal resolution should I use, and 
with which acquisition protocol? All of these questions are motivated by the more 
important general concern: How can I be sure that this approach will work? 
Experiments using conscious animals 
In Chapter 5, data are presented which support the argument that, in the context of 
understanding the relevant changes in neural activity that are induced by a psychotropic 
drug of interest, equivalence must be demonstrated between anesthetized and conscious 
preparations before conclusions can be drawn from experiments performed in 
anesthetized animals alone. Currently, few drugs have been investigated by phMRI in 
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conscious animals, and the burden of proof is on the investigator to perform any 
validating experiments before working with anesthetized preparations. In addition to the 
technical difficulty of performing experiments using conscious animals, factors may 
confound the comparison of data acquired from conscious animals to data acquired from 
anesthetized animals. These factors include the stress and sensory stimulation of 
conscious rats that are restrained inside the magnet and exposed to auditory stimulation 
during an MRI scan. These factors can be minimized by acclimation to the restraint 
apparatus and auditory experience of an MRI scan, and acclimation has been shown to 
reduce corticosterone release with repeated exposure to a simulated scanning 
environment (King et al., 2005). 
Considerations for selecting the functional imaging modality, image acquisition 
protocol, and route of drug administration 
Regrettably, there is no single approach that is ideal for all pharmacological MRI 
investigations, and there is no guarantee that a particular approach will be successful 
under novel circumstances. Dependency on the drug under investigation, the brain 
regions being investigated, the nature of data analysis, available resources (such as 
proprietary blood pool contrast agents), and study design (single session or longitudinal) 
are all important factors in determining the best approach. In any case, a single completed 
study is insufficient grounds for determining the best approach for investigating an 
unrelated drug. For example, consider the data presented in Chapter 3.  
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Based on the data presented in Chapter 3, one might draw the conclusion that 
BOLD measurements should be avoided for their propensity to produce erroneous or 
misleading results. This conclusion is premature in the absence of a comparative analysis 
of BOLD and alternative functional MR imaging modalities under the specific study 
conditions being considered. It is true that BOLD imaging is prone to contamination by a 
wider spectrum of physiological and experimental phenomena than contrast agent 
enhanced CBV or arterial spin labeling CBF measurements, but neither of these alternate 
modalities is failsafe. In Chapter 3, simultaneous acquisition of CBF and BOLD changes 
provided evidence to support the claim that negative BOLD changes observed along the 
cortical surface were artifacts, rather than changes indicative of reduced neural activity in 
these regions. However, the decision to collect this multi-modal information is dependent 
on several factors that may be best informed by understanding the specific limitations 
encountered in the presented research. 
Figure B – 1 illustrates some of the limitations of various phMRI imaging 
modalities, acquisition protocols, and routes of administration, as determined from the 
research presented in the studies herein. As shown in Figure B – 1, phMRI Study Feature 
1, phMRI investigations that anticipate neural activation, especially potent and 
widespread activation as seen with psychostimulants, suffer few, if any, limitations using 
specific functional imaging modalities. The significant hemodynamic response that 
results from neural stimulation is easily detected using BOLD, CBF, or CBV methods 
and specific anomalies such as those presented in Chapter 3 are readily detected and 
resolved with multimodal or sequential, unimodal imaging experiments. Imaging 
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conscious animals during the administration of psychostimulants can be challenging due 
to the increase in motor activity following drug administration, potentially causing severe 
motion artifacts. 
Neural deactivation paradigms, such as the investigation of sedative drugs, present 
a different set of challenges (Figure B – 1, Study Feature 2). Reductions in CBF and CBV 
following neural deactivation have not been widely reported. CBF changes were shown 
to be undetectable in rats following morphine administration in Chapter 5, and decreases 
in BOLD signal contrast and CBF due to visual sensory deprivation have been shown to 
be smaller in amplitude than increases in these measures due to visual sensory 
stimulation in humans (Uludag et al., 2004). As a result, it is reasonable to assume that 
CBF measurements following neural deactivation using arterial spin labeling may be 
especially difficult to make in conscious rats, summarily complicating the measurement 
of changes in CMRO2. Currently, the ease of measuring changes in CBV in conscious 
rats due to neural deactivation is difficult to anticipate, but CBV data reported among 
conscious rats under phMRI neural stimulation paradigms is encouraging (Skoubis et al., 
2006).    
In analyses that require whole brain coverage (Figure B – 1, Study Feature 3), such 
as analyses examining functionally interconnected brain regions that are distal from one 
another (see Chapter 6), adequate coverage of ventral regions of the rat brain mandates a 
spin echo sequence that does not suffer from susceptibility or warping artifacts present in 
gradient echo or echo-planar-imaging (EPI) acquisition protocols. This problem is not an 
issue when regionally specific investigations are being performed of dorsal cortical areas 
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(see Chapter 2, and Figure B – 1, Study Feature 4), but remains an issue if the regions 
investigated are located in ventral or subcortical brain areas affected by the large sinuses 
of the ear canals in the rat skull (Figure B – 1, Study Feature 5). Multi-subject analyses 
that require data set coregistration are especially sensitive to non-linear deformations due 
to EPI image acquisition, and this workhorse of functional imaging is generally 
problematic in rat studies where this geometric distortion is especially prominent (Figure 
6 – 1, Figure B – 1, Study Feature 6). In all acquisition protocols, a balance must be 
struck between spatial and temporal resolution and required sensitivity. In the studies 
presented herein, spatial resolution of 468 x 468 x 1500 μm3 and acquisition times of 2 
sec (EPI) or 6 sec (RARE) represented the minimum volume and repetition times able to 
detect significant changes in BOLD contrast due to hemodynamic effects at 4.7T.  
Peripheral administration of drugs often causes physiological changes that can have 
especially profound effects on the BOLD signal, preventing its reliable use, and 
complicating the estimation of changes in CMRO2 (Figure B – 1, Study Feature 8). It is 
likely that changes in CBV, and, if measurable, changes in CBF will provide a robust 
alternate to BOLD imaging under these conditions. Evidence supporting this speculation 
can be found in the case of apomorphine administration, which was shown in rats not to 
affect CBV measurements using a blood pool contrast agent (Nguyen et al., 2000), but 
was shown to affect BOLD measurements in anesthetized (Kalisch et al., 2005) and 
conscious rats (pilot data not shown). Intracerebral ventricular (ICV) administration of 
the drug under investigation, as opposed to intravenous (IV), intraperitoneal (IP), or 
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subcutaneous (SC) administration, can be used to effectively prevent these physiological 
changes under many circumstances, as illustrated in Chapter 6 and in (Febo et al., 2005). 
CBV measurements using blood pool contrast agents provide a unique combination 
of sensitivity that is greater than CBF measurements using arterial spin labeling, and 
resistance to physiological changes that affect the BOLD signal, suggesting that CBV 
may be an important tool for phMRI research in the future. Unfortunately, the limited 
availability and high cost of contrast agents with a long half-life in the blood, such as 
MION (which has a half life in the blood of more than 4 hours; Jung et al., 1996), 
remains a formidable resource constraint that hinders CBV phMRI studies (Figure B – 1, 
Study Feature 9). In addition to other applications, the future availability of effective 
blood pool contrast agents for CBV studies will enable validation of the findings made 
from the BOLD signal analysis performed in Chapter 6, presumably without the need for 
ICV administration of apomorphine. Furthermore, peripheral administration of the drug 
being assayed by phMRI is a necessary feature of longitudinal studies using the same 
animal in multiple experiments (Figure B -1, Study Feature 7), such as those described in 
the discussion presented in Chapter 7. These advantages may make CBV measurements 
an indispensable aspect of future phMRI research, in conjunction with non-invasive 
BOLD, CBF, and multimodal imaging techniques. 
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Figure B – 1: Considerations for phMRI study design based on experiences gleaned 
from the present studies. 
Limitations of several aspects of phMRI techniques were encountered in the 
presented research and the recommended approaches under these conditions, gleaned 
from the experiences herein, are indicated in the figure. Discussion of these specific study 
features is included in the text of Appendix B.  
 
Figure B-1
 phMRI Study Feature BOLD CBF CBV CMRO2 GE EPI SE EPI RARE IP / IV / SC ICV
1 Expecting neural activation (e.g. stimulant)
2 Expecting neural deactivation (e.g. sedative) ?
3 Analysis requires whole brain exploration
Analysis requires localized exploration
4 of dorsal cortical regions
5 of subcortical or ventral regions
6 Analysis of effects across animals
7 Longitudinal study within same animal
8 Drug effects peripheral systems (e.g. HR, RR)
9 Limited access to MION or other contrast agent
Modality Acquisition Administration
suggested 
for
suggested 
against
not 
pertinent
